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SUMMARY.
There is considerable evidence that certain features of the 
mechanism of transcriptional regulation of the (3rna-10r globin gene are 
common to other erythroid-specific globin and non-globin genes 
(reviewed in chapter 1) . However, my work suggests that there are 
aspects of this regulation which are unique.
My work on the binding of nuclear proteins to the mouse 
globin gene promoter has revealed a modular organisation of 
protein binding sites. These include two binding sites for the 
erythroid-specific factor, NF-E1 (at -65 and -210 bp) and binding by 
non-tissue-specific proteins to the CCAAT (-85 bp), CACCC (-95 bp) and 
Box 1 (-170 bp) motifs and to a nuclear factor 1 (NF-1) binding site 
(-255 bp).
Mutational analysis of the mouse pma9or globin gene proximal 
promoter TATA, CCAAT and CACCC boxes by other researchers had shown 
that they are required for promoter function in erythroid and 
non-erythroid cells. Using site-directed mutagenesis, I have confirmed 
that the CACCC motif is required for promoter function when linked to a 
reporter gene and assayed in transient and stable transfection assay 
systems. Furthermore I have shown by mutagenesis that the NF-E1 site at 
-65 bp is necessary for promoter function.
However mutation of the NF-E1, Boxl and NF-1 sites in the 
distal region of the promoter results in up-regulation of transcription 
from the promoter in uninduced MEL cells and it is proposed here that 
while the proximal promoter is essential for promoter function that the 
distal promoter has a negative regulatory function in uninduced MEL 
cells. This negative regulatory effect is derepressed when the MEL
xiv
cells are induced to differentiate.
In addition to the role of 5' promoter sequences in 
transcriptional regulation of the mouse prna^ or globin gene, I have 
identified sequences 3' of the coding region of the gene which contain 
NF-E1 and Box 1 binding sites and which confer an up-regulatory effect 
on the transcription of a linked reporter gene from the mouse prna^ or 
globin gene promoter. The up-regulatory effect of this enhancer is 
greater when the cells are induced to differentiate.
Work with two different MEL cell lines, F4-12B2 and C88, and 
with two different inducing agents, DMSO and HMBA, suggests that there
are differences in the responses of these cell lines to the same
treatment and also that DMSO and HMBA act through different mechanisms
to induce differen tiation.
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CHAPTER 1 GENERAL INTRODUCTION.
1.1 ERYTHROPOIESIS AS A SYSTEM IN WHICH TO STUDY REGULATED GENE
EXPRESSION DURING DIFFERENTIATION.
As a system in which to study differentiation, the 
erythropoietic system offers several advantages:
(i) the differentiation pathway along which the erythroid cell 
progresses from the pluripotent haematopoietic stem cell is well 
characterised at each stage by proliferative capacity and response no 
the hormone erythropoietin (Stephenson et al. (1971); Gregory and Eaves 
(1977) .
(ii) gene expression in the erythroid lineage is well characterised by 
markers such as spectrin, glycophorins and globins (Reviewed by 
Harrison (1984).
(iii) there exist erythroleukemic cell lines which can be induced in 
vitro to undergo differentiation in a way that mimics the morphological 
and biochemical changes taking place in vivo during normal 
erythropoiesis (Friend et al. (1966), Beug et al. (1982), Lozzio and 
Lozzio (1975).
1.1.1 Erythropoiesis.
During the development of the mouse, which has a gestation 
period of 21 days, erythropoiesis occurs in the embryonic yolk sac 
(days 8-12), the fetal liver (days 12-17) and in the bone marrow after 
day 16 (Barrowman and Craig (1961); Craig and Russell (1964) .
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Erythropoiesis also occurs in the spleen starting at day 16 but ceases 
at birth. Under conditions of anaemia, erythropoiesis is induced in the 
adult spleen and liver (Conkie et al. (1975) . In humans, erythropoiesis 
takes place in the embryonic yolk sac (2-6 wks post conception), the 
fetal liver (4 wks post conception until 6 wks after birth), the spleen 
(15 wks post-conception until 4 wks after birth) and in the bone marrow 
from 16 wks post-conception through adult life (Karlsson and Nienhuis 
(1985) .
Erythrocytes are derived from pluripotent stem cells which 
become committed to different lineages in response to growth factors. 
Growth factor response was first studied using the colony forming unit 
assay (Gusella et al. (1976); Till and McCulloch (1980); Dexter et 
al. (1984) . When bone marrow from a healthy adult mouse is injected into 
a mouse whose own haemopoiesis has been ablated by X-ray irradiation, 
the donor cells colonise the irradiated host. Such colonies develop in 
the host spleen and the discreteness of the nodules suggests that each 
colony is a clone of a single founding stem cell, which has been called 
a colony-forming unit (CFU-S). These colonies can be explanted and 
grown in culture. In combination with other culture techniques 
(including the growth of dispersed bone marrow cells on semi-solid 
medium), the CFU assay has identified the erythrocyte colony forming 
unit (CFU-E), which is highly sensitive to erythropoietin and gives 
rise to mature erythrocytes after less than 6 divisions. The 
erythrocyte burst forming unit (BFU-E) has also been identified and 
responds only to high concentrations of erythropoietin and divides at 
least 12 times before becoming mature (Gregory (1976) . Thus the BFU-E 
appears to be a progenitor of the CFU-E and cells intermediate between
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BFU-E and CFU-E which have intermediate proliferative capacity and 
erythropoietin responsiveness have been identified.
Other growth factors, including GM-CSF and interleukin 3 (11-3 
act on earlier erythroid progenitor cells) which influence different 
cells in the haematopoietic lineage have been purified from culture 
media and their genes cloned (Clark and Kamen (1987) . They may
eventually be used in the clinical treatment of disease (Sachs (1988) .
1.1.2 Gene Expression During Erythropoiesis.
The erythropoietin receptor is the earliest known erythroid
marker expressed, being switched on at the first erythroid committed
stage, the BFU-E (Krantz and Goldwasser (1984) . The erythropoietin 
receptor is internalised when it binds erythropoietin and is
metabolised within the cell. The receptor has been purified and there 
seem to be two forms of the receptor which differ in size and affinity 
for erythropoietin (Krantz et al. (1988). Chemical cross-linking 
studies show that the high affinity erythropoietin receptor consisas 
of two sub-units (McCaffery et al. (1989) of molecular weight lOOkD and 
85kD. Protease digestion of these subunits generates identical peptide 
fragments suggesting that they may be encoded by the same gene. A cDNA 
clone for the erythropoietin receptor has been obtained from MEL cells. 
From the sequence of the cDNA, the receptor is predicted to have a 
molecular weight of 55kD (D'Andrea et al. (1989). There is evidence 
that the molecular weight observed for the receptor on the surface of 
erythroblasts is generated by glycosylation and dimerisation of the 
55kD polypeptide to yield the biologically important high affinity
3
receptor (Dube et al. (1988).
Early during erythroid differentiation, at the CFU-E stage, 
the a and (3-spectrin genes are expressed (Eisen and Ikawa (1977) . The 
genes encoding the other components of the red blood cell cytoskeleton 
are also expressed at this stage. Some of these proteins are not 
exclusively red blood cell specific and have in fact a wide tissue 
distribution (Lazarides and Nelson (1982).
The glycophorin proteins are erythroid specific and their 
genes are first expressed in mid-erythroblast stage (Kasturi and 
Harrison (1985), before activation of globin gene transcription.
Some of the enzymes of the haem biosynthetic pathway are 
expressed at higher levels in erythroid tissue where large quantities 
of haem are required for haemoglobin synthesis, compared with other 
cells, where the haem requirement for cytochrome synthesis is satisfied 
by lower levels of expression. The genes encoding the haem biosynthetic 
enzymes have not all been cloned but evidence suggests that expression 
of these genes is sequentially induced (Sassa (1987). Up-regulation of 
the human 6-amino levulinic acid synthetase, in erythroid tissue, is 
achieved by having two genes, one of which is expressed in all cells 
and the second of which is only expressed in erythroid tissue (Yamamoto 
(1985) . The human porphobilinogen-deaminase gene has two promoters, one 
of which is regulated in an erythroid specific fashion (Romeo et al.
(1987) . Evidence shows that the mouse gene is similarly regulated 
(Grandchamp et al. (1987) .
The five different isozymic forms of carbonic anhydrase show 
different tissue specificities. Carbonic anhydrase (CA) is the second 
most abundant protein in erythrocytes after globin. The predominant
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form of CA in human erythrocytes is CAI although CA II is also 
present. (CAII is active in a number of other tissues). CA expression is 
developmentally regulated in erythrocytes and up-regulation of CAI 
egression occurs at approximately the same time as the y to (3 
(foetal to adult) globin switch suggesting possible coregulation of CAI 
and adult globin genes in development (Boyer et al. (1983). In the 
differentiation of MEL cells, mouse CAI levels decrease upon induction 
while those of CAII increase (Fraser and Curtis (1987). The mouse CAI 
gene has two promoters, one of which is erythroid specific (Fraser et 
al. (1989). This is analogous to the mouse PBG-D gene.
The globin genes are switched on in late erythroblast stage; 
the a-globin genes are transcribed before the (3-globin genes in the 
differentiation of MEL cells and (3-globin levels accumulate faster due 
to greater message stability (Orkin et al. (1975) to give equimolar 
amounts of a and (3 globin chains.
Later in erythropoiesis, the nucleus is extruded and 
organelles are broken down, an activity involving the "red blood cell 
specific" lipoxygenase-15 (Thiele et al. (1979) .
1.1.3 Differentiation of Erythroleukemic Cell Lines.
The Friend virus complex was first isolated from a filtrate of 
mouse spleen tumour cells (Friend (1957) and consists of two C-type 
retroviruses, a replication defective spleen focus-forming virus (SFFV) 
and a replication-competent Friend murine leukaemia virus (F-MuLV) . The 
target cell for this virus complex is one of the early erythroid 
progenitor cells which is erythropoietin-responsive (Mirand (1967) .
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95% of Friend virus induced murine erythroleukaemias have a common SFFV 
proviral integration site called Spi-1 (for SFFV proviral integration 
site) (Mbreau-Gachelin et al. (1988) . Transformation induced by SFFV 
occurs in two steps: limited proliferation which is erythropoietin
independent followed by immortalisation. An intact SFFV envelope 
glycoprotein gp55 is necessary for transformation (Linemeyer et al. 
(1982) and in vitro evidence shows that gp55 binds directly to the 
erythropoietin receptor to generate erythropoietin and 11-3 independent 
cell lines (Li unpublished data). This suggests that gp55 causes 
prolonged proliferation of SFFV infected cells by stimulating the 
erythropoietin receptor and bypassing the normal requirement for
erythropoietin. The role of Spi-1 as a putative oncogene is being
investigated although it does not bear homology to any previously
identified oncogenes. There is also evidence to suggest that the p53 
oncogene is rearranged or mutated in Friend virus induced
erythroleukaemias (Mowat et al. (1985) .
Friend virus derived erythroleukaemia cell lines will 
undergo erythroid differentiation in vitro, independent of 
erythropoietin (Hankins and Krantz (1975) when treated with agents such 
as DMSO (Friend et al. (1971). Other agents which induce Friend cell 
differentiation include polar-planar compounds such as hexamethylene 
bisacetamide (HMBA), actinomycin D, hemin, purines and fatty acids 
(Preisler et al.(1976), Gusella et al. (1976). HMBA is a particularly 
strong inducer in that virtually the entire population of cells is 
induced at low concentrations of HMBA (4 mM) and a higher proportion of 
total protein synthesis is globin (Reuben et al. (1976).
Different inducing agents probably act via different pathways
6
since variant cell lines which are resistant to induction by one agent 
are sensitive to induction by another (Ohta et al. (1976). It is 
possible that inducing agents initiate reactions similar to those 
functioning in vivo but the precise nature of the reactions is not
understood.
If Friend cells are incubated for 30-35hrs in DMSO, they will 
differentiate into erythroid cells even if the inducer is removed. If 
they are only incubated for 15-25 hrs with DMSO, only a small 
proportion of the cells will differentiate after the drug is removed. 
However, if these cells have first been UV-irradiated, a much larger 
proportion of cells differentiate suggesting that DMSO and UV act
synergistically to induce differentiation (Nomura and Oishi (1983). One 
agent may be inhibiting DNA. replication while the other possibly acts 
via a membrane mediated reaction. A factor has been identified which 
induces erythroid differentiation when introduced into
non-differentiated Friend cells. This factor which is present in the 
cytoplasm is induced when non-erythroid and Friend cells are treated
with agents that inhibit DNA replication (Nomura et al. (1986) .
Other gene products which may be involved in the regulation of 
erythroid differentiation include the product of the c-erb A gene, the 
receptor for tri-iodothyronine (Sap et al. (1986), a hormone which is 
known to stimulate erythropoiesis in vitro (Dainiak et al. (1978). The 
v-erb A oncogene is known to potentiate the transformation properties 
of the v-erb B oncogene (both oncogenes are cotransduced by the avian 
erythroblastosis virus) to induce acute erythroleukemias and sarcomas 
in vivo (Graf and Beug (1978) . A chicken cell line, HD3, generated by 
infection of chicken bone marrow cells with AEV carrying a temperature
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sensitive v-erbB gene, fails to differentiate at 36°C but can be 
induced to differentiate when shifted to the non-permissive temperature 
of 42°C (Beug et al. (1982) . The c-erb A mRNA is transcribed in late 
erythroblasts and has a short half-life (Hentzen et al. (1987) . These 
results suggest that c-erb A may play a role in the late stages of 
erythroid differentiation.
The role of other oncogenes in erythroid differentiation is 
also being studied . It has been shown that normal expression of the 
membrane-bound tyrosine kinase product of the c-sea gene is required 
for normal erythropoietin-responsive erythroid differentiation (Hayman
(1985) . Down-regulation of expression of the c-myb gene is a 
prerequisite for commitment to erythropoietin responsive erythroid 
differentiation (Todokoro et al. (1988). c-myb and c-ets are both 
DNA-binding proteins located in the nucleus of erythroid progenitor 
cells but their role in differentiation is not yet understood (Golay et 
al. (1988).
Recently, a factor called erythroid differentiation factor 
(EDF), has been isolated from human tumour cell line THP-1 induced with 
phorbal 12-myristate 13-acetate (PMA) which stimulates differentiation 
of MEL and K562 cells (Murata et al. (1988). The factor has been 
purified and its gene cloned. The factor has an identical amino acid 
sequence to the (3 chain of activin A and inhibin A which respectively 
enhance and inhibit secretion of follicle-stimulating hormone from 
pituitary cells in vitro. In addition to this activity, activin A ((3 ) 2 
enhances colony formation by stimulated human bone marrow erythroid and 
multipotential progenitor cells (Yu et al. (1987) while inhibin A 
(OpA) decreases activin but not 11-3, GM-CSF or 11-4 enhancement of
erythropoietin-stimulated colony formation by erythroid and 
multipotential progenitor cells (Broxmeyer et al. (1988) .
Radiation induced murine erythroleukaemic cell lines have been 
derived which are erythropoietin responsive (Itoh et al. (1988) . These 
cells differentiate into haemoglobinised cells if cultured in the 
presence of erythropoietin. Supplementation with 11-3 augments the 
erythropoietin-mediated differentiation although 11-3 alone does not 
induce differentiation (Shiozaki et al. (1989) .
Various human erythroid cell lines have been established: 
K562 (Lozzio and Lozzio(1975) which was derived from a pleural effusion 
of a patient with chronic granulocytic leukaemia in terminal blast 
crisis; HEL cells established from a patient with Hodgkin's Disease 
who later developed erythroleukaemia (Martin and Papayannopoulou 
(1982); and KMOE derived from patients with acute erythremia (Okano
(1981). These cells express erythroid markers indicative of commitment 
to the erythroid lineage but they also express markers of the myeloid 
and granulocytic lineages suggesting that they arose by transformation 
of early progenitor cells. The globin gene expression pattern of K562 
cells is typical of erythroid cells in the embryonic stage of 
development expressing e and y globin RNAs. HEL and KMOE cells are 
typical of erythroid cells in the foetal stage of human development 
expressing both yand (3 globin RNAs. Two new human erythroid cell 
lines have been developed, 0C1-M1 (embryonic) and 0C1-M2 (foetal) and 
from studies of expression in these five lines it appears that 
transformation of erythroid progenitor cells to generate 
erythroleukaemias activates embryonic and foetal globin gene expression 
patterns and that there is a failure to set up an adult pattern of
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expression in human cell lines (Enver (1988) .
1.2 THE ROLE OF CHROMATIN CONFORMATION IN REGULATING GENE EXPRESSION.
Given the large number of inactive genes in the eukaryotic 
nucleus at any one time, it is likely that the dominant mechanism of 
repression of gene expression is general as opposed to specific, and 
evidence suggests that this is mediated by condensation of chromatin in 
the inactive regions of the genome (Brown (1984), Weisbrod (1982).
1.2.1 Chromatin Structure and Nucleosome Phasing.
The nature of chromatin structure is reviewed at length 
(Pederson et al. (1986), Eissenberg et al. (1985), Dilworth and Dingwall 
(1988) .
In decondensed chromatin, nucleosomes space out regularly 
along DNA (Olins (1973) but there is evidence that this positioning of 
nucleosomes is not random"(Ramsey et al. (1984). The regular spacing of 
a DNA molecule around the nucleosome core is referred to as nucleosome 
phasing. Even when chromatin is decondensed, nucleosomes could still 
limit access of regulatory factors to the DNA that is to be 
transcribed, but there is evidence that in areas of gene activity that 
nucleosome phasing is disrupted (Simpson and Stafford (1983) .
It has been demonstrated by methidiumpropyl-EDTA-Fe (II) 
cleavage that nucleosomes are phased without interruption along the 
mouse pmajor globin gene between -3000 and +1500 in L cells where the 
gene is not expressed but that this phasing is interrupted between -200 
and +500 in MEL cells where the gene is expressed. This region is
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however protected from MPE-Fe(II) cleavage and is flanked by MPE-Fe(II) 
hypersensitive sites suggesting that other factors involved in 
transcription are binding there (Benezra et al. (1986) .
Recent work has shown that while nucleosomes assembled on DNA 
can prevent transcriptional initiation in vitro (Knezetic and Luse
(1986), Matsui (1987), they do not prevent elongation of transcription 
by pre-initiated transcription complexes (Lorch et al. (1987), Knezetic
(1988) and that RNA polymerase II will read through nucleosomes, 
displacing hist ones. This may explain why altered nucleosome phasing 
occurs over promoter and enhancer sequences but does not extend right 
through the gene.
The linker DNA between nucleosomes, which varies in length 
from 20 to lOObp depending on the organism and tissue (Kornberg (1977), 
complexes with histone HI to hold adjacent nucleosomes together and to 
condense the lOnm fibre into a 30nm solenoid (Felsenfeld (1978), McGhee 
and Felsenfeld (1980) . HI is a class of polymorphic proteins which are 
frequently modified and exhibit tissue and organism specificity 
(Pederson et al. (1986). In nucleated erythrocytes HI is replaced by 
H5 during maturation of the erythroblast (Neelin (1974).
Evidence suggests that beyond the 30nm fibre, chromatin is 
organised into loops which are radially attached to a central protein 
scaffold called the nuclear matrix (Zehnbauer and Vogelstein (1985). In 
histone depleted metaphase chromosomes, electron micrography identifies 
DNA loops emerging from sites on the scaffold and returning to the same 
site (Paulson and Laemmli (1977) in a similar fashion to lamprush 
chromosome loops (Callan and MacGregor (1958) . Goldman (1988) has 
suggested that each loop is in fact a chromatin domain which contains
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several transcription units and replication origins, is independently 
supercoilable and may be assembled during replication into an open or 
closed transcription state depending on the relative abundance of 
limiting transcription factors and histones. There is evidence
suggesting that transcriptionally active DNA. is closely associated with 
the nuclear matrix: experiments show that active proviral sequences in
avian sarcoma virus transformed rat fibroblasts associate with the 
matrix while in the revertant, this association is lost (Cook et al.
(1982) . Supercoiling may generate altered DNA structures, such as DNA 
bending, which increase the affinity of transcription factors for
regulatory sequences or it may induce altered DNA conformations such as 
Z-DNA which may reduce the binding affinity of histones (Wu (1988), 
Garner and Felsenfeld (1987).
Non-histone proteins found associated with chromatin include 
the high mobility group of proteins although evidence suggesting that 
HMG14 and 17 are found associated with nucleosomes at active sites in
the chromatin (Sandeen et al. (1980), is controversial (Goodwin et
al(1985). Histone acetylation and ubiquitination are also associated 
with gene activation (Allfrey (1977), Hebbes et al. (1988). However 
the role of HMG proteins, ubiquitination and acetylation in gene 
regulation remains ambiguous.
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1.2.2 DNA Methylation.
In vitro methylation of DNA. sequences inhibits their 
expression in vivo, in either mouse fibroblasts or in Xenopus oocytes 
(Vardimon et al (1982), Fradin et al (1982), Stein et al (1982) while
5-aza-cytidine, a hypomethylating agent activates expression of 
previously silent genes (Jones (1985).
In the genome methylation occurs at the 5 position of the
cytosine ring in CpG dinucleotides, which are present in the genome at
a frequency of approximately 0.2 times that expected (Russell et al. 
(1976). About 60-90% of all CpGs in the genome are methylated.
Non-methylated CpGs tend to be clustered into what have become known as 
HTF (Hpall Tiny Fragments) islands because they contain many sites for
Hpall which recognises the unmethylated site CCGG while its
isoschizomer MspI recognises the methylated site C^CGG (Bird et al.
(1985). HTF islands are found at the 5' end of non-tissue specific
genes such as the X-linked hypoxanthine phosphoribosyl transferase gene 
in mouse (Yen et al. (1984) and human dehydrofolate reductase gene 
(Stein et al. (1983) but are also found 3' of genes like the islands 3' 
of the glucose-6-phosphate dehydrogenase gene (Wolf et al. (1984). 
Methylation of HTF islands inhibits expression of the associated gene. 
Bird (1986) has proposed that HTF islands mark out large regulatory 
sequences which are bound by multiple factors which sterically exclude
methylases. Methylation at HTF islands would sterically prevent binding
!
by regulatory factors.
Many tissue specific genes do not have HTF islands partly 
because CpGs are rarely found near tissue-specific genes. However,
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demethylation may be important in regulating some tissue specific 
expression since treatment of muscle cells with 5-aza-cytidine rapidly 
induces differentiation (Jones (1985). Treatment of determined red 
blood cells with 5-aza-cytidine induces globin gene expression but has 
no effect on globin gene expression in non-erythroid cells implying 
that methylation is at most a secondary event in tissue-specific gene 
regulation (Hsiao et al. (1983) . Methylation of the yglobin genes in 
MEL-human foetal erythroid somatic cell hybrids only occurs after the 
developmental switch to adult (3-globin gene expression again suggesting 
a secondary role for methylation (Enver et al (1988) .
The human a globin gene promoter lies in an HTF island which 
contains multiple copies of Spl binding sites which positively regulate 
transcription of the gene. The a globin gene functions in the absence 
of an enhancer when transfected into non-erythroid cell lines. In 
contrast, the mouse a-1 globin gene promoter is not promiscuous and 
does not lie in an HTF island. In non-replicating systems, the human 
a-globin gene becomes enhancer dependent like the mouse a-1 globin gene 
(Whitelaw et al. (1989). This suggests a role for methylation in 
regulating expression of the human a globin gene in cell-cycle 
dependent manner, by blocking binding of Spl to upstream regulatory 
sequences.
Methylation plays an important role in stable inactivation of 
viral sequences (Krucek and Dorfler (1983), in achieving equal gene 
dosage in mammalian females by inactivation of one X-chromosome 
(Venolia et al. (1982) and in generating hemizygosity and altered 
expression at loci in a manner dependent on the gametic origin of the 
locus (McGowan et al. (1989).
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1.2.3 Nuclease Sensitivity of Active Chromatin Domains.
That DNA. in active chromatin is preferentially sensitive to
digestion by DNAase 1 compared to inactive chromatin or bulk chromatin, 
was initially shown by Weintraub and Groudine (1976) . Digestion of
isolated nuclei by DNAase 1 preferentially degrades globin DNA 
sequences from nuclei obtained from chick red blood cells but not from 
nuclei obtained from non-erythroid cells or from a population of red 
blood cell precursors. In contrast, the non-transcribed ovalbumin 
sequences in nuclei from red blood cells and fibroblasts were resistant 
to DNAase 1 suggesting that active genes are preferentially sensitive 
to DNAase 1. Stalder et al. (1980) extended this study by identifying a 
DNAase 1 sensitive region which extended from 7 kb 5'to 8 kb 3' of the 
(3 globin gene cluster in chick red blood cells. Moreover by using low 
concentrations of DNAase 1, he was able to identify DNAase 1 
hypersensitive sites (DHSS) which were tissue-specific and some of
which were developmental-stage specific. These DHSS are thought to 
represent sites made accessible to transcription factors by the 
displacement of nucleosomes. Sites identified by genomic footprinting 
as being nucleosome free in vivo have been further characterised in
vitro as sites bound by transcription factors. For example the chicken 
aD globin gene genomic footprint from -130 to +80 bp relative to the 
initiation site contains a binding site at -63 to -55 bp for the 
erythroid specific transcription factor, Eryf I as well as other 
protein binding sites (Kemper et al. (1987). In embryonic red blood 
cells, there is a DHSS immediately 5' of the embryonic gene, e and in 
adult erythrocytes there are two sites, 6 kb and 2 kb 5' of the adult
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globin gene. The DHSS close to the 5' end of the chicken (3^ globin 
gene was more finely mapped to between 60 bp and 260 bp 5' of the 
initiation site of the gene and its presence correlates with gene 
expression (McGhee et al. (1981).
In mouse, the a and the (3 globin genes are DNAase 1 sensitive 
in erythroid tissue and in MEL cells. These sensitive domains are 
present in both uninduced and induced cells even though the globin 
genes are not being actively transcribed in uninduced cells (Miller et 
al. (1978). This illustrated that while an open chromatin conformation 
is necessary, it is not sufficent for transcriptional activation of 
globin genes. Sheffery et al. (1982), Sheffery et al. (1983) mapped 
two DHSS in the mouse (3ma 0^r globin gene. One site within the second 
intron of the gene becomes less hypersensitive upon induction while the 
other site, immediately 5' of the gene becomes more hypersensitive upon 
induction. A third DHSS has been mapped approximately 3 kb upstream of 
the mouse globin gene by Smith and Yu (1984) who also showed
that following commitment to differentiation, DNAase 1 hypersensitivity 
is stably maintained even in the absence of inducer. In MEL cells, 
which only express the adult globin genes, the adult genes contain DHSS 
whereas the embryonic genes do not (Smith et al. (1984).
In human foetal liver, DNAasel HSS have been mapped to the 5' 
regions of the human y^, y^, 5 and (3-globin genes whereas in human bone 
marrow DHSS have only been mapped 5' of the 5 and (3 globin genes. In 
the same study, no DHSS could be mapped within the (3 globin domain in 
leukocytes (Groudine et al. (1983) . Tuan et al. (1985) mapped all the 
major and minor DHSS within the human P globin domain. All the minor 
sites mapped close to the 5' ends of each gene in the domain and
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correlated with transcriptional activity of the activity of the 
downstream gene but the major DHSS map to the boundaries of the DNAase 
1 sensitive domain and are present in embryonic, foetal and adult 
erythroid tissues which are expressing globins. These 5' and 3' domain 
boundaries have been cloned (Grosveld et al. (1987) and brought next to 
the adult (3 globin gene in a construct which was used to generate 
transgenic mice. Previously, globin transgenes were poorly expressed in 
transgenic animals relative to the endogenous genes and were highly 
sensitive to the site of integration in the genome (Townes et al.
(1985). But when these domains boundaries, which normally map 
approximately 20 kb 5' and 3' of the gene are cloned next to the 
transgene, 100% expression is observed relative to the endogenous gene. 
Moreover, expression is completely copy number dependent, is 
independent of position and orientation and confers absolute tissue 
specificity on expression. These dominant control regions also operate 
on (3-globin gene promoters in stable transfection assays (Van 
Assendelft (1989) and will operate on heterologous promoters such as 
the HSV-TK, Thy-1 and a-1 globin gene (Ryan et al. (1989). It has now 
been found that only 6.5 kb from the 5' domain boundary is necessary 
for dominant control and this region is currently being packaged into 
retroviral vectors for potential use in gene therapy to treat 
thalassemias and sickle cell anaemia (Talbot et al. (1989) . Dominant 
control regions conferring T-cell specific, copy-number dependent, 
position independent expression have also been identified at 4.5 kb 
5' and 9 kb 3' of the CD2 T-cell marker gene (Greaves et al. (1989) .
DHSS marking out regulatory regions have been mapped for 
non-globin genes. The avian leukosis virus (ALV) integrates in bursal
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lymphomas into a region flanked by two DHSS in the 5' region of the 
unrearranged c-myc gene. Following integration, the two DHSS disappear 
and a new single DHSS appears in the ALV LTR enhancer reflecting the 
change in transcriptional regulation of the DNA in the region (Schubach 
and Groudine (1984) .
1.3. REGULATION OF TRANSCRIPTIONAL INITIATION.
Regulation of gene expression by control of initiation of 
transcription has been widely studied in a number of systems (Reviewed 
by Maniatis et al. (1987), Jones et al. (1988) .
Some promoter elements regulate basal level transcription, 
such as the Spl binding site (Dynan and Tjian (1983) while others 
control inducible expression, such as the heat shock responsive element 
(Pelham (1982) or tissue-specific expression, such as the octamer box 
of immunoglobulin gene promoters in B-cells (Grosschedl and Baltimore
(1985).
The distinction between promoter and enhancer elements has 
become arbitrary but initially enhancers were distinguished from 
promoters by their ability to stimulate transcription initiation in an 
orientation and position independent fashion (Serfling et al. (1985). 
As analysis of enhancer elements has become more detailed it emerges 
that each enhancer is itself made up of core elements or "enhansons", 
which can be duplicated or combined in a heterologous fashion to 
generate new enhancers. Within a given enhancer, the relative spacing 
of enhansons is critical and determines the overall efficiency of the 
enhancer (Ondek et al. (1988) . Consequently, an element such as the
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octamer box can act as a promoter element in the context of the sea 
urchin histone II2B 5' flanking sequence where it is position and 
orientation dependent and as an enhanson in the context of the SV40 
enhancer where it interacts with other enhansons to generate the 
functional enhancer which is orientation and position independent. It 
has been shown that multimerisation of the octamer motif to generate a 
tissue-specific enhancer will create a negative regulator which is 
dominant to the SV40 enhancer (Yu et al. (1989) illustrating that the
activity of a particular enhanson depends upon the context in which it 
is found.
1.3.1 THE NODULARITY OF ENHANCERS AND PROMOTERS EXEMPLIFIED BY THE SV40 
ENHANCER.
The 300 bp region between the early and late transcription 
units of SV40 contains a number of regulatory elements as illustrated 
in figure 1.1 below.
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Figure 1.1 The SV40 Promoter and Enhancer.
The top figure illustrates the organisation of SV40 promoter and 
enhancer elements with respect to *the start site of early and late
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transcription. The lower figure gives an expanded view of SV40 enhancer 
elements. The interactions of these elements with their cognate binding 
factors and with each other is discussed in the text.
Next to the T antigen gene (Tag) is the DNA origin of 
replication (Myers and Tjian (1980) which overlaps with three Tag 
binding sites and the initiation site of early transcription (Khoury et 
al. (1973). Disruption of the replication origin prevents repression 
of early transcription by eliminating Tag binding sites (Rio and Tjian, 
(1983) and reduces the number of templates available for late mRNA 
synthesis reducing late gene transcription (Myers, et al. (1981); Rio, 
et al. (1980). The AT-rich region adjacent to the DNA origin of 
replication bears similarity to the TATA box motif described by 
Goldberg but deletion of this region has little effect on early 
transcription (Benoist and Chambon (1980) . In contrast, deletion of 
the 3 adjacent GC-rich 21 bp direct repeats severely reduces early 
transcription and virus viability (Fromm and Berg (1982) . Each 21 bp 
repeat contains two copies of the hexanucleotide GGGCGG which is the 
core recognition site for the transcription factor Spl (Dynan and Tjian
(1983); Briggs et al. (1983). The affinity of Spl for each of the six 
sites varies depending on sequence flanking the GC core element and 
this combined with steric constraints determines that only five of the 
six sites are occupied at any one time (Gidoni et al. (1985) .
The 72 bp repeats adjacent to the late transcription start 
site constitute the SV40 enhancer which confers enhanced transcription, 
independent of orientation and of position (Banerji et al. (1981). 
The SV40 enhancer was the first to be discovered and functions in 
different cell types from different species, including non-mammalian
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systems (Nenhaus et al.(1984). The SV40 enhancer can activate 
transcription from the early or late promoter from anywhere in the 
viral genome and can also activate transcription from heterologous 
promoters such as the (3-globin promoter (Banerji et al. (1981), the 
conalbumin and the adenovirus major late promoters (Moreau et al. 
(1981) . The human a-globin gene seems to be resistant to SV40 enhancer 
activation (Humphries et al. (1982); Treisman et al.(1983).
The SV40 enhancer has been extensively analysed (Zenke et al.
(1986); Herr and Clarke (1986); Clarke and Herr (1987) and has been 
shown to be made up of three domains A, B and C which are 21, 22 and 15 
bp respectively. Each domain consists of modules, termed enhansons, 
such that the activity of one enhanson can be compensated for by the 
duplication of another, where enhansons cooperate with each other and 
spacing between enhansons is critical to enhancer activity (Ondek et 
al. (1988) . Individual enhansons are found associated with other viral 
and cellular enhancers and promoters.
Domain A contains an imperfect direct repeat of a 9 bp 
element, SphI and II. Mutation of these elements down regulates SV40 
enhancer activity in HeLa cells and in embryonal carcinoma cells but 
not in B cells (Nomiyama et al. (1987) . The direct repeat of the Sph 
elements generates an overlapping octamer box recognition site, 
homologous to that found in Ig enhancers, the histone H2B promoter and 
the U2 snRNA promoter (Grosschedl and Baltimore (1985); Sive et al.
(1986); Mattaj et al. (1985) . Mutation of this octamer box reduces 
SV40 enhancer activity in B cells but not in HeLa or in embryonal 
carcinoma cell lines (Nomiyama et al. (1987) . The factor binding to 
this element, OBP 100 may be related to the lymphoid specific octamer
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binding factor. Domain A also contains the P element which binds AP-1.
Domain C contains 3 elements GT-11A, B and C which interact 
with four distinct factors GT-11A, GT-llBa, GT11B|3 and GT-11C/TEF-1 
(Xiao et al. (1987) . Factors GT-11A, GT-llBa and GT-llBf are found in 
HeLa, undifferentiated embryonal carcinoma cell lines and in B cell 
lines but mutation of their cognate binding sites has little 
detrimental effect on SV40 enhancer activity in these three cell lines. 
This suggests that these elements play only a minor role in SV40 
enhancer activity. In contrast, mutation of GT-11C reduced the 
activity of the SV40 enhancer dramatically in HeLa and embryonal 
carcinoma cell lines but has no effect on activity in B cells. The 
cognate binding factor, TEF-1 (also called AP4), is absent or inactive 
in B cells. TEF-1 binds to SphI and II but with weaker affinity, 
explaining why GT-11C and Sph motifs are interchangeable. TEF1 binds 
to both Sph and GT-11C despite no obvious sequence homology between the 
two sites. Sph and GT-11C compete with each other for TEF-1. TEF-1 
binds cooperatively to multiple copies of its cognate binding site, 
GT-11C or Sph (Davidson et al. (1988) and binding to Sph by TEF-1 is 
augmented by binding of API to the P element of domain A (Mermod et al. 
(1988).
Integrity of the GT-1 motif of domain B is crucial to full 
activity of the enhancer in HeLa, and embryonal carcinoma cell lines. 
Mutations in the TC-11 motif has a down-regulatory effect in HeLa cells 
and B cells. The activity of these elements in each cell line 
correlates with the presence of their binding factors (Rosales et al.
(1987). While GT-1 bears a high degree of homology to GT-11C (10/12 
bp) it binds different factors to closely overlapping sites. GT-1
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binds three factors GT-1A, B and C of which GT-1A and B are ubiquitous 
while GT-1C is absent from B cells. Competition studies indicate that 
GT-1A is probably Spl while GT-1C/ TEF-2 is the same CACC-binding 
factor(s) involved in globin gene regulation. Different forms of each 
factor may be active in different cell lines (Xiao et al. (1987) . In 
HeLa cells TC-I and II bind AP2 (Mitchell et al. (1987) . AP2 can bind
also to the Spl and Tag binding sites in the early promoter and
evidence suggests that Tag mediated repression of transcription may be 
achieved in part by protein-protein interaction between Tag and AP2, 
preventing AP2 from binding to TC-I and II of the enhancer.
In certain cell types GT-1 and GT-11C act cooperatively 
within the enhancer, in a fashion which depends not so much on their 
stereoalignment but on the overall distance between the elements 
(Fromenthal et al. (1988). Similarly, there is a distance-dependent 
cooperativity between SphI and Sphll.
From their detailed analysis of the SV40 enhancer, its
constituent enhansons and their binding factors, Pierre Chambon and
co-workers have proposed a scheme for the functional organisation of 
enhancers (Fromenthal et al. (1988); Davidson et al. (1988). It is a 
scheme which extends the original proposal by Ondek et al. (1988) and 
which accommodates Ptashne' s model of how protein activators work 
(Ptashne (1988). (Figure 1.2).
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S c h e m e  o f  F u n c t i o n a l  O r g a n i z a t i o n  o f  E n h a n c e r s
P a s s  A —
(prototype: GT-flC and  
S ph motifs -f TEF-t 
e n h an ce r factor)
P a s s  B
(prototype: GT-1 motif *
TEF-2 enhancer factor)
P a s s  C  —
(prototype: octam er 
motif ♦  lymphoid celt-specific 
oc tam er factor)
P a s s  0  —
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Second  Level 
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type It
multi-domain e n h an ce r
single dom ain  en h an cer
1 T andem  duplication; stringent 'sp a c in g ' requirem ent.
2 Association with no stringent 'sp a c in g ' requirem ent.
3 E nhansons c la ss  C  p o sse ss  proto-enhancer properties on their own.
4 E nhansons d a s s  D p o sse ss  enhancer properties on their own.
* Homo-oligomefixation o r association of pro to-enhancers belonging to different types. No stringent 'sp a c in g ' requirem ent.
Figure 1.2 Scheme of the Functional Organisation of Enhancers.
This figure was produced by Fromenthal et al. (1988) and summarises 
their proposals for the organisation of enhancers based on their 
analysis of the SV40 enhancer and work by others on different systems. 
Their scheme is discussed in the text.
It is proposed that there are three levels of enhancer 
organisation. The first level is the level of the enhanson which is 
categorized as types A, B, C or D depending on the type of factor they 
bind. Class A factors bind cooperatively to repeats of their cognate 
binding sites such as TEF-1 binding to GT-11C or Sph. Class B factors 
do not bind cooperatively to tandem repeats of their cognate binding 
site and by themselves generate little enhancer activity. However, in 
association with Class A factors, Class B factors act synergistically 
to generate enhancer activity, e.g. TEF-2 and GT-1. Class C factors 
can act synergistically with other factors when the cognate binding 
sites are not closely appositioned. Examples are OBF and NFKb . Class 
D factors possess intrinsic enhancer activity when bound to single 
copies of their recognition site although they can also act
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synergistically to increase enhancer activity, for example the human 
oestrogen receptor and the oestrogen responsive element.
The proto-enhancer which is a combination of enhansons is the 
second level of enhancer organisation to be proposed. There are four 
types of proto-enhancer. Type 1 is generated by tandem repetition of 
Class A enhansons; type 2 by combination of class A and class B 
enhansons; type 3 composed of a single copy of class C enhansons and 
type 4 which already has enhancer activity and consists of a class D 
enhanson.
Finally, the third level of organisation corresponds to 
combinations of different proto-enhancers.
There are two models to explain the mechanisms by which 
enhancer sequences work: the scanning model and the looping model
(Ptashne (1986), Mailer et al. (1988a) . Both models attempt to explain 
how sequences independent of position of the promoter interact with the 
transcription initiation complex at the promoter. The scanning model 
proposes that high affinity enhancer sequences act as entry sites for 
transcription complexes, including RNA polymerase, which then slide 
along the DNA until they reach and recognise sites within the proximal 
promoter. The looping model proposes that enhancer sequences interact 
with proximal promoter sequences where transcription is to be initiated 
via proteins bound at both sites with the looping out of intervening 
DNA. Evidence confirms that binding of factors at a distance is 
cooperative (Cohen and Meselson (1988), Schule et al. (1988) . Moreover, 
the looping model predicts that enhancers should be able to act in 
trans to stimulate transcription from genes that are not linked to the 
enhancer sequence. Muller et al. (1989) have shown that the SV40
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enhancer will enhance transcription from the rabbit (3 globin gene in 
vitro when separated from it by a non-covalent bridge.
1.3.2 DNA BINDING DOMAINS AND ACTIVATOR DOMAINS OF TRANSCRIPTION 
FACTORS.
Protein factor interactions with DNA regulatory sequences 
are mediated by the DNA binding domain of the protein (Wharton and 
Ptashne (1985) while the activating domain mediates the protein-protein 
interactions which modulate initiation of transcription (Bushman and 
Ptashne (1988). In eukaryotic transcription factors, the DNA-binding 
domain and the activating domain are usually physically separated 
(Ptashne (1988).
The nature of DNA binding domains and activator domains of 
transcriptional regulators is reviewed by Mitchell and Tjian (1989). 
1.3.2A DNA Binding Domains.
The Helix-Tum-Helix Domain.
Progress in understanding eukaryotic transcription control 
mechanisms is due partly to the extensive research that has been 
carried out on prokaryotic gene control systems. The characterisation 
of the phage X repressor and cro proteins and how they interact to 
control the life cycle of X has revealed features of protein-DNA and 
protein-protein interactions which have implications for similar 
interactions in eukaryotes (reviewed by Ptashne (1986). The 
helix-tum-helix has been identified in prokaryotic proteins including 
X repressor and cro proteins (Pabo and Sauer (1984); Anderson et_ al. 
(1981); Pabo and Lewis (1982) but also in eukaryotic proteins such as
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the yeast MAT a2 protein (Laughon and Scott (1984) and in the 
homeodomain of Drosophila segmentation genes (Shepherd et al. (1984).
The helix-tum-helix motif is a pair of protein a-helices, 
one helix of which lies along the major groove of the DNA to allow 
specific contacts to be made between the amino acids facing the major 
groove and the bases lying in the recognition site (Wharton and Ptashne 
(1985) . X repressor binds as a dimer to operator sites with two-fold 
symmetry with the recognition helices from each monomer fitting into 
adjacent major grooves in the DNA and bound to the same side of the DNA 
helix. The interactions between the amino acids in the recognition
helix and base pairs in the major groove are highly specific and the 
specificity of the repressor for the operator site can be altered by 
making amino acid changes in the recognition helix facing the major 
groove (Wharton & Ptashne (1985) .
The Homeo-Domain.
The homeo-box domain is a 60-amino acid DNA-binding motif 
consisting of a helix-tum-helix of the type described above for the X 
repressor and was first identified in the developmental regulatory 
genes of Drosophila (Laughon and Scott (1984) . The role of
homeo-domain proteins in transcriptional regulation is reviewed by
Levine and Hoey (1988) . It has since been shown in vitro that the
homeo-domain proteins of the fushi-tarazu, paired and zen genes 
synergistically upregulate expression from the engrailed promoter (Han 
et al. (1989) and that the products of the even-skipped and engrailed 
genes repress activity. The biochemical nature of the transcriptional 
activity of Drosophila homeo-domain proteins is being analysed with
27
particular attention to protein-protein interactions and synergy.
The B-cell specific transcription of the immunoglobulin genes 
is critically dependent upon the presence of an intact octamer box. 
This site is recognised by two factors; OTF-1, which is ubiquitous and 
OTF-2, which is lymphoid-specific. cDNAs encoding both factors have 
been obtained and sequence comparisons reveal the presence of a shared 
highly charged domain of 160 amino acids which is conserved not only 
between OTF-1 and OTF-2, but also in the unc-86 gene of C.elegans and 
in the Pit-1 gene (Clerc et al. (1988), Sturm et al. (1988), Muller et 
al. (1988b), Scheidereit (1988). This domain referred to as the POU 
(Pit-OTF-Unc) domain is made up of two sub-domains: the homeo-domain
and the POU-specific domain. The homeo-domains of these proteins are 
also conserved in three Drosophila homeo-box proteins, from which they 
derive their name, Antennapedia, engrailed and even-skipped. The POU 
domain is necessary for DNA-binding and may alter the sequence 
specificity of this sub-group of homeo-domain proteins.
Specific mutations in helix 2 of the OTF-1 homeodomain 
disrupts protein-protein interactions with the viral transcription 
factor, VP16, in a way that does not affect DNA. binding activity. These 
mutations are analogous to the ^.repressor positive control mutations 
which do not affect DNA binding or negative regulation but disrupt 
protein-protein interactions with BNA polymerase (Stem et al. (1989) .
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The Zinc Finger DNA Binding Domain.
The zinc finger DNA binding domain was first identified in
TFIIIA of Xenopus and is reviewed by Evans and Hollenberg (1988) .
TF111A has nine Zn fingers which are formed by the coordination of a
2+  . . . . .Zn ion by cytosine and histidine residues at invariant positions
(Miller et al. (1985).
A large number of transcription factors have since been found 
to bear primary sequence which could form zinc finger motifs including 
the steroid hormone receptors, Spl, GAL4, testis-determining factor 
(TDF) and erythroid factor 1 (NF-E1) and several of these factors such
to
as SP1 and the steroid hormone receptors have been shown^do so.
There are two types of zinc finger protein: the 9rouP of
which TFIIIA and SP1 are members in which pairs of cysteines and
histidines are separated by loops of 12 amino acids (Berg (1986); and 
the Cx group in which variable numbers of cysteine residues are 
arranged periodically and of which the steroid hormone receptors, EF-1 
and GAL4 are members. Nuclease analysis of TFIIIA bound to the 5S RNA 
gene revealed that each finger bound in the major groove and contacted 
5 nucleotides (Fairall et al. (1986).
Spl was originally identified in HeLa cells as a factor which
bound to the GGGCGG motif of the SV40 promoter and stimulates
transcription from a number of cellular promoters in vitro (Dynan and 
Tjian (1983); Gidoni et al. (1985). Spl exists in two active forms of 
molecular weight 95kD and llOkD and the 95kD form may be a truncated 
version of the HOkD factor which has been generated by proteolytic 
cleavage. (Briggs et al. (1986) . Both the 95kD and llOkD forms of Spl 
bear equal amounts of this 0-linked glycosylation (Jackson and Tjian
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(1988). Certain members of the CTF and API family of proteins have 
been shown to be glycosylated and this differential glycosylation of 
factors in the same family may alter their response to biologcal 
signals. Spl binds to its cognate DNA binding sites via a 
OX^H-terminal domain consisting of 3 C2^2 z -^nc fibers (Kadonaga et 
al. (1987) but the mechanism by which Spl activates transcription and 
the commonality between Spl regulated genes is still not determined.
The glucocorticoid receptor is activated by binding of
hormone to its steroid binding domain. This binding elicits a
conformational change which increases the affinity of the receptor's
DNA binding domain for the glucocorticoid response element (GRE)
(Holeriberg et al. (1987) . The DNA binding domain contains two zinc
finger motifs formed from periodically spaced cysteine residues and 
2+depends upon Zn for its activity (Weinberger et al. (1982). The 
glucocorticoid receptor bound at its GRE can interact cooperatively via 
protein-protein interactions with a CACCC binding factor in the 
tryptophan oxygenase gene promoter (Schule et al. (1988) and also with 
another glucocorticoid receptor bound at a second GRE in the promoter 
of the human tyrosine aminotransferase gene promoter (Jantzen et al.
(1987); Tsai et al. (1989). The zinc finger domain of the oestrogen 
receptor is similar to the glucocorticoid receptor and a two amino acid 
change in the first zinc finger of the glucocorticoid receptor changes 
its recognition of the glucocorticoid response element to that of the 
oestrogen response element (Danielson et al. (1989) while a three amino 
acid change converts the oestrogen receptor into recognising the 
glucocorticoid response element (Mader et al. (1989).
The zinc finger motif has clearly evolved separately from the
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helix-tum-helix motif and it would be interesting to determine whether 
any bacterial proteins bear this motif.
1.3.2B Activator Domains.
’’Domain swap" experiments and analysis of factors mutant in 
activating potential but still able to bind specifically to DNA have 
defined three types of activating domain of regulatory proteins:
(i) stretches of negatively charged amino acids (Hope and Struhl (1986) 
which can form amphipathic a-helices, with the negatively charged 
groups all on one surface of the helix and hydrophobic groups on the 
other (Hope et al. (1988) examples of which include GAL4 (Ma and 
Ptashne (1987); GCN4 (Hope (1988); API (Struhl (1988); the HSV viral 
protein, VP16 (Sadowski et al. (1988), Triezenberg, S. et al(1988); 
and the glucocorticoid receptor (Hollenberg and Evans (1988),
(ii) highly basic stretches of amino acids rich in glutamine, 
examples of which include Spl (Courey & Tjian (1988); OTF-1 (Sturm et 
al. (1988); OTF-2 (Clerc et al. (1988); AP2 (Williams et al. (1988); 
SRF (Norman et al^ (1988) ;
(iii) proline-rich domains which are functional domains in CTF and NF-1 
(Mermod et al. (1989) and which may also play a role in API (Struhl 
(1988), AP2 (Williams et al (1988), OTF-2 (Clerc et al (1988) and SRF 
(Norman et al (1988).
There are probably other types of activating domain which 
have not yet been structurally characterised, for example the A/B 
domain of the human oestrogen receptor which is not an acidic 
activating region unlike the A/B region of the glucocorticoid receptor 
(Tora et al. (1989) .
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Activating domains of different proteins differ in density 
of charge, the extent of secondary structure and presumably in their
affinity for the target protein. Ptashne has suggested that those 
proteins with activating regions with highest affinity for the target 
protein will be the most effective in "acting at a distance" (Ptashne
(1988) such that activators bearing the same DNA-binding domain but 
with different activating regions, will differ markedly in their 
abilities to activate.
Ptashne has also proposed "squelching" whereby proteins with 
strong activating domains could bind the target protein off the DNA 
preventing interaction of the weaker activating domain of the protein 
bound on the DNA, with the same target protein. This "squelching" 
phenomenon would effectively inhibit gene expression and may explain 
why some viral proteins which are strong activators depress expression 
of cellular genes (Treizenberg et al. (1988). Given the squelching
effect of strong activators, each activator must be blocked when not 
required and this may happen by binding of the activator by an 
inhibitor, e.g. pGAL4 is blocked by pGAL80 in the absence of galactose 
(Ma & Ptashne (1987).
Consistent with Ondek et al. who demonstrated that enhansons 
can be arranged combinatorially to form functional enhancers, Ptashne 
proposes that multiple weak activators might cooperate to interact 
efficiently with the target protein when bound to DNA, although none 
taken separately would be sufficient to interact significantly with the 
target protein.
Since these activating domains can operate in a number of 
different organisms (yeast, Drosophila, tobacco plant, mammalian
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cells), it is presumed that they all interact with a target protein 
common to all these cell types, either RNA polymerase or possibly 
TFIID. Both GAL4 and ATF have been shown to interact with TFIID in such 
a way as to modify TFIID activity (Horikoshi et al. (1988); Horikoshi 
et al. (1988), which may explain how GAL4 and ATF cooperate with each 
other to stimulate transcription by greater than 50 fold while either 
GAL4 or ATF alone only stimulate transcription by 2 to 4 fold (Lin et 
al. (1988); Lee et al. (1987). Cooperative interactions have also been 
demonstrated for factors binding to the CACC motif and the 
glucocorticoid response element in the tryptophan oxidase gene promoter 
(Schule (1988).
Ptashne's model predicts that the total number of activators 
is small compared with the number of regulated genes in a higher 
eukaryote such that common elements are used in different combinations 
to confer the many patterns of cell specific gene expression. If the 
interaction between activator and target was specific, this 
combinatorial organisation of enhansons would not operate.
Ptashne's model of how protein activators operate is 
consistent with the structural and functional analysis of multi-domain 
enhancers such as the SV40 enhancer (figure 1.2) . However, the 
properties of the single domain enhancer, such as the human oestrogen 
responsive element (hERE) (Fromenthal et al. (1988) do not obviously 
fit into Ptashne's model. However recent work with the hERE has shown 
that the human oestrogen receptor (hER) is a multi-domain protein and 
that in addition to the DNA binding domain, there are two activator 
domains, the hormone binding domain (TAF-2) and the A/B domain (TAF-1) 
(Tora et al. (1989). TAF-1, which is cell-type specific, and TAF-2 are
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independent activator domains which can act synergistically with each 
other and with other activators. Thus the hERE is functionally 
equivalent to the multi-domain enhancer and L.Tora et al. suggest that 
modular transcription factors would be particularly useful in the
combinatorial activation of transcription during development when the 
supply of transcription factors is limited.
Ela, which is encoded by the Adenovirus genome, is involved in 
transactivation of a number of different viral and cellular genes as 
well as playing a role in transformation. Ela does not bind DNA 
specifically and stimulates genes which do not appear to share a 
specific promoter element (Berk (1986). The Ela protein region 
necessary for transcriptional activation has been identified (Green et 
al. (1988). Designated Region 3, it consists of two domains one of
which is necessary for activation and the other which mediates 
interaction with the promoter (Lillie and Green (1989) . The activator 
domain of Ela can be replaced by the activator domain of VP16 and the 
promoter binding domain can be replaced by the DNA binding domain of 
GAL4 to activate only genes containing GAL4 recognition sites. However, 
since Ela does not bind a specific DNA sequence, it is proposed that 
Ela is targeted to the promoter by binding of its promoter binding 
domain to the protein binding sites of DNA bound proteins, for example, 
ATF. Given the promiscuity of Ela transactivation, it is likely that it 
recognises many target proteins.
The DNA binding domain and activator domain of GAL4 are
separable (Keegan et al. (1986), and fusion proteins between the GAL4
activator domain and the LexA DNA binding domain renders yeast genes 
with upstream LexA operator sites inducible by galactose (Brent and
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Ptashne (1985).
The observation that GAL4 will activate transcription of 
mammalian genes with a UAS~ (Upstream Activator Sequence of GAL4) and a 
TATA box in mammalian transcription systems (Lin et al. (1988) and will 
function synergistically with both the glucocorticoid receptor 
(Kakidani and Ptashne (1988) and the SV40 enhancer (Webster et al.
(1988) illustrates that the mechanisms of transcription activation have 
been conserved from yeast to man.
The transcription factor TFIID is conserved from yeast to man 
and may be one of the common "target" proteins bound by the activator 
domains of both yeast and mammalian transcription factors (Buratowski 
et al. (1988); Cavallini et al. (1988). In fact, work by Horikoshi et 
al. (1988) shows that GAL4 mediated activation of Adenovirus E4 gene 
involves an alteration in TFIID interactions with the TATA box and that 
these altered TF11D-TATA box interactions are not observed when the 
activator region of GAL4 is deleted. The yeast TFIID gene has been 
cloned (Horikoshi et al. (1989) and sequence analysis reveals that it 
bears homology at the amino acid level to the bacterial sigma factor 
which determines the specificity of RNA polymerase initiation in 
prokaryotes and dissociates from the polymerase shortly after 
initiation . The other factors which associate with the eukaryotic 
transcription initiation complex (TFIIA, TFIIB and TFIIE) may be 
functionally homologous to other subunits of the bacterial RNA 
polymerase (Buratowski et al. (1989).
1.3.3 Modulation of Transcription Factors by Phosphorylation.
Phosphorylation of serine or threonine residues in the 
activating domain of a transcription factor may affect its activity by
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altering protein conformation or by altering hydrogen bonding 
interactions with RNA polymerase or other trans-activators, and may 
provide a mechanism by which activators can respond to external stimuli 
(Hoeffler et al. (1988). Glycosylation of serine or threonine residues 
of proteins may affect activity by preventing phosphorylation (Jackson 
et al. (1988). Induction of heat shock genes is not blocked by protein 
synthesis inhibitors (Zimarino and Wu (1987) and work done to determine 
how heat shock transcription factors (HSTF) are activated upon heat 
shock from their pre-existant inactive form has implicated HSTF 
phosphorylation. In human and Drosophila cells, activation increases 
DNA. binding affinity (Sorger et al. (1987) but in yeast, activation by 
phosphorylation does not affect DNA binding and presumably works by 
potentiating the activator domain of the protein to stimulate 
transcription (Sorger and Pelham (1988).
Phosphorylation is also reported to be responsible for the 
cAMP mediated hormone induction of the rat somatostatin gene (Yamamoto 
et al. (1988) . Genes respond to cAMP via a 43 kD nuclear
phosphoprotein, the CREB factor (also known as ATF) which binds to the 
cAMP Response element (CRE) (Montminy et al. (1986); Montminy et al.
(1987) . CREB binds to CRE as both monomer and dimer but
transcriptional activity is only associated with dimer binding
(Yamamoto et al. (1988) . Yamamoto et al. also showed that treatment of
CREB with protein kinase C (but not protein kinase A) resulted in
increased dimer formation and that phosphatase treatment of CREB 
reduced its transcriptional activity. Their proposal is that cAMP 
activated phosphorylation shifts the equilibrium between inactive
monomers and active dimers towards dimer formation, causing
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transcriptional activation.
The transcription of a number of mammalian genes including 
proto-oncogene c-fos and the cytoskeletal actins is induced by 
stimulation with growth factors and whole serum (Kelly et al. (1983) . 
This serum induced response is mediated by the serum response factor 
which is present but not active in most uninduced cells (Treisman
(1987); Prywes and Roeder (1986) and which binds to the serum response 
element found upstream of serum responsive genes (Treisman (1986) . The 
mechanism by which SRF is activated is not clear but it is probably 
activated by modification of the activator region, not by altering DNA 
binding activity. Phosphorylation probably mediates serum responsive 
induction since agents such as TPA and the calcium ionophore, A23187, 
which induce the same genes, with the same kinetics as serum and act 
through the SRE also activate protein kinase C (Greenberg and Ziff
(1984); Nishizuka (1986).
1.3.4 The Leucine Zipper Motif.
The leucine zipper is a structural motif which was first 
described for the CCAAT/Enhancer binding protein (Landschulz et al.
(1988) but has since been identified in other protein sequences 
including Myc (Landschulz et al. (1988); ATF (Hai et al (1989); Fos 
and Jun (Kouzarides and Ziff (1988).
McKnight et al. originally proposed that the leucine zipper 
facilitates the dimerisation of proteins which contain periodic repeats 
of leucine amino acid residues. Specifically, the monomer contains an 
a-helix with a leucine repeated at every seventh position. It is 
proposed that the leucine side chains extending from each a-helix
37
interdigitate with those from another such a-helix.
The leucine zipper mediates the formation of Fos-Jun 
heterodimers (Ransome et al. (1989); Turner and Tjian (1989); Geinzer 
et al. (1989); Schuermann et al. (1989). Fos, Jun and GCN4 proteins 
bind to the AP-1 recognition site/TPA-response element via a basic 
region which is contributed to by both subunits of the dimer 
(Kouzarides and Ziff (1989) . Domain swap experiments in which the 
leucine zippers of Fos, Jun and GCN 4 are interchanged indicate that 
the leucine zipper is critical in determining the DNA binding activity 
and that the DNA binding domains of these proteins are interchangeable. 
Fos-Jun heterodimers bind strongly to the API recognition site, Fos-Fos 
homodimers fail to bind at all while Jun-Jun homodimers bind only 
weakly (Halazonetis et al. (1988). Scatchard plot analysis indicates 
that the DNA binding activities of different homo- or heterodimers is 
determined by the thermodynamic stability of that dimer which is in 
turn determined by the differing capacities of their leucine zippers to 
interact (Smeal (1989).
DNA binding by C/EBP also involves a bipartite domain 
consisting of basic regions juxtaposed to the leucine zipper of each of 
the two C/EBP polypeptides which make up the functional activator 
(Landschulz, W.H. et al. (1989).
Figure 1.3 illustrates examples of regulatory domains of transcription 
factors which are conserved in a number of different factors as 
discussed above.
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Figure 1.3 Regulatory Domains of Transcription Factors.
This figure illustrates the various structural motifs which have been 
identified in different transcription factors. These motifs are 
involved in DNA. binding, activator function or in dimerisation of the 
factors as discussed in the text.
1.3.5 Nuclear Factor 1 and Members of the CCAAT Box Binding Family.
NF-1 was originally identified as a factor necessary for 
Adenovirus replication (Nagata et al. (1982) which bound to a 
palindromic sequence TGGCMSINNNGCCAA in the adenovirus replication 
origin (Rawlins (1984); Hay (1985). NF-1 has since been shown to bind 
to both viral and cellular gene sequences necessary for the regulation 
of transcription. In particular NF-1 has been shown to bind to sites 
within the promoters of several globin genes including the chicken [3 
and globin genes (Plumb et_ al. (1986), Emerson et_ al. (1985) and at 
-200 bp in the human (3-globin gene (Jones et_ a^ . (1987) . NF-1 has been 
affinity purified and forms a family of polypeptides of molecular
weight 60-66kD (Rosenfeld et al. (1986). Jones et al. (1985, 1987)
presented evidence that NF1 was identical to CTF which recognises the 
CCAAT box of the HSV tk promoter. Antibodies to CTF cross-reacted with 
NF-1. However, more recent work which has attempted to determine the 
extent of identity between CCAAT box binding factors, has demonstrated 
that CTF is a family of factors (including NF-1) which all differ in 
their affinities for different recognition sequences (Chodosh et al
(1988). Comparison of the protein sequence of CPI and NF-1 reveals that 
while there are stretches of shared protein sequence (this may explain 
the cross-reactivity of antibodies), there are also considerable 
differences (Meistemst et al. (1988) . Chodosh et al. also identified 
CP2 which binds to the rat y-fibrinogen promoter CCAAT box and is 
distinct from either CPI or NF-1.
CCAAT/enhancer binding protein (C/EBP) is a heat-stable 
DNA-binding protein first isolated from rat liver (Graves et al. (1986) 
and involved in the regulation of a number of genes including the serum 
albumin gene (Friedman et al. (1989) . The cDNA for C/EBP has been 
obtained (Landschulz et al. (1988) and analysis of the protein reveals 
the presence of a leucine zipper and dimerisation to generate the 
functional transcriptional activator as described previously. The gene 
encoding C/EBP has been localised to chromosome 7 and high levels of 
C/EBP mRNA have been detected in fully differentiated tissues that 
metabolise lipids and cholesterol (Birkenmeier et al. (1989). Evidence 
suggests that C/EBP expression is induced in response to changing 
physiological conditions during development.
NF-Y recognizes the Y-motif of Major HistoCompatiblity (MHC) 
Class II genes which contains an inverted CCAAT motif, mutation of
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which abolishes NF-Y binding (Dorn et al. (1987). NF-Y has been shown
, , 2+to be present m  most cells, is sensitive to Zn chelators and has a 
molecular weight of about 250-300 kD (Hooft van Huijsduijnen et al.
(1987) . Another factor, NF-Y* also binds to the Y motif but does not 
cross-compete with NF-Y suggesting that it is a distinct protein.
ACF is a liver specific factor which recognizes and binds to 
the CCAAT box of the rat albumin gene (Raymondjean et al. (1988) and
may be the same factor identified by Lichtsteiner et al. (1987) as
binding to half an NF-1 site in the albumin promoter.
What is the function of all these different CCAAT binding 
factors and to what extent are they conserved? Santoro et al. (1988) 
presented evidence that a family of CCAAT binding factors are all 
encoded by a single gene in the human genome and that diversity is 
generated by differential RNA splicing. Chodosh et al. demonstrated 
that CP-1, CP-2 and NF-1 are all heteromeric and that the DNA binding 
domain of each protein was separate from the activator domain. 
Moreover, they demonstrated that the HAP2 and HAP3 proteins of yeast 
which activate CYC1 expression from UAS2 could substitute for the CP1B 
activator subunit and CP1A DNA binding subunit respectively, 
illustrating that the CCAAT binding factor is functionally conserved in 
evolution. The multimeric organisation of the CCAAT binding factor 
could conceivably allow it to respond to a variety of environmental 
signals with different activator domains operating in response to 
different signals.
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1.4. GLOBIN GENE EXPRESSION.
Mammalian globin proteins are encoded by a family of genes, 
all derived from a common ancestral gene which has duplicated and
diverged over a period of 500 M years (Romero-Herrera et al. (1973). 
Different globin genes as already discussed are expressed at different 
stages in mammalian development (embryonic, foetal and adult) but all 
are expressed exclusively in erythroid tissue. The a and (3 globin 
genes are organised into two distinct clusters, which map to different 
chromosomes (Deisseroth et al. (1977, 1978). a and [3 globin genes are 
highly conserved in their coding regions but diverge significantly in 
flanking and intervening sequence. Both a and (3 globin genes are 
interrupted by two introns at similar positions but intron 2 of the (3 
globin gene is considerably larger than that of the a globin gene. 
(Review by Maniatis et al. (1980) . Figure 1.4 summarises the 
organisation of globin genes in the three species most extensively 
studied.
There are three related aspects of globin gene expression to 
be analysed; how different globin genes come to be expressed at
different stages of development (Reviewed by Karlsson and Nienhuis
(1985), how globin genes are exclusively expressed in erythroid tissue 
and how globin gene expression is regulated during erythropoiesis.
The regulation of the human a and (3 globin genes differs in 
a number of aspects. In humans, the adult a globin gene is transcribed 
earlier in development than the adult (3 globin gene (Peschle et al. 
(1984, 1985). Another observation which illustrates differential a- and 
(3-regulation is the enhancer dependence of the (3-globin gene in
transient transfection assays (Banerji et al. (1981); Humphries et al.
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(1982). This enhancer dependence can be compensated for by trans-acting 
viral products (Green et al. (1983); Treisman et al. (1983). Following 
stable integration into the MEL cell genome the human a-globin gene is 
expressed constitutively while (3 is expressed only at low and inducible 
levels (Chao et al. (1983); Charnay et al. (1984); Wright et al.
(1983). However, despite these differences in regulation the a and (3 
globin chains come to be expressed in vivo in equimolar amounts in the 
terminally differentiated cell.
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Figure 1.4 The Organisation of Globin Genes.
The figure illustrates the spatial organisation of the globin genes in 
the a- and (3- globin gene loci of chicken, mouse and human. Individual 
globin genes are represented by open boxes. Arrows indicate the
presence of DHSS which have been mapped in vivo. Arrows are
superscripted by GFP to indicate the presence of a genomic footprint at 
that DHSS; "E" to indicate that the DHSS is only present in cells at
the embryonic stage of development and by "A" to indicate that the DHSS
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is only present in cells at the adult stage of development. Hatched 
boxes superscribed by "e", indicate the presence of an erythroid 
specific enhancer.
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Figure 1.5 Modularity of Globin Gene Promoters.
The figure illustrates the organisation of regulatory elements within 
the promoters of six different globin genes and within the erythroid 
promoter of the human porphobilinogen deaminase gene. There are four 
types of element; the TATA box, CCAAT-like sequences, the CACC box and 
the NF-E1 recognition element containing the consensus sequence GATAA. 
The position- of the TATA box is conserved in all of the globin gene 
promoters but the organisation of other elements differs between 
promoters. It is argued here that these differences in organisation 
will be reflected in the conformation of the transcription complex and 
in the efficiency with which the promoter interacts with enhancer or 
other regulatory sequences.
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1.4.1 Globin Gene Promoter Elements.
As previously discussed in 1.3.1, analysis of different 
promoters and enhancers, including globin gene regulatory elements, has 
revealed their modular nature.
The demonstration by Wright et al. (1984) that sequences both 
5' and 3' of the human adult (3-globin gene are necessary for regulated 
expression of the gene was followed by intensive deletion and mutagenic 
analysis of flanking sequence in the search for regulatory elements. 
In the rabbit (3-globin 5' region, three elements were shown to be 
essential for expression in transient assay; the ATA box at -30 bp, the 
CCAAT box at -75 bp and the CACC box at -85 bp and -100 bp (Dierks et 
al. (1983) . These elements were subsequently shown to be conserved in 
the 5' promoter region of all the globin genes studied and their 
importance to regulation confirmed by mutagenic analysis of each 
element in the context of each promoter (Myers et al. (1986); Cowie et 
al (1988) . Figure 1.5 summarises the organisation of promoter modules 
in different globin genes.
A nuclear factor aCPl which binds to the CCAAT box of the 
mouse al-globin gene had been previously partially purified (Cohen et 
al. (1986) and did not show erythroid specific tissue distribution. 
Subsequent work (Barnhart et al. (1988) identified a second factor aCP2 
binding to a second site overlapping the CCAAT box. The binding 
activity of OCP2 is activated 2 to 3 fold when MEL cells are induced to 
differentiate whereas the binding of aCPl is reduced 3- to 5-fold. 
Both aCPl and OCP2 are distinct from CTF/NF1. A third binding factor, 
a-IRP which interacts with a site, adjacent to that of aCPl, contains 
the sequence motif, CACCC (Barnhart et al. (1988) . Binding of aCPl to
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its cognate binding site prevents binding of OCP2 and alRP. Barnhart 
et al. (1988) propose that aCPl acts as a repressor of al-globin gene 
expression during MEL cell differentiation and may be analagous to the 
CCAAT Displacement Protein (CDP) identified in sea urchin embryo 
(Barberis et al. (1987).
Cohen et al. (1986) showed that aCPl binds weakly to the mouse 
(fna-'°r CAAT box. My own work indicates that the pma o^r CCAAT box is 
bound by two factors, one of which is aCPl.
Interestingly, while Myers et al. (1986) showed that mutation 
at -79 bp and -78 bp of the mouse (3ma-]0r CCAAT box from G— >A, caused
up-regulation of expression in HeLa cells, Cowie et al. (1988) have
shown that this same mutation has no effect on expression in MEL cells 
while mutation at -69 bp and -65 bp reduces expression in MEL cells but 
not in HeLa cells. This work suggests that the pp^01" CCAAT box is 
bound by different factors in the different cell types.
Cowie et al. compared CCAAT box sequences from a, P and y
sequences from several different species.
a AG CCAAT GA
(3 GG CCAAT CT
J GA CCAAT AG
It was suggested the differences in the 5' and 3' flanking sequences
played a role in determining the differences in timing of expression of
the genes in development.
The human ^ y-globin promoter contains two adjacent CCAAT box 
elements -85 bp and -100 bp which interact with two different factors 
(Superti-Furga et al. (1988) . The proximal element has greater 
affinity for the ubiquitous CPI factor which interacts with the human
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a-globin gene (Chodosh et al. (1988).
The distal CCAAT box binds an erythroid specific factor, 
NF-E1, which binds simultaneously with CPI binding to the proximal site 
(Superti-Furga et al (1988). Flanking sequence is critical in 
determining NF-E1 binding. NF-E1 also binds to the CCAAT box of the 
human ^-globin gene. A third factor which has similar properties to the 
sea urchin CDP also recognizes the proximal CCAAT box and may compete 
with CPI for this site, but its role in y-globin gene regulation is not 
understood.
Identifying the molecular lesions responsible for human 
thalassaemias and the mapping of deletion and point mutations led to an 
early understanding of how human globin genes are developmentally 
regulated. A G— >A transition at -117 bp of the ^y-globin gene results 
in continued expression of this foetal globin gene in the adult 
organism, a condition known as Hereditary Persistance of Foetal 
Haemoglobin (HPFH) . This mutatioh at -117 bp alters the binding 
activity of all three factors CPI, CDP and NF-E1 for their cognate 
binding sites; the binding activity of CPI and CDP increases while that 
of NF-E1 decreases. Superti-Furga et al. suggest that NF-E1 may 
specifically repress y-globin gene expression in adult erythroid 
tissue but stimulate expression of the adult (3-globin gene. A variant 
form of HPFH in which there is a deletion of 13 bp in this region which 
abolishes the binding of all three factors, induces the same phenotype 
as the point mutant (Mantovani et al. (1989).
A different form of HPFH involves a T— >C transition at
Q
-175bp of the y-globin gene. This change abolishes binding of OTF-1
Q
to the octabox of the y-globin gene promoter and simultaneously
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increases binding of the erythroid factor, NF-E1 (Mantovani (1989). 
Abolishing the NF-E1 site abolishes the mutant overexpression 
phenotype while inactivation of the OTF-1 site has no effect on 
overexpression, suggesting that it is the mutation of the NF-E1 site 
which is responsible for overexpression (Nicolis et al. (1989); Martin 
et al. (1989).
Figure 1.6 Lesions in the Human y-Globin Gene Promoters which Leads to 
HPFH.
The figure is taken from "Highlights of Modern Biochemistry:Proceedings 
of the 14th International Congress of Biochemistry", and a paper 
published therein by Superti-Furga' and Busslinger. It shows the
entr<*r ***«
r. —  " a 5**!!"**1fc*, O,Ml*H ©  |  (pAYMTH ' j '* * » 0rw rn
TCCTCnd G G r,G C C C C n C a a CACACTATCTCA^TGCAAATlATCTGTCTGA
TGATAG -ics
CCAAT CCAAT
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position of recognition sites for DNA-binding proteins and the position 
of HPFH mutations which map within or close to these sites.
et al. (1985); Plumb et al. (1986) has identified four protein binding 
elements: a G-rich sequence, two overlapping CACC binding sites, a CAAT 
box and an inverted repeat sequence which bind factors BGP1, CON, CAT
and PAL respectively. In in vitro transcription systems, PAL can be
substituted for by purified NF-1 (Emerson et al. (1989) and PAL binding 
activity increases during chick development (Jackson et al(1989). PAL
has an inhibitory effect on (3^ globin gene transcription and it has
been shown that binding of PAL and CON are anti-cooperative. As 
development progresses and the PAL site becomes occupied, binding of 
CON to the CACC site is lost. BGP1 is erythroid specific and its 
activity is correlated with nucleosome displacement from the region of 
the chicken (3^ globin gene promoter (Lewis et al. (1988) .
sequences of the human {3 adult promoter (Antoniou et_ al. (1988) . The
promoter contains a TATA box (-30), a CCAAT (-70), two CACC boxes 
(-85,-100) and an NF-E1 site (-120) which are necessary for correct 
expression. The distal region of the promoter contains four elements: 
a sequence AAGCCAGTG (-155) called Box 1 which is conserved at a 
similar position in the promoter of the mouse g]_0bin gene, two
copies of NF-E1 (-120,-190) and nuclear factor 1 (-200). The presence 
of Box 1 and NF-E1 (-120) is necessary for inducible expression (de 
Boer et al. (1988).
Analysis of the 5' (Emerson
There has been extensive analysis of the important regulatory
49
1.4.2 Globin Gene Enhancer Sequences.
As well as sequences found 5' of globin genes, 3' sequences 
have been shown to be critical. These include sequences in the second 
intron of the mouse pma30r globin gene (Gabon and Housman (1988), 
sequences 3' of the chicken adult a- (Knezetic and Felsenfeld (1989) 
and (3-globin genes (Choi et al. (1986); Hesse et al_. (1986), and 
sequences 3' of the human y- and (3-globin genes (Bodine and Ley, 
(1987); Kollias et al. (1987); Wall et al (1988); Behringer et al.
(1987).
The chicken (3 globin gene enhancer lying 307 bp 3' of the 
adult gene is required for correct tissue-specific expression but also 
for correct developmental expression of both the adult (3 and chicken 
embryonic 8 globin genes (Choi and Engel (1986); Nickol and Felsenfeld
(1988). The enhancer upregulates expression from a linked reporter gene 
in transient transfection experiments into chicken cells by 60-fold 
(Reitman and Felsenfeld (1988) . Functional studies and analysis of the 
protein factors interacting with the 3' enhancer reveals that it 
consists of five enhansons: the TGGCA protein (an NF-1 like factor) 
binds to Region I (Rupp and Seppel (1987); AP-1 and AP-2 bind to Region 
II; a CACC binding factor binds to Region III and finally erythroid 
specific factor, NF-E1, binds to Region IV (Emerson et al. (1987). To 
date it is the only enhancer detected in the p-globin locus. It is 
proposed that in definitive erythrocytes expressing adult (3 globins, 
the enhancer interacts with positively acting element(s) present 
between -20 bp and -112 bp in the promoter of the adult P globin gene, 
called the stage-selector element (SSE).
The SSE of the chicken P^ globin gene may be competing with a
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similar element in the promoter of the £ globin gene for interaction 
with the enhancer such that in the adult, the (3 SSE is dominant over 
the 8 SSE, but in the embryo the interaction is reversed. A 
trans-acting factor, termed NF-E4, which recognises the sequence 
AAGAGGA (from -55 to -61 bp) in the chicken p^ globin gene promoter has 
been shown to be active exclusively in adult erythroid tissue. This
suggests that it may be involved in developmental regulation of chicken 
P globin genes and its recognition site may be the SSE. It remains to 
be shown that this factor bound at its site in the promoter of the j3^ 
globin gene affects interactions of that promoter or the £ globin gene 
promoter with the chicken P globin gene enhancer. It has not been 
reported whether there is any overlap in function between NF-E4 and 
PAL, which has also been shown to have developmentally regulated
activity (Jackson et al (1989); Gallarda et al. (1989).
A tissue-specific enhancer directing correct developmental 
expression is also present in the 3' region of the human P globin gene 
(Kollias et al. (1987) and like the chicken enhancer it is necessary
for proper expression of not just the adult genes, but is also
important for expression of the foetal y genes (Trudel and Costantini 
(1987). Unlike the chicken p-globin gene locus, a second 
tissue-specific enhancer in the P cluster 3' of the gene has been 
identified but the role of this enhancer in developmental regulation is 
not clear.
Human foetal y-globin genes when introduced into transgenic 
mice are expressed as embryonic genes while human p globin is expressed 
only in the adult mouse. A hybrid 7p globin gene containing y 5' 
sequences and p 3' sequences is expressed in both embryonic and adult
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tissue of the transgenic mice (Kollias et al. (1986). This work points 
out that although the developmental regulatory sequences and factors 
have been conserved from mouse to man, the actual timing of the 
developmental switch has changed, presumably as a result of altered 
timing of the activity of a regulatory factor. This work also 
indicates that the adult (3 3' enhancer is sufficient in this context 
for activation of transcription from the y promoter and that the y 3' 
enhancer is not essential.
Fusion of uninduced MEL cells with human K562 cells resulted 
in activation of the mouse embryonic (3 globin genes and activation of 
the human adult (3 globin genes (Baron and Maniatis (1986) illustrating 
that the mouse embryonic globin genes are not irreversibly repressed in 
adult tissue and can be activated by human trans activating factors. 
The switch from human foetal to adult globin gene expression in these 
hybrids depends upon retention of human chromosome 11 (Papayannopoulou, 
et al. (1986) suggesting that the trans-acting factors involved in the 
y - (3 switch are linked to the (3-globin cluster on chr.ll (Melis et al. 
(1987). Behringer et al. (1987) have demonstrated that in a similar 
fashion to the chicken {3 globin gene enhancer, the human (3 3' enhancer 
interacts functionally with 5' sequences in transgenic mice. Grosveld 
suggests that the expression pattern is determined by the relative 
affinities of stage-selector elements in the promoter for limiting 
transcription factors in chicken and in human and that the 
concentrations of these transcription factors vary through development. 
Grosveld, F. (pers. comm.) has shown that in transgenic mice, deletion 
of the adult (3 globin gene promoter results in up-regulation of tissue 
specific expression of the y-globin genes in the adult mouse and
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conversely deletion of the y-globin gene promoter results in tissue 
specific up-regulation of the adult [3 gene.
1.4.3 Erythroid Factor 1 (NF-E1).
The recognition site for erythroid factor 1 is present in the 
promoters and enhancers of human, mouse and chicken globin genes and 
also in the erythroid promoters of the human and mouse porphobilinogen 
deaminase gene (Plumb et al. (1989); deBoer et al. (1988); Mignotte et 
al. (1989); Evans et al. (1988); Perkins et al (1989); Mantovani et 
al. (1988); Porscher et al. (unpublished results). NF-E1 binding sites 
are also present within the human (3 globin gene dominant control 
regions (F.Grosveld et al. (pers.comm.) . This work suggests that NF-E1 
has a role not only in modulating the transcription initiation complex 
of erythroid specific genes but also in activating chromatin domains in 
an erythroid specific fashion.
The NF-E1 cDNA has been obtained for mouse, human (Tsai et al. 
(1989b) and chicken (Evans and Felsenfeld (1989) and Southern blot 
analysis indicates that the NF-E1 gene is present in a single copy in 
the genome of mouse. The factor has been purified as 20 kD, 38 kD, 50 
kD and 115 kD polypeptides for mouse, chicken- and human. It is 
suggested that the 20 and 38 kD peptides, which have retained DNA 
binding activity, are degradation products of the 50 kD protein and 
that the 115 kD species is a functional dimer of the 50 kD monomer 
(Tsai et al (1989b). NF-E1 is a member of the class of zinc finger 
DNA binding factors. There are two putative zinc finger motifs in the 
mouse, human and chicken proteins and while there is a high degree of 
homology between all three proteins within the zinc finger domains
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(88-90%), the amino acid sequence of the chicken protein has diverged 
considerably from the mouse and human proteins at its N-terminal and 
C-terminal ends. The zinc fingers of each protein are themselves well 
conserved suggesting that they are duplications of each other (Tsai et 
al (1989b), Evans & Felsenfeld (1989), Trainor et al (1990).
Preliminary studies of the expression of NF-E1 show that the 
mRNA is present only in erythroid tissue as expected from previous work 
on the tissue distribution of NF-E1 protein DNA binding activity. NF-E1 
mRNA and DNA binding protein are detected in erythroid cells before 
globin genes come to be expressed and given the presence of NF-E1 
binding sites in the dominant control regions (Fraser pers.comm.), it 
is likely that NF-E1 first comes to be expressed in one of the earlier 
erythroid progenitor cells possibly in response to erythropoietin 
stimulation.
1.5 OUTLINE OF EXPERIMENTAL WORK.
My work began at a time when it had just been shown by saturation 
and linker scanning mutagenesis that intact TATA (-30 bp), CCAAT (-75 
bp) and CACC (-90 bp) boxes were an absolute requirement for correct 
initiation from the mouse globin gene promoter (Chamay et al.
(1985), Myers et al. (1986). The function of these mutant promoters had 
been tested under the control of the SV40 enhancer in HeLa cells, a 
non-erythroid cell line.
Both the TATA box (-30 bp) and the CCAAT box (-75 bp) are 
conserved in the sequence and position in many RNA polymerase II 
transcribed genes. The CACC box (-90 bp) was originally identified in
the rabbit p globin gene (Dierks et_ al. (1983) and is conserved in most
globin gene promoters but has since been identified in the promoters of 
non-erythroid genes. As such it was not obvious how these particular 
elements could confer erythroid and developmental regulation upon 
individual globin genes.
I set out to characterise promoter elements necessary for correct 
tissue-specific and developmental regulation of the mouse pma-^°r globin 
gene. The approach I chose was based on work by Sheffery et al.; they 
identified a DHSS in MEL cells in the mouse pfna3or globin gene promoter 
stretching from -250 to -50 bp 5' of the start site of initiation, so I 
used DNAase 1 footprinting and gel shift assays to identify any protein 
binding sites in this promoter sequence (Chapter 3) . DNAase 1 
footprinting studies of the chicken P^ and pH globin genes had revealed 
the presence of protein binding sites in the promoters of these genes 
which were important in their transcriptional regulation (Emerson et
al. (1985), Plumb et al. (1986).
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I expected to observe footprints over the TATA, CCAAT and CACC 
boxes and hoped to observe additional footprints which may be erythroid 
specific. I was successful in identifying several new protein binding 
sites (Chapter 3) and characterised the binding activity to these sites 
by gel retardation assay (Chapter 4). The function of these elements 
was then examined in transient (chapter 6) and stable (chapter 7) 
transfection assays in murine erythroleukaemia cells and in 
non-erythroid cell lines. The conclusions drawn from my results are 
summarised and discussed in chapter 8.
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Figure 2.1 Recombinant Plasmids.
Figure 2.1 illustrates the recombinant plasmids used in this work.
pHSV-flgal. used as internal control to standardise for transfection 
efficiency, is derived from the lac Z - containing plasmid pCHHO (Hall 
et al (1983). Transcription of the lac Z gene is driven by the HSV-2 
IE-5 promoter (IE-5), obtained as a 210 bp BamHl fragment, via cloning 
into the BamHl site of the shuttle vector pIC20H and inserted as a 310 
bp Hindi 11 fragment into the Hindi 11 site created by removal of the 
mouse mammary tumour virus promoter used to drive transcription in 
pCHHO.
Homer 6 used to confer neomycin resistance upon cells in the generation 
of stable transfect ant s. This plasmid was originally derived as 
described by Spandidos & Wilkie (1984) .
paCATl contains a 700 bp Ncol fragment from the mouse al-globin gene 
blunt-end ligated into Smal site of a pUC12 derived plasmid containing 
a 900 bp Xbal/BamHl CAT reporter gene fragment and HSV-2 IE-5 
transcription termination signals.
pIC20R used in sub-cloning and as carrier plasmid in transfection 
experiments. Generated as described by Marsh et al (1984) .
pOGH used as a negative control plasmid for hGH expression in transient 
and stable transfection assays.
pTKGH used as a positive control for hGH expression in transient and 
stable transfection assays.
Both pOGH and pTKGH were obtained from Biogenesis Ltd. and were 
originally described by Selden et al (1986).
pP346GH used as a basic test construct and from which all mutant 
promoter constructs are generated. A 366 bp Hindlll/BamHI fragment 
spanning from -346 to +20 bp of the mouse p™a9or globin gene was cloned 
into the Hindi 11/BamHl sites of pOGH.
p|3 (M) GH was derived from pP346GH by the blunt-end ligation of a 415 bp 
PCR generated fragment spanning from +1693 to +2108 3'of the
transcription initiation site of the mouse pf1^ 017 globin gene into the 
Eco RI site of pp346GH.
pp (A) GH was derived from pp346GH by ligation of a 600 bp Eco RI 
fragment containing the chicken P globin gene enhancer spanning from 
+1616 to +2216 3' of the transcription initiation site of the chicken 
pr globin gene into the Eco RI site of pp346GH.
pp7.2 was generated by ligation of a 7.2 kb Eco RI fragment from -1415 
to +5785 bp relative to the transcription initiation site of the mouse 
pma-*or globin gene into the Eco RI site of pUC18.
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CHAPTER 2 MATERIALS AND METHODS.
PART A : Materials.
2.1 Molecular Clones.
Recombinant plasmids used in this study are listed in Figure 2.1. 
These clones were stored in TE buffer (10 mM Tris, 1 mM EDTA, pH 
8.0) at -20°C. pUC8 based clones were propagated in E.coli 
K12-derived bacterial strain JM83 (ara, A(lac-proAB), rpsL, <D80, 
lacZAM15) .
2.2 Chemicals, Enzymes and Other Materials.
All restriction enzymes, polymerases and other DNA modifying 
enzymes were obtained from Boehringer Mannheim, Lewes, East 
Sussex, with the exception of Taq 1 DNA polymerase which was 
obtained with lOx Taq polymerase buffer from NBL, Cramlington, 
Northumberland.
Protease inhibitors, protein kinase A catalytic subunit, 
ribonuclease A, Brij-35, diethylpyrocarbonate, |3-Mercaptoethanol, 
lysozyme, calf thymus DNA cellulose,
o-nitrophenyl-p-D-galactopyranoside, Triton X-100, HMBA 
(N,N'-hexamethylene-bisacetamide) and phosphatase inhibitors were 
obtained from The Sigma Chemical Company, Poole, Dorset. 
Deoxyribonucleotides, deoxyribonuclease 1, yeast t-HNA, DNA size 
markers, dialysis tubing, agarose, low melting point agarose and 
urea were obtained from Gibco/BRL, Paisley.
Double-stranded poly(dl) (dC) was obtained from Pharmacia Ltd., 
Milton Keynes.
Geneclean Kit for DNA fragment purification was obtained from
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Stratatech Scientific Ltd.,London.
Elutitip-D columns for DNA fragment purification was obtained 
from Schleicher and Schuell, Dassel, FRG.
Biogel A-50M agarose beads for gel filtration column 
chromatography were obtained from Bio-rad Laboratories Ltd., 
Watford.
Single stranded oligodeoxyribonucleotides were synthesised on an 
Applied Biosystems 381A automated DNA synthesiser and purified by 
high performance liquid chromatography (Oswell DNA Service, 
University of Edinburgh).
Polymerase chain reactions were carried out using the Perkin 
Elmer Cetus DNA Thermal Cycler.
Phosphate Buffered Saline tablets were supplied by Oxoid Ltd. 
Water-saturated phenol was obtained from Rathburn Chemicals Ltd., 
Walkerbum.
Gauze was obtained from Vemon-Carus Ltd. Preston.
Absolute ethanol was obtained from James Burroughs (FAD) Ltd., 
Essex.
Nalgene filters were obtained from Techmate Ltd., Luton.
Thin layer chromatography plates were obtained from Camlab, 
Cambridge.
Maxam-Gilbert sequencing reagents were obtained from Du Pont 
International.
X-QMAT AR XAR5 Film was obtained from Kodak, Glasgow.
All other chemicals and solvents were obtained from BDH Ltd., 
Poole, Dorset.
58
2.3 Media and Antibiotics.
L-broth
2xTY
L-agar
H-agar
H-top agar
Superbroth 
Soln. A
1% w/v bacto-tryptone, 0.5% w/v yeast extract, 
1% w/v NaCl. (Ampicillin added where required 
at 5oug/ml.
1.6% w/v bacto-tryptone, 1% w/v yeast extract, 
0.5% w/v NaCl.
L-broth containing 1.5% w/v agar.
1% w/v bacto-tryptone, 0.8% w/v NaCl,
1.2% w/v agar.
1% w/v bacto-tryptone, 0.8% w/v NaCl,
0.8% w/v agar.
12.5% w/v K2HP04, 3.5% w/v KH2PC>4
: 1.2% w/v bactotryptone, 2.4% w/v yeast extract
0.5% v/v glycerol.
Soln. B :
(Mix soln. A and soln. B in ratio 9:1 and pH to 7.2) 
Bacto-tryptone, bacto-agar and yeast extract supplied by DIFCO 
Laboratories, Detroit. Antibiotics supplied by The Sigma Chemical 
Company. X-GAL (5-bromo-4-chloro-3-indolyl-f3-galactoside) and 
IPTG (isopropyl-[3-D-thio galactopyranoside) were supplied by BRL.
2.4 Cell Lines and Cell Culture Media.
Cell Line
F4-12B2
M707/T
C88
Characteristics 
Adherent mouse erythroleukaemia cell line 
(Ostertag etal (1979).
Suspension mouse erythroleukaemia cell line. 
(Harrison et al (1978).
Suspension mouse erythroleukaemia cell line.
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(Deisseroth & Hendrick (1978).
F4-12B2, M707/T and C88 are Friend virus induced erythroleukaemic 
cell lines.
STO
NIH 3T3 
J774.2 
K562 
HeLa 
F9
Media.
F4-12B2, M707/T, C88, STO, J774.2, Hela and K562 were all grown
in Special Liquid Medium (SIM) fortified with 10% foetal calf 
serum and 4mM L-Glutamine. NIH 3T3 were grown in SIM plus 10% 
new-born calf serum and 4mM L-Glutamine. F9 cells were grown in 
Dulbeccos Modified Eagle Medium plus 10% foetal calf serum, 4mM 
L-Glutamine and ImM sodium pyruvate.
All media, minerals and GENETICIN/G418-sulphate was supplied by 
GIBCO/BRL Ltd.
2.5 Radio-labelled Materials.
14 32
D-threo-dichloroacetyl-1- C-chloramphenicol and [a- P]dCTP,
[y-32P]ATP, [a-32P]ddATP were supplied by Amersham
Adherent mouse fibroblast cell line.
(Martin & Evans (1975) .
Adherent mouse fibroblast cell line.
(Anderson et al (1979) .
Adherent mouse macrophage cell line.
(Ralph & Nakoinz (1977).
Suspension human erythroid cell line.
(Lozzio & Lozzio (1975).
Adherent human cervical carcinoma cell line. 
(Gey et al (1952).
Suspension mouse embryonal carcinoma cell line 
(Bemstine et al (1973) .
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125International. [ I] labelled monoclonal antibody to human 
growth hormone was supplied by BioGenesis Ltd. as part of their 
Allegro hGH immunoassay.
2.6 Buffers and Solutions.
lOx TBE 10.8% (w/v) Tris-Cl (pH 7.8),
5.5% (w/v) boric acid, 0.93% (w/v) EDTA. 
lOx TAE 4.84% (w/v) Tris, 1.142% (v/v) acetic acid,
1.8612% w/v EDTA, pH 7.8.
Storage Buffer (SB) 50 mM NaCl, 20 mM HEPES (pH 7.9),
5 mM MgCl2, 0.1 mM EDTA,
20% (v/v) glycerol,
1 mM dithiothreitol.
X mM (NH4)2S04, 20 mM HEPES, 5 mM MgCl2,
0.1 mM EDTA, 1 mM dithiothreitol,
20% (v/v) glycerol, 0.1% Brij 35, (pH 7.9). 
0.25 M sucrose, 5 mM MgCl2,
10 mM Tris-Cl (pH 7.9).
1 M NaCl, 20 mM Tris-Cl (pH 7.4),
1 mM EDTA.
0.2 M NaCl, 20 mM Tris-Cl (pH 7.4), 1 mM EDTA.
0.1 M NaCl, 10 mM Tris-Cl (pH 7.8) 1 mM EDTA.
10 mM Tris-Cl (pH 7.8), 1 mM EDTA.
2.5 mM ATP, 10 mM spermidine, 20 mM DTT,
2 mM EDTA, pH 7.8 
0.2 M NaCl, 0.2 M Tris-Cl (pH 7.8),
50 mM MgCl2.
E Buffer x
TMS
High Salt 
Buffer (HSB) 
Low Salt 
Buffer (LSB) 
STE 
TE
lOx Ligation 
Buffer (LB) 
5x Ligation 
Salts (LS)
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lOx T4 Buffer 330 mM Tris-acetate (pH 7.9), 660 mM KCHgCC^
100 mM Mg(CH3C02)2, 5 nM DTT, 1 mg/ml BSA. 
lOxKinase buffer 0.5 M Tris-Cl (pH 7.6), 0.1 M MgCl2, 0.05 M DTT. 
lOx CIP buffer 0.5 M Tris-Cl (pH 9.0), 10 mM MgCl, 1 mM ZnCl,
10 mM spermidine.
5% polyacrylamide 0.25% (w/v) N,N'-methylene bisacrylamide
4.75% (w/v) acrylamide (1:19 bis.:acryl.) 
0.2% (v/v) N, N, N', N' -tetramethylethylenediamine,
6% denaturing 
polyacrylamide
lx TBE, 0.1% (w/v) (NH4)2S2Og 
4.75% (w/v) acrylamide, 8 M urea,
0.25% (w/v) N,N'-methylene bisacrylamide 
0.2% (v/v) N,N,N' ,N' -tetramethylethylenediamine,
lxTBE, 0.1% (w/v) (NH4)2S20?
lOx Loading 
Buffer 
Sequencing Loading 
Buffer
Proteinase K 
Buffer 
Solution 1
Solution 2 
Footprinting
Stop Buffer
50% (v/v) glycerol, 50% (v/v) TE,
0.5% bromophenol blue.
95% (v/v) deionised formamide,
0.1% (w/v) xylene cyanol FF,
0.1% bromophenol blue.
10 mM Tris-Cl (pH7.8), 5 mM EDTA, 0.5% SDS.
50 mM glucose, 25 mM Tris-Cl (pH 7.8),
1 mM EDTA, 5 mg/ml lysozyme.
0.2 M NaOH, 1% SDS.
83 mM Tris-Cl (pH 7.9), 8.3 mM EDTA,
1% (w/v) SDS,
107 mM NaCl, 0.4 mg/ml proteinase K,
67 fig/ml yeast tRNA.
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2x HBS 1 mM Sorensen Salt, 50 mM HEPES (pH 7.1),
0.28 M NaCl. Filter sterilise. 
(3-galactosidase assay.
Solution A 60 mM Na2HP04, 40 mM NaH2PC>4, 10 mM KC1,
1 mM MgCl2, 50 mM p-Mercaptoethanol.
Solution B 60 mM Na2HP04, 40 mM NaH2PC>4,
2 mg/ml o-nitrophenyl-p-D-galactopyranoside (ONPG) .
Solution C 1 M Na2C03
PART B : METHODS.
Nucleic Acid Preparation.
2.7 Large Scale Preparation of Plasmid DNA.
(This was carried out by a modified version of the alkaline lysis 
method for plasmid preparation described initially by Birnboim 
and Doly (1979) .
A fresh 5 ml overnight bacterial culture was used to inoculate 
200 ml of superbroth and was incubated in an orbital shaker at 
37°C for 30 hours. The bacteria were pelleted at 4000 g for 10 
minutes at 4°C. The supernatant was discarded and the pellet 
washed with 5 ml cold STE pH 8.0. The pellet was then resuspended 
in 5 ml of Solution 1 and incubated at 19°C for 5 minutes, 
incubated on ice for 2 minutes before 10 ml of Solution 2 was 
added. The mixture was incubated on ice for a further 10 minutes 
before adding 7.5 ml 3 M sodium acetate pH 5.2, vortexing for 10 
seconds and leaving on ice for 10 minutes. After centrifugation 
at 3000 g for 15 minutes at 4°C, the supernatant was filtered 
through gauze and isopropanol (0.6 volumes) was added. After 15 
minutes at 19°C, nucleic acids were pelleted by centrifugation at
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3000rpm for 15 minutes at 19°C. The pellet was resuspended in 5ml 
of TE and incubated with 50 (il of boiled ribonuclease A solution 
(10 mg/ml) for 30 minutes at 37°C. Nucleic acids were extracted 
three times with an equal volume of 1:1 phenol: chloroform and 
once with an equal volume of chloroform. Plasmid DNA was then 
precipitated with 2 volumes of absolute ethanol at 19°C for 15 
minutes, pelleted at 3000 g for 15 minutes at 4°C and resuspended 
in 1 ml of TE/0.1% SDS. Plasmid DNA was further purified gel 
filtration chromatography. The DNA solution was loaded onto a 30 
cm xl.5 cm Biogel A-50M agarose bead column equilibrated with 
TE/0.1% SDS. The column was run in TE/0.1% SDS and the absorbance 
at 260 nm and 280 nm of 1.5 ml fractions collected from the 
column was determined by spectrophotometry. The first peak in 
absorbance represents plasmid DNA and these fractions were 
pooled, the DNA precipitated twice in ethanol and resuspended in 
TE at a concentration of 1 mg/ml. The second peak, which is well 
separated from the first, contains small molecular weight 
impurities and was discarded. It was found that running the 
column in 0.1% SDS, as well as inhibiting any nuclease activity, 
also increased the separation of the first plasmid DNA-containing 
peak from the second peak of low molecular weight impurities. 
Typically, this method of plasmid DNA preparation yielded 1-2 mg 
of plasmid DNA. The quality, yield and the extent of plasmid 
supercoiling was routinely checked by spectrophotometry and 
agarose gel electrophoresis.
2.8 Small Scale Preparation of Plasmid DNA.
1. 5 ml of L-broth containing selective antibiotic was inoculated
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with the plasmid carrying bacteria and incubated overnight at 
37°C.
2. 1 ml of overnight culture was pelleted in the microfuge for 30 
seconds.
3. The supernatant was discarded and the bacterial pellet 
resuspended in 100 (ll of Solution 1 at 19°C for 5 minutes.
4. 200 fil of Solution 2 was added and incubated on ice for 10
minutes.
5. 150|il of 3M NaAc (pH5.2) was added, vortexed briefly,
incubated on ice for 10 minutes and spun in the microfuge for 5 
minutes.
6. 400(11 of supernatant was transferred to a fresh Eppendorf tube 
and extracted twice with an equal volume of 1:1 phenol: chloroform 
and once with an equal volume of chloroform.
7. 800(11 of 95% ethanol was added and incubated at 19°C for 5
minutes.
8. Nucleic acids were pelleted in the microfuge for 5 minutes, 
the pellet dried and resuspended in 50 (ll of pure distilled water 
containing 1 (ll of 10 mg/ml RNAase A.
Nucleic Acid Manipulation.
2.9 Restriction Analysis of DNA.
Plasmid DNA was digested with 1-5 units of enzyme/(ig DNA for 2 to 
3 hours at 37°C under conditions specified by the enzyme 
manufacturer. Where further manipulation of the restricted DNA 
was necessary, the fragments were purified as described in 2.14.
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2.10 Gel Electrophoresis.
For analysis or preparation of DNA fragments ranging in size from 
100 bp to 8 kb flat bed agarose gel electrophoresis in lx TAE/lx 
TBE was used. Where purification of the restricted fragment was 
required, low melting point agarose was used and the gel was run 
in lx TAE buffer. Agarose gels were poured at a concentration of
0.8%-2% w/v depending on the size of fragments to be resolved. 
Samples were loaded in lx loading buffer and electrophoresed for 
20 minutes to 16 hours and at 10-100 mA depending on the size of 
the gel and the resolution required. Gels were stained for 20
minutes in 1 |ig/ml ethidium bromide solution followed by 10
minutes destaining in distilled water to remove excess ethidium 
bromide. Nucleic acids were visualised by illumination with short 
wave ultra violet light and photographed through a red filter on 
Polaroid 57 high speed film. When a fragment identified on a gel
was to be purified, it was excised from the gel on the UV
illuminator and purified as described in 2.14
For analysis or purification of fragments less than 150 bp, 5-10% 
polyacrylamide lx TAE/lx TBE vertical gel electrophoresis were 
used. The gels were electrophoresed at 10-100 mA for 1-4 hours. 
Gels were stained and fragments visualised as described for 
agarose gels above.
For analysis and separation of single stranded DNA/RNA, 0.4 mm 
thick vertical 6% denaturing polyacrylamide gels were used which 
were poured between siliconised glass plates. Gels were 
electrophoresed for 1-4 hours at 40 mA. Gels were 
pre-electrophoresed for 1 hour prior to the loading of samples
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and samples were loaded in sequencing loading buffer and heated 
to 90°C for 2 minutes before loading. After electrophoresis, the 
gel was transferred to Whatmann 3mm paper and dried for 1-2 hours 
under vacuum at 80°C.
2.11 DNA Fragment Purification.
Two methods were used to purify DNA fragments from low melting 
agarose. For fragments greater than 500 bp, fragments were 
purified using GeneClean:
1. 2.5 volumes of 5M Nal were added to the excised block of 
agarose containing DNA, heated at 55°C for 5 to 10 minutes and 
vortexed occasionally.
2. 5 pi of glassmilk for up to 5 (Jg DNA were added, vortexed and 
incubated on ice for 5 minutes before being spun down for 5 
minutes in the microfuge.
3. The pellet was resuspended in 450 \il NewWash and spun down 30 
seconds. Repeat three times.
4. The pellet was taken up in 10 Mi of IE/ incubated for 3
minutes at 50°C and spin down for 30 seconds.
5. 10 Mi °f supernatant was transferred to fresh tube and step 4 
above was repeated with a second aliquot of TE.
6. The supernatants were pooled and a sample analysed on a 
mini-gel.
For fragments less than 500 bp, purification from agarose is more 
efficient using Elutitip-D columns which are equilibrated with 3 
ml of HSB followed by 5 ml of LSB. The agarose block containing
the DNA fragment was melted in 1 ml of LSB at 65°C for 15
minutes, mixed with a further 8 ml of LSB and vortexing, and
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incubated at 42°C for 15 minutes. 5 ml of the solution was pushed 
through an Elutitip-D column using a 5ml syringe. The column is 
washed quickly with 5 ml of LSB at 42°C and the DNA. fragment is 
then eluted with 0.6 ml of HSB and precipitated with 30 |ig of 
carrier yeast tRNA and 0.6 ml of absolute ethanol at -20°C 
overnight. This procedure is repeated for the remaining 5 ml of 
molten agarose solution.
DNA fragments are purified from acrylamide by elution overnight 
into 0.2 ml of 0.5 M NH4CH3CC>2, 10 mM Mg(CH3CC>2)2, 0.1 mM EDTA,
0.1% SDS at 37°C followed by ethanol precipitation in the 
presence of 30 pg carrier yeast tRNA.
2.12 Sub-cloning of DNA Fragments.
DNA fragments were subcloned into a vectors either by:
(a) ligation into a restriction site containing complementary 
sticky ends to those of the DNA fragment, or
(b) blunt-end ligation carried out by generating blunt ends on 
both the insert and the vector, phosphatasing the 5' ends of the 
vector (to reduce the possibility of the vector religating to 
itself) and then blunt-end ligating the insert into the vector. 
Blunt ends were generated by treating DNA fragments with the 
Klenow fragment of DNA polymerase 1/T4 DNA polymerase in the 
presence of 0.2 mM deoxyribonucleotides, in lx T4 buffer and 
incubating at 19°C for 30 minutes. Reactions were stopped by 
incubating at 70°C for 5 minutes. Vector fragments were 
phosphatased with 1 unit of calf intestinal phosphatase/50. pg DNA 
in lx CIP buffer at 37°C for 30 minutes.
Ligation reactions were typically carried out in a volume of 20
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JLLl with 200 ng of insert and 200 ng of vector in the presence of 
lx ligation buffer, lx ligation salts and 1 unit of T4 DNA 
ligase. In addition, 1 unit of T4 RNA ligase was added to blunt 
end ligation reactions. The ligation reactions were incubated 
overnight at 14°C for ligations involving sticky ends and at 4°C 
for blunt end ligations.
2.13 Transformation of DNA into E.coli.
Bacterial strain JM83 was made competent for tranformation 24 
hours prior to transformation by the following procedure:
1. 1 ml of a fresh overnight of JM83 was inoculated into 100 ml 
of L-broth and incubated at 37°C in an orbital shaker until the 
culture reached an optical density of 0.6 at A£qq when the 
bacteria should be growing exponentially.
2. The bacteria were pelleted by centrifugation at 1500 g at 4°C 
for 15 minutes and resuspended in 20 ml of transformation buffer 
at 4°C, and incubated on ice for at least 30 minutes.
3. The bacteria were pelleted at 1200 g for 15 minutes at 4°C, 
resuspended in 2 ml of transformation buffer and stored overnight 
at 4°C.
Transformation of DNA into competent JM83 is carried out as 
follows:
1. 10 |ll of the ligation reaction described in 2.15 above was 
mixed gently on ice with 100 JLLl of competent JM83 bacteria.
2. The suspension was incubated on ice for 30 minutes and then 
incubated at 42°C for 5 minutes before being immediately returned 
to ice.
3. 2 ml of warm L-broth was added to the suspension, the culture
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was incubated at 37°C for 1 hour, and the bacteria were pelleted 
at 1500 g for 15 minutes.
5. The bacterial pellet was resuspended in 250 pi of L-broth and 
50 JLLl was spread out onto 9 cm diameter L-agar plates containing 
selective antibiotics and incubated at 37°C overnight.
6. Single colonies were then picked and inoculated into 5 ml of 
L-broth plus selective antibiotic. Plasmid DNA. was prepared as 
described in 2.8 above and restriction analysis carried out to 
determine whether the sub-cloning and transformation had been 
successful.
End-labelling of DNA Probes.
2.14 5' end labelling of double-stranded oligonucleotides.
Single-stranded complementary oligonucleotides were annealed at 
a concentration of 0.1 mg/ml in 0.1 M NaCl, lx TE by boiling and 
then cooled slowly to 19°C. The 5' end-labelling reaction was 
carried out as follows:
1. The reaction was set up in a total volume of 10 (il with 2 pi 
double-stranded oligonucleotide (200 ng), 1 jxl lOx kinase buffer, 
1 pi 50 mM DTT, 1 pi 20 mM spermidine, 2 pi [y-^P]ATP (370 
MBq/ml), 2 JLLl water and and 1 pi T4 polynucleotide kinase.
2. The reaction mix was incubated at 37°C for 30 minutes, 70°C 
for 5 minutes, 37°C for 10 minutes and 19°C for 5 minutes.
3. End-labelled double stranded oligonucleotides for use in gel 
retardation assays were treated with Klenow fragment in a total 
volume of 20 pi made up of 10 fll of end-labelling reaction, 1 |ul 
lOx T4 buffer, 4 JLLl 5mM deoxyribonucleotides, 2 units Klenow and 
4 pi water and incubated on ice for 2 hours. This filling-in of
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sticky ends on oligonucleotide probes reduces non-specific 
interactions with DNA binding proteins.
4. The end-labelled probes were purified by gel electrophoresis 
on an 8% polyacrylamide lx TBE gel. The probes were eluted from 
acrylamide overnight into 1 ml TE at 37°C. The probes were
g
labelled to a specific activity in the range 2-8x10 cpm/|ig.
2.15 5' end labelling of DNA restriction fragments.
50 |ig of plasmid DNA was cut with the appropriate restriction 
enzyme to generate 5'overhanging ends, extracted, precipitated 
and resuspended at 1 fig/p.1. The restricted plasmid was then 
treated with 0.5 units of calf intestinal phosphatase in lx CIP 
buffer in a total volume of 50 |il and incubated at 37°C for 30
minutes when a second aliquot of 0.5 units of phosphatase was
added and the incubation extended for a further 30 minutes. The
reaction was stopped by the addition of 50 \il water and 5 (ll 10% 
SDS and incubated for 15 minutes at 68°C. Following this the DNA 
solution was organically extracted, precipitated twice and 
resuspended at 1 flg/fil. The end-labelling reaction was carried 
out in a total volume of 50 jil with 10 |il restricted, 
phosphatased DNA, 7 |il [y-22P]ATP (370 MBq/ml), 5|Jl lOx kinase 
buffer, 2.5 jjl 20 mM spermidine, 2.5 |Ul 100 mM DTT, 3 (ll T4 
polynucleotide kinase (1 unit/fll) and 20 |ll water.
2. The reaction was incubated at 37°C for 30 minutes and then 
stopped by the addition of 2 |Jl 0.2 M EDTA and 150 |LLl lOx TE.
4. The DNA was extracted twice with an equal volume of 1:1 (v/v) 
phenol:chloroform and once with an equal volume of chloroform.
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The DNA was ethanol precipitated twice, first in 0.4 M NaCl and 
then in 0.1 M KCH3C02.
5. Where end-labelling was required on one strand of the probe 
(for DNAase 1 footprinting and for Maxam-Gilbert sequencing), the 
pellet was resuspended in 35 |ll of water, 5 |H of BSA (10 mg/ml), 
5 M-l lOx restriction buffer and 5 pi of an appropriate 
restriction enzyme (5 units/|ll) and incubated at 37°C for 3 
hours.
6. The end-labelled probe was purified by gel electrophoresis on 
a 1.5% low melting point agarose gel, fragments visualised by 
autoradiography and the fragment purified from agarose using 
Elutitip-D column as described in 2.14. Probes were generated at
-a specific activity in the range of 2-8x10^ cpm/|jg.
2.16 5' end labelling of single-stranded oligonucleotides.
The end-labelling reaction was set up with 0.2 |ig of
single-stranded oligonucleotide, 1 pil lOx kinase buffer, 1 (il 100
32mM DTT, 2 \il [y- P]ATP, 1 unit T4 polynucleotide kinase and made 
up to a total volume of 10 |ll with water. The reaction mixture 
was incubated at 37°C for 30 minutes and then the reaction was 
stopped by incubation at 65°C for 10 minutes. The labelled 
oligonucleotide was used directly for generating 5'end labelled 
DNA fragments by PCR amplification.
2.17 Polymerase Chain Reaction (PCR) Mediated End Labelling of 
DNA Fragments.
The conditions for polymerase chain reactions are discussed in 
more detail in 2.24. Where no suitable restriction enzyme sites 
existed to generate the desired end-labelled DNA fragments, PCR
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mediated extension on the chosen template was used. The reaction 
was primed with an end-labelled oligonucleotide primer 
complementary to the region of the template from which the probe 
was generated and with an unlabelled primer complementary to the 
opposite strand at the distal end of the template. The PCR 
reaction contained 10 Ml of the single-stranded oligonucleotide 
labelling reaction described above, 0.2 |ig of the second 
oligonucleotide primer, 10 ng of template, 5 |H of lOx Taq 
polymerase buffer, 5 (ll of dimethylsulphoxide (DMSO), 4 pi 10 mM 
deoxyribonucleotides, 1 \il lOOmM MgC^ and made up to a total 
volume of 50 fll with water. Two drops of mineral oil were applied 
to the surface of the reaction mix before the reaction was boiled 
for 5 minutes and then allowed to cool slowly to 19°C. 2 units of 
Taq DNA polymerase were added to the reaction mix and the desired 
DNA fragment end-labelled at one end only was amplified in the 
Perkin Elmer Cetus DNA Thermal Cycler. Typically 30 cycles of 
amplification were carried out overnight at a denaturation 
temperature of 91°C for 90 seconds/cycle, an annealing 
temperature of 50°C for 90 seconds/cycle and a polymerisation 
temperature of 72°C for 180 seconds/cycle. The DNA probe is 
extracted once with an equal volume of chloroform and purified by 
gel electrophoresis on a 1.5% low melting point agarose gel. The 
DNA probe is extracted from the agarose using an Elutitip-D 
column. Typically the specific activity of fragments generated in
g
this way was in the range 2-8x10 cpm/|ig.
2.18 Maxam-Gilbert Sequencing.
Maxam-Gilbert sequencing reagents were provided by Du Pont
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Figure 2.2 PCR Mediated Site Directed Mutagenesis. I
The figure summarises the method described in section 2.19 to generate ! 
desired mutations in sequences as originally described by Higuchi et al 
(1988).
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International. End-labelled probes were generated as described 
above and Maxam-Gilbert sequencing reactions were carried out 
according to the manufacturer's specifications.
2.19 PCR Mediated Site Directed Mutagenesis.
The use of polymerase chain reaction as developed by Saiki et al. 
(1987) to generate specific mutations in genes of interest was 
first described by Higuchi et al. (1988) and further described by 
Vallette et al. (1988) (The general applications of polymerase 
chain reaction for nucleic acid analysis and manipulation is 
reviewed by White et al. (1989) . In this study, the technique was 
modified in several ways until such time as the yield and 
fidelity of amplification of the specifically mutated DNA 
fragment was maximised. The procedure for generating mutant DNA. 
fragments for sub-cloning is summarised in Figure 2.2. The 
reactions were carried out as follows:
PCR Reactions 1/2 0.3 (ig mutant primer 1/2 (mutant primers
1 and 2 are complementary)
0.3 |Jg linker primer 3/4 (linker primers 3 
and 4 contain restriction sites which will 
be used for sub-cloning)
10 ng wild-type template
5 \il lOx Taq polymerase buffer
5 |ll DMSO
4 |ll 10 mM dNTP
1 Hi 100 mM MgCl2
water up to a total volume of 50 jji.
74
Two drops of mineral oil were added to the surface of the
reaction mix and boiled for 5 minutes, and then cooled slowly to
19°C. 2 units of Taq DNA. polymerase were added and amplification
/
carried out in the Perkin Elmer Cetus DNA Thermal Cycler at a 
denaturation temperature of 90°C for 90 seconds/cycle, an 
annealing temperature of 40-45°C (depending on the extent of 
mismatch between the mutant primer and the wild-type template) 
for 90 seconds/cycle and a polymerisation temperature of 72°C. 
Typically 30 cycles of amplification were carried out.
The products of PCR reactions 1 and 2 were separated by gel 
electrophoresis on a 1.7% low melting point agarose gel and 
purified on an Elutip-D column. The yield of the desired product 
is typically 1-2 jog.
PCR Reaction 3 5 fig PCR reaction 1 products
5 |lg PCR reaction 2 products
0.3 (ig linker primer 3
0.3 Jig linker primer 4
5 |ll lOx Taq polymerase buffer
5 pi DMSO
4 Hi 10 mM dNTP
1 Hi 100 mM MgCl2
Water to a total volume of 50 |fl.
2 drops of mineral oil were added to the surface of the reaction 
mix, boil for 5 minutes, cooled slowly to 19°C and 2 units of Taq 
polymerase were then added. 30 amplification cycles were carried 
out in the Thermal cycler at a denaturation temperature of 90°C 
for 90 seconds/cycle, an annealing temperature of 50°C for 90
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seconds/cycle and a polymerisation temperature of 72°C for 180 
seconds/cycle. 4 units of the restriction enzyme appropriate to 
the restriction site contained within the linker primers at each 
end of the PCR product were added. The PCR products were
separated by gel electrophoresis on a 1.7% low melting point
agarose gel. The desired PCR generated fragment was subcloned
into a suitable vector, positive recombinants screened for by 
restriction analysis and Maxam-Gilbert sequencing carried out to 
confirm successful mutagenesis. Where appropriate a unique 
restriction site was generated at the site of mutagenesis to
facilitate the screening for successful mutagenesis and to 
obviate the need for DNA sequencing as a screening procedure.
Cell Culture and Expression Analysis.
2.20 Growth of Cells in Culture.
The cells used in this study are listed in 2.4. Cells grown in
suspension were kept growing exponentially by subculturing every
three to four days maintaining the cell density within the range 
4 65x10 to 2x10 cells/ml. Cells grown in an adherent monolayer 
were also passaged every three to four days such that they were 
always maintained, depending on the cell line, within the range
A O £ O
30-80% confluent, that is 3x10 cells/cm to 2x10 cells/cm .
Adherent cells were removed from culture flask or dishes by
removing the culture medium, washed with an appropriate volume of 
phosphate buffered saline and then removed from the flask with
0.025% (w/v) trypsin in citrate buffer (pH 7.8) . The trypsin was 
then inactivated with an equal volume of fresh culture medium.
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Cell number and integrity was determined by haemocytometry.
7
Stocks of cell lines at 10 cells/ml in 10% (v/v) glycerol were
stored in liquid nitrogen. Frozen stocks were made by slow
freezing overnight to -70°C before transfer to liquid nitrogen. 
Cells were taken up from liquid nitrogen by rapid thawing at 37°C 
and immediate transfer to culture medium also at 37°C. Cells in 
culture were discarded after no more than 20 passages in favour 
of fresh cells taken up from frozen stocks.
2.21 Calcium Phosphate Mediated Transfer of DNA into Cells in 
Culture for Functional Analysis Under Transient Transfection 
Conditions.
106 exponentially growing cells in 10 ml of fresh medium were 
placed in 9 cm Petri dishes and incubated overnight at 37°C, in a 
humid atmosphere and at 5% CC^.
DNA./calcium phosphate precipitates were generated by making a 
solution of 0.25 M CaC^ containing 40 |ig of DNA (test 
plasmid+reference plasmid+carrier plasmid) up to 1ml with
Tris-Cl (pH7.1) . This solution was then added slowly while
gently shaking to 1 ml of 2xHBS (pH 7.1) and mixed by aeration. 
The calcium phosphate precipitate was allowed to fom at 19°C for 
at least 30 minutes before being gently added to the cells set up 
in culture 24 hours earlier.
Approximately 16 hours after addition of the precipitate, the 
medium on the cells was replaced with fresh medium and the cells 
returned to the incubator at 37°C, in 5% CC>2
Culture medium/cell lysates (depending on the nature of the
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functional assay) were assayed for activity of the reporter gene 
product 24 hours following change of medium.
The efficiency of transfection varies between cell lines and in 
some cases it may be more efficient to use different methods of
transfection, for example lipofection or electroporation.
However, in this study, although there were differences in
transfection efficiencies between cell lines and between
experiments, these differences were controlled for by
cotransfecting the test plasmid with the pHSV-IE-p-galactosidase 
reference plasmid and standardising levels of expression from the 
test plasmid to that from the reference plasmid.
2.22 Generation of Stable Transfect ants for Functional
Analysis.
The DNAs to be assayed were transfected into cells in culture 
dishes as described above for transient transfection except that 
instead of the pHSV-IE-(3-galactosidase reference plasmid, the 
test plasmid was cotransfected with HOMER 6 (Spandidos & Wilkie) 
which encodes the neomycin resistance gene. On day 3 when the 
culture medium was changed and fresh culture medium added, 80 
|lg/ml of G418 is also added to the culture medium. Three days 
later, only those cells which had stably incorporated and 
expressed the neomycin resistance gene from HOMER 6 survived the 
G418 selection. It was assumed that those cells which had stably 
incorporated the neomycin gene into their genome will also have 
incorporated the test plasmid sequences. The medium on these 
cells was replaced with fresh medium containing 80 pg/ml of G418.
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Three days later colonies of the cells that had survived
selection were seen with the naked eye. Each colony represented a
different clone each having incorporated different numbers of
copies of the resistance gene and the test plasmid sequences at
different locations in the genome. More than 50 clones were
pooled by trypsinising them from the culture dish and reseeding
4
in fresh medium at a density of 4x10 cells/ml. The cells were 
then cultured and passaged as for other cells as described above 
except that 80 pg/ml of G418 was added to the culture medium. 
Cells could then be induced to differentiate with 4 mM HMBA or 
with 2% DMSO and changes in expression from the reporter gene 
monitored at 24 hour periods. The cells were set up as normal and 
allowed to grow for 24 hours before the inducing agent was added.
2.23 Human Growth Hormone Assay.
This technique was first described by Selden et al. (1986) . The
human growth hormone reporter gene was driven by the test
promoter and/or enhancer sequences. When the expression construct
was transfected into cells in culture in either transient or
stable transfection experiments, expressed human growth hormone
(hGH) was secreted from the cells and the culture medium was
assayed directly for growth hormone activity. The
radioimmunoassay, supplied by Biogenesis Ltd., was carried out
according to their specifications. hGH in the culture medium was
125bound by a mouse anti-hGH [ I]-labelled monoclonal antibody. A 
second biotin-linked mouse monoclonal antibody raised against a 
different epitope of hGH also binds hGH and the hGH sandwiched
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between two antibodies is recovered from the reaction mix by
incubation for 4 hours at 19°C with avidin coated glass bead. The
beads bind the biotin linked monoclonal antibodies and having
125washed off unbound antibody, the amount of [ I] indirectly
linked to the glass bead was taken as a measure of the ammount of
125hGH present m  the sample of culture medium. The amount of [ I] 
on the glass beads is measured by its gamma emission in a Beckman 
Gamma Counter. The hGH assay is more sensitive than the CAT 
assay and as such is useful for the functional analysis of weak 
promoter sequences. Similarly, the assay is easy and fast and 
since hGH is secreted from the cells, stable transfectants can be 
continuously cultured and culture medium assayed at different 
time points.
2.24 Generating Cell Lysates.
Following transient transfection, cell lysates were made to assay 
for p-galactosidase and CAT activity within the cells.
Medium was removed from the culture dish, cells washed in 10 ml 
of PBS, and then scraped off the dish in 1 ml of PBS. The cells 
were pelleted at 2500 g for 30 seconds and the cell pellet 
resuspended in 200 (Jl of 0.25 M Tris-Cl (pH 7.8). The cells were 
lysed by repeated rapid freezing and thawing. Cell debris was 
pelleted at 2500 g for 2 minutes and the supernatant assayed for 
(3-galactosidase/CAT activity.
2.25 ft-Galactosidase Assay.
60 \il of cell lysate, 1 ml of solution A and 0.2 ml of solution B 
were mixed by pipetting and then incubated at 37°C for 30 to 60 
minutes. The reaction was stopped by addition of 0.5 ml of
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solution C. The absorbance at 420nm is determined as an indirect 
measure of (3-galactosidase activity. Absorbance values in the 
range of 0.15-1.00 were obtained.
2.26 Chloramphenicol Acetyl Transferase Assay.
This technique was carried out as described by Gorman et al.
(1982) and modified as follows:
1. lOmM stock (8.1mg/ml) of acetyl Co-A was made and mixed with
14D-threo-dichloroacetyl-1- C-chloramphenicol (2.11GBq/ml) in the 
ratio 10:1.
2. Cell lysate was made up to 89}il where necessary with 0.25 M 
Tris-Cl (pH 7.8) heated to 60°C for 7 minutes before adding the 
acetyl Co-A mix in order to inactivate endogenous cellular 
chloramphenicol acetyl transferase activities. 11 |ll of the 
acetyl Co-A mix was added to the lysate.
3. The reaction was incubated at 37°C for 30 minutes, stopped by 
placing on ice and 300 |Jl of ethyl acetate was added. After 
vortexing, the organic and aqueous phases were separated by 
centrifugation in the microfuge at 2000 rpm for 2 minutes.
4. The organic phase was removed to a clean Eppendorf tube, dried 
under vacuum and the pellet resuspended in 20 |Jl of ethyl 
acetate.
5. The 20 |ll samples are spotted slowly onto a thin layer 
chromatography plate and reaction products separated by running 
in a 95:5 CHCl^CH^OH liquid phase.
6. The plate was then allowed to air dry and exposed overnight 
against Kodak XAR-5 film.
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Analysis of DNA-Protein Interactions.
2.27 Preparation of Crude Nuclear Protein.
Crude nuclear protein was prepared from animal tissue or from 
cells grown in culture in a modified version of the procedure 
initially described by Emerson et al. (1982) . The protocol for 
preparation from cells in culture is essentially the same as for 
preparation from animal tissue after step 1 below which is for 
animal tissue only. All solutions used in the preparation were 
kept at 4°C and contained 0.5 mM PMSF, 0.1 mM EGTA, 1 |ig/ml of 
each of aprotinin, leupeptin, pepstatin A, 0.1 |UM sodium 
vanadate, 10 mM sodium butyrate, 0.5 mM benzamidine and 10 mM 
p-glycerophosphate.
1. Typically 100 NIH mice aged 2-4 months were used for each
preparation. The tissue was collected immediately into 200 ml of 
PBS on ice and minced into 200 ml of TMS/0.25% Triton X-100,and 
homogenised in a Dounce homogeniser and filtered through gauze. 
The nuclei were pelleted at 2000rpm, 4°C for 20 minutes.
3. The nuclei were washed three times with IMS. During the third
wash 100 jLll of resuspended nuclei were added to 0.9 ml of water
and then added to 9 ml of 1 M NaOH. Following sonication of this 
10 ml solution the concentration of nucleic acid was determined 
by spectrophotometry to give an indirect measure of the 
concentration of nuclei in the preparation (A^ q^ 20 = 1 mg/ml).
4. After the third wash in IMS, the nuclei were resuspended in 
fresh TMS at a nucleic acid concentration of 5 - 10 mg/ml.
5. Non-histone proteins were extracted from the nuclei stirring
with 0.3 M NaCl on ice for 15 minutes and the supernatant
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clarified by centrifugation first at 15 000 g for 15 minutes and 
then at 100 000 g for 1 hour at 4°C.
6. Solid (NH^^SO^ was added to the solution at 0.35 mg/ml and 
stirred on ice for 30 minutes. Precipitated proteins were 
recovered by centrifugation at 10 000 g for 30 minutes at 4°C.
7. The protein pellet was resuspended in 3-5 ml of ECA buffer
5 U
and dialysed overnight at 4°C against SB (or against E,_q buffer 
for partial purification by DNA affinity chromatography).
8. The crude nuclear protein preparation dialysed overnight 
against SB was then clarified at 100 000 g for 1 hour at 4°C and 
stored at -70°C.
2.28 Partial Purification of Nuclear Protein by DNA Affinity 
Chromatography.
5g of calf thymus DNA. cellulose was equilibrated in 50ml of e^qq
buffer and used to pack a Pharmacia C 10 column. The column was
washed through with a small volume of e^qq buffer. The column was
equilibrated overnight with 200 ml E ^  buffer at 4°C. 5 ml of the
crude nuclear preparation generated in 2.27 which had been
dialysed against E^q buffer was loaded on to the column. 1 ml
fractions were collected and the protein content measured by
spectrophotometry. Once the first peak of activity came off the
column, DNA binding prteins were eluted with step-wise increases
in NaCl concentration; first En then Eocn and fraction
1 U U  z 5 U
collection continued until the second peak comes off the column. 
Fractions from the E25q peak were pooled and dialysed overnight 
against SB at 4°C. The pooled fractions were stored at -70°C for 
use in DNAase 1 footprinting assays.
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2.29 DNAase 1 Footprinting.
This technique was used to identify protein binding sites within
DNA fragments of interest and was carried out as described by
Plumb and Goodwin in Chapter 12 of Methods in Molecular Biology
Chapter 4.
End-labelled probe was generated as described in section 2.15 and 
less than 20 ng was incubated in storage buffer on ice in the 
presence of non-specific DNA competitor (1 pg poly (dl) (dC), 
0-800 jig of nuclear protein extract in a total volume of 100 |il. 
Sequence specific DNA oligonucleotide competitor was added where 
necessary at a 250 M excess. The reaction was incubated on ice 
for 60 minutes before DNAase I was added at an appropriate 
concentration. The concentration of DNAase I to be added depended 
on the protein extract and competitor DNA concentration and was 
determined by carrying out a set of preliminary digestion 
reactions varying the DNAase I concentration from 1-10 pi of
serial dilutions in SB/0.1 mM CaC^ of a stock DNAase I solution 
of 2 pg/pl. The concentration of DNAase I was selected such that 
only one nick per end-labelled probe molecule was made. After 30 
seconds, the digestion reaction was stopped with 100 jil of stop 
buffer and then incubated at 37°C for 30 minutes and 90°C for 2 
minutes. The DNA probe was extracted by repeated 
phenol/chloroform extraction and precipitated with 10 pi 5 M LiCl 
and 600 jil of absolute ethanol on dry ice for 15 minutes. The DNA 
precipitate was pelleted, washed with 1 ml ethanol, dried under 
vacuum and resuspended in 8 fil of sequencing loading buffer. The 
samples were denatured at 90°C for 2 minutes and resolved by 6%
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denaturing polyacrylamide gel electrophoresis for 90-180 minutes 
depending on the region of the probe to be resolved. 
Maxam-Gilbert sequencing reactions with the same DNA probe were 
run along side the footprinting reactions. The gel was dried 
under vacuum and exposed against Kodak XAR-5 film overnight at 
-70°C in a cassette with intensifying screens.
2.30 Gel Retardation Assays.
This technique was used to analyse the binding characteristics of 
DNA-binding proteins in different tissue and cell extracts to 
different double-stranded oligonucleotide probes. The technique 
was carried out in a modified version of that described by 
Gamer and Revzin (1981) .
The binding reaction was set up in a total volume of 20 |il with 1 
of double-stranded end-labelled oligonucleotide probe (100 
pg), 2 pi poly(dl) (dC) (3 pg/pl), 1 jil 0.1 mg/ml specific
oligonucleotide competitor, 2 pi of nuclear extract and 14 pi of 
SB at a final NaCl concentration of 50 mM or 150 mM. The reaction 
was incubated on ice for 60 minutes and then protein-DNA 
complexes resolved by gel electrophoresis on a 0.2x TBE/0.5xTBE 
5% polyacrylamide gel pre-electrophoresised for 90 minutes on ice 
at 150V. The gel was electrophoresised at 150V constant voltage 
for 2 hours on ice. The gel was then dried under vacuum at 80°C 
for 2 hours and autoradiographed.
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CHAPTER 3 IDENTIFICATION OF PROTEIN BINDING SITES IN THE PROMOTER AND 
3' FLANKING REGION OF THE MOUSE GLOB IN GENE.
INTRODUCTION.
A DHSS has been mapped over the mouse pma-^°r globin gene promoter
and the nuclease sensitivity of this site in MEL cells increases when
these cells are induced to differentiate (Sheffery et al. (1982),
(1983) . Mutagenesis analysis of the mouse globin gene promoter
has shown that there is an absolute requirement for intact TATA (-30 
bp), CCAAT (-75 bp) and CACC (-90 bp) boxes to ensure correct 
initiation of transcription in transient and stable transfection assays 
(Chamay et al. (1985), Myers et al. (1986) . These elements map within 
the DHSS identified over the pma0Or g]_0]oin gene promoter. From this and 
other evidence that nucleosome phasing is disrupted in this region in 
MEL cells (Benezra et al. (1986), it seemed likely that, in common with 
the chicken oP, pP and pk globin gene promoters (Kemper et^  al. (1987),
Emerson et al. (1985), Plumb et al. (1986), that non-histone proteins
bind to these sites, possibly displacing histones and are involved in 
regulating the initiation of transcription from the mouse pma9or globin 
gene promoter. Using in vitro DNAase 1 footprinting as described in 
section 2.29, I set out to identify sites in the mouse p^a9or globin 
gene promoter which bind factors present in crude and partially 
purified nuclear extracts prepared as described in sections 2.27 and 
2.28. Such sites might be involved in the regulation of transcriptional 
initiation and by analysing the sequences bound by nuclear protein 
factors and the tissue specificity of binding activity, I hoped to 
determine whether any of the identified sites were conserved in the
86
promoters of other globin or non-globin genes.
End-labelled probes for DNAasel footprinting were prepared by the 
PCR technique, as described in section 2.17 or by 5'end kinase 
labelling, as described in section 2.15. The PCR technique uses plasmid 
p(3745GH as template and oligonucleotides FP1-6 as primers to generate 
probes (3730, (3600, (3460, (3280 and pl60. pp7.2 was used as template and
oligonucleotides FP7-8 as primers to generate probe (3415. The 
recombinant plasmids used here are illustrated in figure 2.1 and 
oligonucleotides used are illustrated in "fabit 3-1 , Figure 3.1
summarises the organisation of probes and primers on the promoter and 
3'sequences.
3.1 The Proximal Promoter.
The proximal promoter can be defined as the region 5' of the mouse
globin gene spanning from the initiation site of transcription
to a site 100 bp upstream. This region contains the TATA (-30 bp),
fim3
CCAAT (-75 bp) and CACC (-90 bp) boxes and Myers et al. have suggested 
that sequences contained within this region are sufficient to confer 
erythroid specificity and inducibility upon transcription from this 
promoter in transient transfection assays.
To determine whether the functionally important TATA, CCAAT and 
CACC boxes bind nuclear factors and whether any additional protein 
binding sites exist in the proximal promoter region, footprinting 
probe (3730 was incubated in vitro with crude or partially purified 
nuclear extract prepared from a variety of cell lines and mouse 
tissues, in the presence or absence of sequence specific 
oligonucleotide competitors, (as described in section 2.29) except that
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incubations with partially purified nuclear extracts were carried out 
in the absence of poly(dl)(dC) non-specific competitor. The results are 
shown in Figure 3.3A and B. Tab It 3 A  illustrates the oligonucleotides 
used for both DNAase 1 footprinting and gel retardation assays.
The interaction of the proximal promoter region with crude nuclear 
protein extracts (Fig.3.3A) results in the generation of a strong 
DNAase 1 hypersensitive site at -100 bp 5' of the initiation site. This 
DHSS can be competed out with excess of the (3CC oligonucleotide 
competitor (lanes 8 and 16). To determine whether any other nuclear 
factors were involved in the generation of this DHSS at -100 bp, 
competition with other sequence specific oligonucleotide competitors 
was carried out. Incubating probe (3730 in the presence of crude nuclear 
extracts with oligonucleotide competitors (3CT (lanes 7, 15), (3G215
(lane 9), NF-1 (lanes 10, 17) or pNF-1 (lanes 11,18) did not affect
formation of the DHSS.
No footprints are observed in the proximal promoter region. 
The same observation has been made in DNAase 1 footprinting of the 
chicken (3^ globin gene proximal promoter (Goodwin per s. comm.) . It is 
surprising that this region does not footprint since it contains the 
functionally important TATA, CCAAT and CACC boxes. The same crude 
nuclear extracts generate footprints over the proximal promoter region 
of the mouse a-1 globin gene (lanes 19-24). Specifically, footprints 
are observed over the CACC box (-60 bp) of the mouse a-1 globin gene 
which can be competed out by a 250 M excess of oligonucleotide 
competitors, (3CA.CC (lane 22) and aCACC (lane 24) and at a site at -40 
bp 5' of the transcription initiation site previously identified by 
Plumb et al. This suggests that the failure to obtain a footprint over
the functionally inport ant TATA, CCAAT and CACC boxes of the mouse 
pmajL-U  ^ ;1 gene promoter does not reflect degradation or inactivity
of the binding factors. Binding to the proximal promoter region of the 
mouse pma o^r globin gene may depend either upon a critical DNA:protein 
ratio or upon protein:protein interactions which do not occur in this 
in vitro assay system. Failure to obtain a footprint over this region 
may be caused by low binding affinity of these proximal promoter 
sequences for their cognate binding factors.
Partial purification of crude nuclear extracts by DNA affinity 
chromatography (as described in section 2.28) enriches the extracts for 
DNA binding proteins and to determine whether any additional protein 
binding to the mouse (3rna^ 0r globin gene promoter could be detected, 
DNAase 1 footprinting using partially purified extracts was carried 
out.
DNAase 1 footprinting of p730 incubated with partially purified
extract from MEL cells (lane 3) generates a large footprint spanning
CFi gur* 3-38)
from -56 bp to -100 bp 5' of the transcription initiation site ^.This 
region contains the CCAAT (-75 bp) and CACC (-90 bp) boxes and also a 
recognition site for NF-E1 (-60 bp). Binding to this region also 
results in the generation of the strong DHSS at -100 bp described 
above. Competition with a 250 M excess of oligonucleotide pCT 
containing the mouse pma-|0r globin gene CCAAT box sequence resulted in 
a loss of the footprint over this region but the DHSS at -100 bp 
remained (lane 8) . However, competition with 250 M excess of 
oligonucleotide (3CC (lane 9) containing the mouse pma-]0r globin gene 
CACC box sequence resulted in the loss of the DHSS site at -100 bp in 
addition to loss of the footprint over this region. Competition with a
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250 M excess of oligonucleotide pG215 (lane 10) results in a footprint 
reduced in size spanning from -70 to -90 bp but which still covers the 
CCAAT and CACC box sequences. The DHSS at -100 bp persists. Competition 
with a 250 M excess of oligonucleotide NF-1 (lane 4) does not alter the 
size of the footprint in the region or the intensity of the DHSS at 
-100 bp.
These results suggest that at least three different MEL factors 
bind to this region: a CACC box binding factor which is responsible for 
generating the DHSS at -100 bp and whose binding is also necessary for 
binding of NF-E1 and the CCAAT box binding factor; a CCAAT box binding 
factor whose binding is not altered by competition with NF-1 or (3G215 
oligonucleotide competitor but binding of which is competed out with 
excess of the (3CC oligonucleotide; and NF-E1 which recognises the 
sequence AGGATAGA and binding of which is competed out by both (3G215 
and (3CC. The ability of the pCC oligonucleotide to compete out binding 
not only to the CACC box but also the CCAAT box and to the NF-E1 
binding site suggests that the CACC box binding factor is involved in a 
cooperative interaction with the factors binding to these elements. 
This is consistent with work by Schule et al (1988a, 1988b) that the
CACC box is involved in a cooperative interaction with the GRE in the 
promoter of the tryptophan oxygenase gene and that the CACC box 
cooperates with the NF-E1 binding site in the promoter of the human 
PBG-D gene (Walker et al. Unpublished results).
Footprinting of this region partially purified nuclear
extracts from mouse liver (lanes 5-7) reveals a different pattern of 
binding and competition. In addition to the DHSS at -100 bp, binding by 
factors present in the liver extracts generates a second strong DHSS at
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-90 bp and a footprint spanning from -56 to -90 bp (lane 5) . 
Competition with a 250 M excess of oligonucleotide pCT (lane 6) results 
in loss of the DHSS at -90 bp and a weaker footprint over the region 
-56 bp -90 bp. Competition with a 250 M excess of oligonucleotide 
conpetitior pCC (lane 7) results in the loss of the DHSS at -100 bp but 
in an increase in the intensity of the DHSS at -90 bp and a new but 
weak DHSS at -66 bp. These results suggest that binding to the CCAAT 
box in liver does not depend upon binding to the CACC box unlike the 
situation with MEL extracts. The pattern of DHSS generated by the 
binding to the CCAAT box in liver extracts suggests that a different 
CCAAT box binding factor is active in liver to MEL cells.
In addition to footprints observed in the proximal promoter 
region, footprints are also observed in the distal region when 
footprinted with partially purified extracts which are not observed in 
footprinting experiments with crude nuclear extracts.
Footprints are observed over the regions -118 to -134 bp and -160 
to -169 bp when (3730 is footprinted with partially purified extracts 
from both MEL and liver nuclei (lanes 3, 5) . Binding to both these
regions is competed out by an excess of NF-1 (lane 4) and an excess of 
pCT (lanes 6, 8) oligonucleotide competitors. The sequence bound
between -160 to -169 bp is a Box 1 recognition sequence AAGCCAGTG as 
described by Antoniou et al. (1988) . in the human (3 globin gene 
promoter and is a CCAAT box like recognition sequence which explains 
why binding to this site is successfully competed by NF-1 and (3CT 
oligonucleotides. Although this site is bound by factors present in 
both MEL and liver extracts, the pattern of binding in each extract is 
different; the DHSS present at -165 bp in MEL cell nuclear extracts is
91
absent in liver extracts. This suggests that different factors are 
binding to this region in MEL and liver nuclear extracts.
Protection of this region -118 to -134 bp with MEL and liver 
nuclear extracts occurs between two DHSS: at -100 bp caused by binding 
to the CACC box and at -135 bp which is probably generated by the poly 
purine tract in this region and not by protein binding since this DHSS 
is also present in the zero protein control track (lane 2). The
protected region -118 to -134 bp does not contain any known protein
binding recognition sequence. It may represent a novel binding site or 
alternatively, the protection observed in the region may be a 
conformational effect of DNA bending at the two DHSS at -100 and -135 
bp.
In conclusion, crude nuclear extracts from MEL cells do not
generate footprints over the mouse (?na“*0r globin gene proximal promoter 
while partially purified nuclear extracts do. There are several
technical reasons for this; for example, the DNAasel footprinting 
reactions are carried out in the absence of non-specific polynucleotide 
competitor poly (dl) (dC) which may reduce the amount of non-specific 
interactions of the factors specifically recognising the proximal 
promoter binding sites and release them for binding to the DNA probe. 
This is unlikely since even when crude nuclear extract incubations are 
carried out in the absence of poly (dl)(dC), footprints are not 
obtained in this region. Similarly, since partially purified nuclear 
extracts have been separated from residual DNA or RNA present in crude 
nuclear extracts, again non-specific interactions of binding factors 
may be reduced. Partial purification of nuclear protein extract may 
result in the dilution, loss or inactivation of some factor which may
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be inhibiting the proximal promoter binding factors from binding the 
DNA. Alternatively, partial purification may be altering the relative 
concentration of factors such that functional DNA binding complexes can 
now form. Other protein-DNA interactions occurring elsewhere in the 
promoter which prevent complex formation in the proximal promoter, may 
be altered by fractionation of the factors involved. The binding 
activities of these different factors and their tissue and sequence 
specificities is further investigated by gel retardation assay and is 
described in chapter 4.
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Figure 3.1 Generation and Organisation of Footprinting Probes.
Figure 3.1A illustrates the probes which have been generated by PCR 
mediated end-labelling as described in section 2.17 which have been 
purified on a 1.5% low melting point gel.
F O O T P m m G  
PROBES.
Cx -tN No --i -fN9s to o\ QQ Q Q In
oligonucleotide
ATP
Figure 3.IB illustrates the organisation of primers FP1-6 on template 
p[37 4 5GH relative to the transcription initiation site. Primer FP6 is 
common to all amplification reactions and is unlabelled. Primers FP1-5, 
which are 5' end-labelled, are used to generate probes (3730, (3600,
(5460, P280 and (3l60 respectively.
5f PROMOTER REGION.
-725 .346 o
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Figure 3.1C illustrates the organisation of primers FP7 and 8 on 
template p(37.2 to generate (3415. Either FP 7 or 8 can be end-labelled.
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Table 3.1 Oligonucleotides Used as Primers, Competitors and Probes in
DNAase 1 Footprinting and Gel Retardation Assays.
The table illustrates the single stranded oligonucleotide primers (top) 
used to prime the PCR mediated generation of probes for DNAase I 
footprinting as described in section 2.17 and illustrated in figure 
3*1*
The table (below) also illustrates the single stranded oligonucleotides 
which were annealed with their complementary oligonucleotides to 
generate double stranded oligonucleotides which were then used as 
described in the text as sequence specific competitors in DNAase I 
footprinting reactions or as probes and/or competitors in gel 
retardation assays. The recognition sequences for respective cognate 
binding factors are underlined.
FOOTPRINTING OLIGONUCLEOTIDE PRIMERS.
GCA AAT GTC AGG AGC AAC TGA TCC TAC FP1
GAA GCG ATA TTT CTC CCT GGA CAT GCT FP2
GOT CAA TCA ACT ACT GAA TTG TGT T FP3
AGO ATA CAT GAT GAT GAT TCC ATT FP4
GTT TGT GTG GCT TAC TTG TAT ATA TGT FP5
AGC TCA GGG TTT ACT TGA GAG ATC CTG FP6
CAG TTC TCA AGC CAA TAA TTT TTC FP7
CCC ACA CTG GAT ATT CAA GAT AGA T FP8
COMPETITOR OLIGONUCLEOTIDES.
GAT CGC AAA TGC GTT CGC C M A M GGA fiNFl
GAT CTT ATT TTG GCT TGA AGC CAA TAT G NF1
CAT TTT TCT GAT TGG TTA A M GTT GAG NF-Y
GAT CCT GGT AAG GGC CAA TCT GCT CAC BCT
GAT CCA AAC CAG CCA ATG AGA ACT GCT CCA aP2a
GAT CCT GAG ACG TCC TAA GCC AGT GAG BB1
GCC TGA TTC CGT AGA GCC ACA CCC TGG T M BCC
GAT CCG GGC GTG TCC ACC CTG CCT GGA aCC
GAT CCT CTG CAC AGA TAA GGA C M ACA BG215
GAT CCA CAC AGG ATA GAG AGG GCA GGA BG60
GAT CCT TTC TGA TAG GAA GGT TGA GCA BGIVS2
GAT CCT TGC AGA TAA ACA TTT TGC TAT C M GAC TTG CA BAG
Figure 3.2 The Proximal Promoter.
' ~The proximal promoter region is defined here as the region from
the start site of transcription (0) to lOObp upstream (-100). This 
region, as discussed in the text is extensively characterised and 
elememts TATA (-30), CCAAT (-75) and CACC (-90) have been shown to be 
essential for initiation of transcription. In addition to these three 
elements, there is a sequence GATAGA, at -65bp relative to the start 
site, which shows close homology to the recognition site for NF-E1.
The Proximal Promoter.
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GTA GAG CCA CAC CCT GGT AAG GGC CAA TCT GCT CAC
ACA CAG GAT AGA GAG AGG GCA GGA GCC AGG GCA GAG
CAT ATA AGG TGA GGT AGG ATC AGT TGC TCC TGA CA
Figure 3.3A
The Binding of Factors Present in Crude Nuclear Protein Preparations to 
the Proximal Promoter Regions of the Mouse a-1 and [jna o^r Globin Genes.
Lanes 1-4 Maxam-Gilbert sequencing reactions.
Lanes 6-12 Probe p730 (lOng) is incubated with non-specific competitor 
DNA, polydldC (l|lg) and 60 units of crude MEL cell nuclear extract made 
up to a total volume of 100|il with Storage Buffer and a final salt 
concentration of 50 mM.
Lanes 5, 13 As for lanes 6-12 except that no protein extract is added. 
Lanes 14-18 As for lanes 6-12 except using STO crude nuclear extracts.
Lanes 20-24 As for lanes 6-12 except using a650 as probe.
Lane 19 As for lanes 20-24 except that no protein extract is added. 
Specific competitor is added as a synthetic double stranded 
oligonucleotide containing the recognition site for the binding factor
to be competed off the DNA probe. lOOng of specific competitor is added
to the incubation reaction to give a final volume of lOOpl. This 
concentration of competitor gives a 250 M excess of competitor sites 
over probe sites. TabU3 'I illustrates all of the double stranded 
oligonucleotide competitors used in this work.
Lanes 6, 14 No specific competitor added.
Lanes 7, 15, 21 pCT oligonucleotide competitor added.
Lanes 8,16,22 pCACC, Lane 9 (3G215, Lanes 10,17 NF1, Lanes 11,18 NF1,
Lanes 12, 23 aP2a, Lane 24 aCACC
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Figure 3.3B
The Binding of Factors Present in Partially Purified Nuclear Protein 
Preparations to the Proximal Promoter Region of the Mouse Globin
Gene.
Lane 1 Maxam-Gilbert G reaction.
Lane 2 Probe (3730 (lOng) incubated with polydldC (l|ig) and made up to 
a total volume of 100|il with SB at a final salt concentration of 50 mM. 
No protein extract added.
Lane 3-4, 8-10 Probe [3730 (lOng) incubated with polydldC (l|ig) and 60
units MEL partially purified nuclear extract and made up to a total 
volume of 100|il with SB and a final salt concentration of 50 mM.
Lane 5-7 Probe (37 30 (lOng) incubated with 1 jig of polydldC and 60 
units of mouse liver partially purified nuclear extract and made up to 
a final volume of 100|ll with SB and a final salt concentration of 50 
mM.
lOOng of specific oligonucleotide competitor added as described for 
figure 3.3A as follows:
Lanes 6, 8 (3CT
Lanes 7, 9 (3CACC
Lane 4 NF-1
Lane 10 (3G215
0730
3.2 The Distal Promoter.
The distal region of the ^Tia^ or globin gene promoter is defined as 
that region spanning from -100 to -250 bp 5' of the transcription 
initiation site, that is to the 5' boundary of the DHSS which has been 
mapped in vivo (Fig.3.4) . This region is much less well characterised 
than the proximal region. Footprinting reactions were carried out as 
before but using probe (3600.
Two strong footprints are observed in this region with crude 
nuclear extracts from different cell lines (fig. 3.5) . Binding to the 
AGATAAGG motif at -212 bp is only observed with nuclear extracts from 
erythroid cell lines, either MEL or K562 (lanes 12-16 and 22-24) . 
Binding to this site can be specifically competed out with 250 M excess 
of oligonucleotide competitor (3G215 (lanes 7, 15 and 24), aG2
containing the mouse a-1 globin gene NF-E1 recognition site (lanes 8, 
16) or p^G containing the NF-E1 recognition site from the chicken (3^ 
globin gene enhancer (lanes 9 and 17) . This implies that the erythroid 
factor binding to the AGATAAG motif at -212 bp of the (3ma-|0r globin 
gene promoter is the same as the factor that recognises and binds to 
the NF-E1 recognition site in the mouse a-1 globin gene promoter and 
the chicken (3^  globin gene enhancer.
Binding to the GCCAA motif at -249 bp is observed in all of the 
nuclear extracts used (MEL, STO, K562 and HeLa) and can be specifically 
conpeted out with excess of oligonucleotide competitor containing 
either the recognition sequence for nuclear factor 1 (NF 1) (lanes 5, 
14 and 21) or containing its own recognition sequence (lanes 4, 13, 18, 
23 and 27) . As it is not competed out by an excess of oligonucleotides 
containing the recognition site for either the mouse al or the jJTia3or
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globin gene CCAAT boxes (lanes 6, 19, 20 and 26), the factor binding to
this sequence is a member of the NF-1 class of transcription factors
but is not apparently related to the CCAAT box binding factors.
A sequence AAGCCAGT (-160 bp), called Box 1, which is conserved in 
a similar position in the human (3 globin gene and has been shown to be 
necessary for inducible expression from the human promoter in MEL cells 
(de Boer et al. (1988) is not seen to be bound by. sequence-specific 
factors in this DNAase 1 footprinting system. However, as shown in 
figure 3.3B, this sequence is bound by factors present in partially 
purified MEL cell and liver nuclear extracts and gel retardation assays 
show that Box 1 binding activity is present in crude nuclear extracts
from MEL cells (Chapter 4) . This suggests that the DNAase 1
footprinting conditions used are not sensitive enough to detect it.
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Figure 3.4 The Distal Promoter. f
The distal promoter is defined here as the region immediatl^y_ upstream 
of the proximal promoter region spanning from -lOObp to ^2§0bp. This 
region has not been previously characterised either for protein binding 
sites or for function in initiating transcription.
The Distal Promoter.
-2Vr
CGT TCG CCA AAA AGG ATG CTT TAG AGA CAG TGT TCT
CTG CAC AGA TAA GGA CAA ACA TTA TTC AGA GGG AGT
CCC AGA GCT GAG ACG TCC TAA GCC AGT GAG TGG CAC
AGC ATG TCC AGG GAG AAA TAT CGC TTC GTC CTC ACC
GAA GCC TGC TTC CGT
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Figure 3.5 The Binding of Factors Present in Crude Nuclear Extracts to 
the Distal Promoter Region of the Mouse Globin Gene"
Lanes 1, 10 Maxam-Gilbert G reaction.
Reactions were set up as described previously for figure 3.3.
60 units of crude nuclear extract was added to each reaction as
follows:
Lanes 2, 11 Zero protein control.
Lanes 3-9, 12-16 MEL cell crude nuclear extract.
Lanes 17-21 STO crude nuclear extract.
Lanes 22-24 K562 crude nuclear extract.
Lanes 25-27 HeLa crude nuclear extract.
Specific oligonucleotide competitor was added (at a concentration of
lOOng in lOOp.1 of reaction mix, that is a 250 M excess) as follows: 
Lanes 4,13,18,23,27 pNFl, Lanes 5,14,21 NF1, Lanes 6,19,26 (3CT, Lanes 
7,15,24 pG215, Lanes 8,16 aG, Lanes 9 p G, Lanes 20 ocCT
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3.3 The Upstream Region.
In addition to promoter sequences which map immediately 5' of a 
gene, other regulatory sequences which act at a distance have been 
identified both 5' and 3' of different mammalian genes. For this reason 
in vitro DNAasel footprinting was used to determine whether these sites 
actually bind their cognate factors. However, given that this region 
lies outside the DHSS mapped in vivo and whose 5' boundary is at -250 
bp, it is unclear whether this region is functional in vivo. This is 
dealt with further in chapter 6. Footprinting of this region is carried 
out using probes (3280 and (3160 and is shown in figure 3.7.
A second high affinity NF-E1 recognition site is present at -520 
bp 5' of the initiation site (fig. 3.7A) . This site binds a factor 
present in MEL and K562 crude nuclear extracts (lanes 3 and 7) and 
binding is competed out by excess of (3G215 competitor (lanes 4 and 8) . 
Binding at this site is not detected with STO, HeLa or J774.2 crude 
nuclear extracts.
An additional footprint is observed at -455 to -485 bp with STO 
crude nuclear extracts (lanes 5, 6) and the sequence bound contains a
perfect TGGAATCA direct repeat. No footprint was observed in this 
region with MEL, K562, HeLa or J774.2 cell nuclear extracts and the 
sequence does not appear to be conserved in promoter/enhancer sequences 
of other globin or non-globin genes. For this reason, binding to this 
site was not followed up.
A site present at -550 bp contains the sequence AAGGCAGT which is 
recognised by the Box 1 factor (fig. 3.7B) . Binding to this site is 
erythroid specific; binding is present with crude MEL nuclear extracts
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(lanes 3-8, 16-19) but not with extracts from mouse kidney (lanes 9-11)
or STO (lanes 12-13), although mouse liver extracts were not tested.
Binding to this site by factor(s) present in MEL nuclear extracts can 
be competed out by 250 M excess of specific double-stranded 
oligonucleotide competitor pBl (lanes 5, 10, 13, 18) but not by pCT
(lanes 4, 17) or by pNFl (lane 8) . The figure also shows binding to the 
NF-E1 site at -520 bp, described in figure 3.7A.
In addition to a second high affinity NF-E1 binding site (-520 
bp), the upstream region bears a Box 1 site (-550 bp) which binds 
nuclear factors present in crude nuclear extracts from MEL cells. This
binding activity is not present in crude nuclear extracts from mouse
STO or kidney. Figure 3.3A and 3.3B described DNAase 1 footprinting of 
the proximal region of the mouse (3ma 0^r globin gene with crude and 
partially purified nuclear extracts respectively. It was shown that a 
footprint was obtained over the Box 1 sequence, AAGCCAGT (-169 bp), 
with partially purified MEL and liver nuclear extracts but not with 
crude extracts. The Box 1 sequence at -550 bp, AAGGCAGT, is however 
bound when footprinted with crude MEL extracts. This may be explained 
if the Box 1 recognition sequence at -550 bp has a higher affinity for 
Box 1 binding factor than the site at -160 bp. There is only a single 
base pair difference (G to C) between them but this may explain the 
difference in binding activity. This would need to be tested out by gel 
retardation assay and comparison of the ability of oligonucleotides 
containing these different sequences to compete for binding by the Box 
1 recognition factor. Given that this region lies outwith the DHSS 
mapped in vivo, it is unclear whether these sites are active in vivo.
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Figure 3.6 The Upstream Region.
" This region maps from -250 at the 5' end of the distal promoter 
region to -745bp upstream of the initiation site.
The Upstream Region.
-1iO
GAG CTC AGG GTT TAC TTG AGA GAT CCT GAC TCA ACA
ATA AGG TAT AGA GCA ATC AAG GGC GAT TCT CTG AAG
GCA GTT ATT GAA CTC CTT GTA CAC TCT TCC CAC ACA
CAC GTG TTC AGA GAA CTT GAT AAA ACA CAT ATA TAC
AAG TAA GCC ACA CAA ACA TTC ACA TGA GAG AAG AAA
AAC AAG AGC AAA CTA AGT AAG ATG CAT TTT CTT ATC
AGG AAG TTT AGT TGA CAC CAG AAA GAA GTC ATA TTT
GGA ATC AAA ATG GAA TCA TCA TCA TGT ATG CTA AAG
ATG TTT TTT TCA CAT TCT TGA GCA ATG TGG ACA GAG
AAG GAG ATT CAT CCA TGC ACT CAA ACT GGG AAA CAA
AGA AAA GAA ATC CTC TTC TAA GCT TTG CTT CTC AAT
TTC TTA TTT GCA TAA TGA GAA AAA AAG GAA AAT TAA
TTT TAA CAC AAT TCA GTA GTT GAT TGA GCA AAT GCG
-W
Figure 3.7 Protein Binding Sites Upstream of the Mouse |jTiaJQr Globin
Gene.
Figure 3.7A The Proximal Upstream Region.
Footprinting using [3280 as probe identifies protein binding sites in 
the region -346 to -550.
Lane 1 Maxam-Gilbert G reaction.
Lane 2 Zero Protein Control.
60 units of crude nuclear extracts were added to reactions as follows:
Lanes 3-4 MEL cell crude nuclear extract
Lanes 5-6 STO
Lanes 7-8 K562
Lanes 9-10 HeLa
Lanes 11-12 J774.2
All the above footprinting incubations are carried out as before in a 
total volume of 100|il with SB and a final salt concentration of 50 mM. 
Specific oligonucleotide competitor (3G215 was added to reactions 4, 6,
8, 10 and 12 at a concentration of lOOng in lOOfll, that is in 250 M
excess.
13280
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Figure 3.7B The Distal Upstream Region.
To identify protein binding sites in the distal part of the upstream 
region, probe (3160 was used in footprinting reactions. Footprinting 
reactions were carried out as described previously.
Lanes 1, 14 Maxam-Gilbert G reaction.
Lanes 2, 15 Zero Protein Control.
Crude nuclear extracts were added to reactions as follows:
Lanes 3-7, 15-19 60 units of MEL cell crude nuclear extract
Lanes 9-11 60 units of mouse kidney crude nuclear extract
Lanes 12-13 40 units of brain crude nuclear extract.
Footprinting reactions were carried out as described previously. 
Specific double-stranded oligonucleotide competitor was added to 
reactions as follows:
Lanes 4, 7 pCT 
Lanes 5, 10 13, 18 pBl 
Lanes 6, 11, 19 pG215
Lane 7 aG
Lane 8 pNFl
0160
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3.4 The 3' Flanking Region.
During the course of my study, sequences in the 3' flanking region
identified (Knezetic and Felsenfeld (1989); Choi et al. (1986); Bodine 
and Ley (1987); Kollias et al. (1987) which upregulate transcription
from linked genes in an erythroid and developmental specific fashion. 
The chicken p enhancer sequences have since been characterised in terms 
of protein binding sites and it has been demonstrated that these 
enhancers as well as containing variable combinations of AP-1, CACC 
boxes and other previously characterised binding sites, possess 
multiple copies of NF-E1 binding sites. Figure 3. 8A illustrates 
diagrammatically the binding sites present in p globin gene 3' 
enhancers and their relative positions within that enhancer. The 
chicken p^ enhancer has been shown to act upon both the adult gene (p^ ) 
and the embryonic gene (e) . No such enhancer sequence had been 
identified for the mouse p globin gene locus.
By analysing DNA sequence 3' of the mouse pma o^r globin gene at a 
position equivalent to that where the chicken and human adult P globin 
gene 3' enhancer sequences had been found, I was able to identify a 
number of potential binding sites for sequence specific DNA binding 
proteins (figure 3.8B). These sequences included several potential 
NF-E1 binding sites, an AP-1 site, an AP-2 site and a Box 1 binding 
site. I was interested firstly in determining whether these potential 
binding sites actually bound factors and secondly whether these 
sequences were involved in the transcriptional regulation of the gene. 
DNAase 1 footprinting was used to look for protein binding to these
of the chicken p^ and the human yand p globin genes were
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sites.
A factor present in MEL cell nuclear extracts binds to the
sequence AAGCCAAT present at +1705 relative to the start site of
transcription (fig.3.90). This sequence contains the recognition 
sequence for both CCAAT box binding factors, for (3NF-1 and for Box 1 
binding factor. However binding to this sequence is competed out by 
oligonucleotide competitor pBl (lane 6) but not by (3CT (lane 9) or by 
pSIFl (lane 7) . This indicates that this site is bound by Box 1 binding 
factor, the same factor that binds to sites in the promoter and
upstream region of the gene, and is not bound by CCAAT box or pMF-1 
binding factors.
By DNAase 1 footprinting (fig.3. 9A), I was able to show that only 
one of the NF-E1 binding sites at +2088, bound NF-E1 and that this 
binding could be competed out by excess of oligonucleotide competitor, 
(3G215 containing the NF-E1 binding site from -212 bp in the [3rna-lor 
promoter, suggesting that the same factor binding to the promoter
sequence is also binding to this 3' NF-E1 recognition site. There are 3 
additional potential NF-E1 recognition sites and their failure to bind 
NF-E1 in the DNAase 1 footprinting assay suggests that they may be 
similar to the NF-E1 site at -60 bp within the 5' promoter region which 
also fails to bind NF-E1 in DNAase 1 footprinting assays with crude 
nuclear extracts. DNAase 1 footprinting of the proximal promoter with 
partially purified nuclear extracts shows a footprint over the NF-E1 
binding site at -60 bp (fig. 3.3) . However, footprinting of the 3' 
region was not carried out with partially purified extracts and it is 
therefore not possible to make further comparisons between these sites. 
The potential AP-1 and AP-2 sites in the 3' region also did not bind
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although they are not perfect recognition sequences and this may 
account for their failure to bind.
The Box 1 site at +1705 bp binds factor which can be specifically 
competed out by oligonucleotide competitor containing the Box 1 
recognition site from -160 bp in the promoter but not by 
oligonucleotide containing the pima-10r globin gene CCAAT box sequence.
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Figure 3. 8A Comparison of thp Position of Regulatory Elements in the 3' 
fIarikinq~Region of Chicken P , Human (3 arid Chicken a Globin Genes.
The" figure shows the presence in the human and chicken adult (3 and the 
chicken adult a globin gene enhancers of multiple copies of the NF-E1 
recognition sites. In addition, there are API, AP2, CACC and NF-1 
elements. The human and chicken enhancers map to a positions 400 to 
900bp 3' of the polyadenylation signal of each gene. .Looking in this 
region 3' of the mouse adult p globin gene, the p™3 0^17 gio^in gene 
(figure 3.8B), I was able to identify several copies of the NF-E1 
recognition site, a Box 1 binding site and potential API and AP2 
binding sites.
(Boil)
API
EF1
Chicken 6(A)
+ 1600
^ACCj EF1
+1900
EF1 EF1 Chicken a (A)
+1400 EF1 +1500
f~CPT
EF1 EF1
Human 6
+2000 EF1 EF1 +2500
Figure 3.8B Comparison of the Sequence of the Mouse (3ma^or Globin Gene
3/ Region and the Chicken [3 Globin Gene Enhancer.
The figure shows the sequence of the mouse globin gene 3' region
(A) and the chicken p globin gene enhancer (B).
Sequences bearing homology to previously described protein binding 
sites are underlined for the mouse pma o^r globin gene 3' region as are 
characterisedbinding sites in the chicken p globin gene enhancer.
The mouse p globin gene 3' region contains a Box 1 recognition
site (AAGCCAAT) , five NF-E1 recognition sites (AGATAA, AATAAG, GATAT, 
AGATAGA & GATAT), a weak API recognition site (TGACTG) and an AP2 site 
(ATGGGATTTC).
The chicken p globin gene enhancer contains an NF-1 like sequence 
(TGGCA), an API site (TGACTC) , a weak AP2 site (CTGGGC) , a CACCC box 
and two NF-E1 sites (AGATAA, GATAG).
The organisation of these elements within the mouse globin gene
3' region is similar to that within the chicken fr globin gene 
enhancer./I
+ibA3
CAGTTCTCAA GCCAATAATT TTTCTTTTGT AAAACTACCA 
TTATTCTCTA AACTTTTCCC TCTGTGTTTA CCAAGCAACA 
TTATTTATCT TTTCATAAAT CCTGTTGCCT TAGACAGCTT 
CAGTAGCAAT AGAGGTAGGA TTAAGGAGAG AATAGAAGTT 
CATACCATGC CTGCACAGTC AATAGTCACT ATGGGATTTC 
AAATGGCACT TTGCCTGGGA CCTTTACACT TCACACCATA 
CTCTGGCTTG AGTTAGGAGT TAAGAATGAG AGAAATATAA 
TCTAGAGAGA ATAAGAATAT CTAGTTTTTA AGGCTCATTA 
CTGGGGTCTT ATGAAATTTC CATAATACCC TGTAAATGGA 
AGCATTTATT TTTTCAATAA ATCTATCTTG AATATCCAGT
+ U O Z
B.
+ 1820
TCG ACC TCG AGG ATC ATT  TC TG G C ATT CAG 
CCT CCC CGA AAG GAG CTG ACT CAT GCT A GC 
CCA GCAGCC A G C TG G G TG G G G G C A G G TTG C  
AGA TAA A CA TTT TGC TAT CAA GAC TTG CAC 
AGA CCT TGT TTC TAG + / ^ 2 0
Figure 3.9 DNAase 1 Footprinting of 3' Sequences.
Probe (3415 is generated as decribed in figure 3.1, using primers FFP7 
and 8, such that one primer is 5' end-labelled and the other is
unlabelled.
Figure 3.9A illustrates footprinting with (3415 generated using
end-labelled FP8 and figure 3.9B illustrates footprinting with (3415 
generated using end-labelled FP7.
Figure3.9A
Lane 1 Zero protein control.
Crude nuclear extracts were added to reactions as follows:
Lanes 2-6 60 units MEL cell crude nuclear extract
Lanes 7-9 80 units STO nuclear extract.
Specific oligonucleotide competitor was added in 250 M excess as 
follows:
Lanes 2, 8 
Lane 5 p
Lane 3 (3CT
Lane 6, 9 (3B1
Footprinting with crude nuclear extracts from MEL cells generates a 
footprint st +2088 over the sequence AGATAGA (lanes 2-6) which is not 
obtained over the same sequence with STO nuclear extracts (lanes 7-9) . 
Binding to this site is competed out by 250 fold excess of specific 
oligonucleotide competitor (3G215 (lane 3) and by 250 M excess of 
oligonucleotide competitor p G (lane 5).
04-15
Figure 3.9B
Lane 1, 2 Maxam-Gilbert G, G+A Reactions.
Lane 3 Zero Protein Control.
Lanes 4-10 60 units of crude MEL nuclear extract
Specific oligonucleotide competitor was added in 250 M excess as
follows:
Lane 5 (3G215
Lane 6 pBl
Lane 7 Pnfi
Lane 8 pGACC
Lane 9 pCT
Lane 10 NF-1
0415
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Figure 3.10 Summary of Footprinting Data.
Thg. figure summarises the results of DNAase I footprinting of the mouse 
P J globin gene 5' and 3' flanking regions.
Conserved sequences are underlined and those sequences actually 
protected from DNAase I cleavage by protein binding are boxed. A dotted 
box represents a footprint which is not obtained with MEL cell nuclear 
extracts . The Proximal Promoter.
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GTA GAG CZh CAC CCT GGT AAG GGC CAA TCT GCT CAC
ACA CAG QKL_kQK_ GAG]AGG GCA GGA GCC AGG GCA GAG 
CAT ATA AGG TGA GGT AGG ATC AGT TGC TCC TGA CA
0
The Distal Promoter.
-26U
[CGT TCG_^£A_AAA (AGG ATG CTT TAG AGA CAG TGT TCT
CTG |CAC AGAJEAA GGA C&A ACA TTA TTC AGA GGG AGT
CCC AGA GCT GAG ACG TCC TAA GCC AGT GAG TGG CAC
AGC ATG TCC AGG GAG AAA TAT CGC TTC GTC CTC ACC
GAA GCC TGC TTC CGT
-107
The'Upstream' Region.
-730
GAG CTC AGG GTT TAC TTG AGA GAT CCT GAC TCA ACA 
ATA AGG TAT AGA GCA ATC AAG GGC GAT TCT d p  AAG 
TCC CAC ACA 
CAT ATA TAC 
GAG AAG AAA
CAT TTT CTT ATC
GCA GTT ATT G&&_CEC-CIX GTA~(foC TCT 
CAC GTG TTC AGA GAA CTT GAT AAA ACA 
AAG TAA GCC ACA CAA ACA TTC ACA TGA
AAC AAG AGC AAA CTA AGT AAG A T G ________________
AGG AAp TTT AGT TGA CAC CAG AAA GAA GTC - ATA TJX 
~GGA ~ATC AAA~ ATG~GAA~TCA TCA] TCA TGT ATG CTA AAG 
ATG TTT TTT TCA CAT TCT TGA GCA ATG TGG ACA GAG 
AAG GAG ATT CAT CCA TGC ACT CAA ACT GGG AAA CAA 
AGA AAA GAA ATC CTC TTC TAA GCT TTG CTT CTC AAT 
TTC TTA TTT GCA TAA TGA GAA AAA AAG GAA AAT TAA 
TTT TAA CAC AAT TCA GTA GTT GAT TGA GCA AAT GCG
-264
The 3' Region.
tlW
CAGTfrCTCAA GCCAATAAIjrTTTC TTTTG T AAAACTACCA 
TTATTCTCTA AACTTTTCCC TCTGTGTTTA CCAAGCAACA 
TTATITA TC T TTTCATAAAT CCTGTTGCCT TAGACAGCTT 
CAGTAGCAAT AGAGGTAGGA TTAAGGAGAG AATAGAAGTT 
CATACCATGC CTGCACAGTC AATAGTCACT ATGGGATTTC 
AAATGGCACT TTGCCTGGGA CCTTTACACT TCACACCATA 
CTCTGGCTTG AGTTAGGAGT TAAGAATGAG AGAAATATAA  
TCTAGAGAGA ATAAGAATAT CTAGTTTTTA AGGCTCATTA  
CTGGGGTCTT ATGAA ATTTC CATAATACCC TGTAAATGGA  
AGCATTTATT TTTTCAATA{A~ATCTATCTTG A A jtT C C A G T
+2.IOZ
CHAPTER 4 CHARACTERISATION OF FACTORS BINDING TO SITES IN THE
PROMOTER AND 3' FLANKING REGION OF THE MOUSE GLOBIN GENE.
INTRODUCTION.
DNAase 1 footprinting of the 5' and 3' flanking sequence of the 
mouse pima-*0r globin gene has revealed a limited number of sites which 
specifically bind factors present in nuclear extracts prepared from 
cell lines and mouse tissue. Gel retardation assays carried out as 
described in section 2.30 and using oligonucleotide probes end-labelled 
as described in section 2.14 were then used to further characterise 
binding activities. DNAase 1 footprinting with crude nuclear extracts 
had failed to show protein binding activity to DNA sequences such as 
the CCAAT box, the CACC box, the NF-E1 recognition site at -60 bp and 
the Box 1 binding site at -160 bp. Based on previous work on these 
sites in other genes, it was expected that these sites would bind 
factors. I investigated the binding to these sequences by in vitro gel 
retardation assay which is a more sensitive technique than DNAase 1 
footprinting for determining protein binding to specific sequences. By 
analysing the mobility of shifted bands, competition patterns and 
tissue specificities, it was possible to distinguish binding 
activities.
4.1 Cross Competition Studies to Characterise Binding Activities.
DNAase 1 footprinting revealed that binding to certain sites 
within the promoter and 3' region of the mouse prna''°r globin gene could 
be competed out by an excess of oligonucleotide containing the
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recognition sequence from other sites. For example, binding to the 
GCCAA motif at -250 bp could be competed out by oligonucleotide 
containing the recognition site for NF1 from the Adenovirus origin of 
replication. Gel retardation assays are used here to further 
investigate competition between different protein binding sites in 
uninduced MEL cell crude nuclear extracts.
Figure 4.1A shows that four different NF-E1 binding sites 
differ in their ability to compete for binding to the high affinity 
NF-E1 site present at -212 bp in the mouse globin gene promoter.
Oligonucleotide (3G215 is 5' end-labelled and incubated with 2 units of 
MEL crude nuclear extract in the presence or absence of a 1000 M excess 
of oligonucleotide competitors pG60, p^G or pG1^ ^. The strongest 
competitor is pG215 (lane 2), followed by the NF-E1 binding site from 
the chicken p^ globin gene enhancer (lane 4) . The NF-E1 site from the 
DHSS of the mouse p™3 0^17 globin gene second intron is a less effective 
competitor still (lane 5) but the NF-E1 binding site at -60 bp (pG60) 
hardly competes at all (lane 6). The ability of these oligonucleotides 
to compete for binding to PG215 reflects their relative affinities for 
NF-E1 where pG215 is bound most strongly and (3G60 weakly. pG60 will 
bind NF-E1 sufficiently well to observe a retarded complex in a gel 
retardation assay (Data not shown) . P^G and P G ^ ^  bind NF-E1 with 
intermediate affinity.
Figure 4.IB shows the existence of two p CCAAT box binding 
activities, pCTl and pCT2 (lane 1) . pCTl is competed out by the (XP2a 
oligonucleotide containing the CCAAT box from the mouse al globin gene 
(lane 5) and pCT2 which is partially competed out by binding to PNF1. 
This suggests that one of the prna''or globin gene CCAAT box binding
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factors also binds the al globin gene CCAAT box and that the other
CCAAT box binding factor binds to the pNF-1 binding site at -250 bp. 
Binding to the pCT oligonucletide by factors present in crude nuclear 
extracts in gel retardation assays illustrates that the failure to 
obtain a footprint over the CCAAT box using crude nuclear extracts is 
not due to the absence of these factors in the extracts but as 
suggested in Chapter 3, is probably due to the technical parameters of 
the DNAase 1 footprinting assay system.
Figure 4.1C shows that binding to the NF1 recognition 
sequence is partially competed out by binding to (3NF1 (lane 3) while 
binding to pNFl is completely competed out by binding to NF1 (figure 
4.ID, lane 3). Binding to the NF-1 oligonucleotide generates a shifted
complex which is smeared over a range of mobility unlike the pNF-1
complex which is a tight band. This is consistent with published 
results from gel retardation assays using radio-labelled NF-1 probes 
(Schneider et al. 1986). The NF-1 smear suggests that there is a family 
of factors recognising this sequence of which pNF-1 is a member. This 
may explain why the NF-1 oligonucleotide competes completely for 
binding to the pNF-1 recognition site while binding to the NF-1 probe
is only partially competed out by (3NF-1 oligonucleotide competitor. 
Binding to pNFl is not competed out by pCT (fig.4.ID, lane 4) . Binding 
to NF1 is not competed out by 1000 M excess of pCT, aP2a, BB1 or NF-Y 
oligonucleotides (fig.4.1C, lanes 4-7). These results suggest that 
binding by the NF-1 family of factors is distinct from the binding 
activity of the CCAAT box binding factors, (3CT and OP2a or the Box 1 
binding activity and the NF-Y binding activity.
Binding to the Box 1 recognition sequence is competed out by the
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pCT oligonucleotide (fig.4.IE, lane 5) but not by pNFl (lane 3), NF1 
(lane 4), aP2a (lane 6) or NF-Y (lane 7) . That binding to the Box 1 
motif from position -160 bp of the promoter, can be competed out by pCT 
but not by aP2a suggests that the factor binding to the Box 1 motif may 
be homologous to the pCT2 but not the pCTl binding activity (fig.4.IB) . 
These competition studies reveal that several of the factors shown to 
bind elements within the pma0Or g]_Qbin gene promoter cross compete and 
share aspects of their sequence recognition. This may have significance 
for functional interactions between elements and will be discussed in 
Chapter 8. The results of competition binding studies are summarised in 
Table 4.1 below.
Table 4.1 Competition for DNA. Binding Activities.
PG215 pG60 pWS2,
pG215 +++ + ++ ++
pG60 +++ +++ +++ +++
+++ + +++ ++
p!VS2G +++ + +++ +++
1000 M excess of competitor oligonucleotide
G pCT OP2a Box 1 NF-1 pNF-1
pCTl +++ +++
PCT2 +++ +
Box 1 +++ - +++
NF-1 - - +++ ++
pNF-1 - - - +++ +++
- no competition;
++ moderate competition;
+ weak competition;
+++ complete competition.
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Figure 4.1 Competition Studies to Compare the Roles of Different DNA 
Binding Factors.
Figure 4.1A.
lOOpg of probe pG215 is incubated with 6 |lg of non-specific competitor 
polydldC, 2 units of MEL cell crude nuclear extract in a total volume 
of 20 |ll with SB and salt concentration of 50 mM.
Specific double stranded oligonucleotide competitor is added at lOOng 
per reaction, that is in 1000 M excess as follows:
Lane 1 No specific competitor.
Lane 2 pG215
Lane 3
Figure 4.IB.
lOOpg of probe pCT is incubated with 6 pg of non-specific competitor 
polydldC, 2 units of MEL cell crude nuclear extract in a total volume 
of 20 |ll with SB and salt concentration of 50 mM.
Specific double stranded oligonucleotide competitor is added at lOOng 
per reaction, that is in 1000 M excess as follows:
Lane 1 No specific competitor.
Lane 2 pNFl 
Lane 3 NF1 
Lane 4 (3CT 
Lane 5 OP2a 
Figure 4.1C.
lOOpg of probe NF-1 is incubated with 6 Jig of non-specific competitor 
polydldC, 2 units of MEL cell crude nuclear extract in a total volume 
of 20 [il with SB and salt concentration of 50 mM.
Specific double stranded oligonucleotide competitor is added at lOOng 
per reaction, that is in 1000 M excess as follows:
Lane 1 No specific competitor.
Lane 2 NF1 
Lane 3 pNFl 
Lane 4 pCT 
Lane 5 CxP2a 
Lane 6 ftel 
Lane 7 NF-Y 
Figure 4.ID.
lOOpg of probe pNFl is incubated with 6 Jig of non-specific competitor 
polydldC, 2 units of MEL cell crude nuclear extract in a total volume 
of 20 fll with SB and salt concentration of 50 mM.
Specific double stranded oligonucleotide competitor is added at lOOng 
per reaction, that is in 1000 M excess as follows:
Lane 1 No specific competitor.
Lane 2 pNFl 
Lane 3 NF1 
Lane 4 pCT 
Figure 4.IE.
lOOpg of probe pBl is incubated with 6 jig of non-specific competitor 
polydldC, 2 units of MEL cell crude nuclear extract in a total volume 
of 20 jll with SB and salt concentration of 50 mM.
Specific double stranded oligonucleotide competitor is added at lOOng 
per reaction, that is in 1000 M excess as follows:
Lane 1 No specific competitor.
Lane 2 pBl, Lane 3 pNFl, Lane 4 NF1
Lane 5 pCT, Lane 6 (XP2a, Lane 7 NF-Y
Lane 4
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4.2 An Analysis of the Tissue Specificity of Binding to Mouse jjrnaljc>r
Globin Gene Promoter and 3' Sequences.
Different transcription factors have been shown to be 
developmentally and tissue-specifically regulated. To further 
characterise the factors which bind the mouse pma-]0r globin gene 
flanking sequences, I looked at binding activity to oligonucleotide 
probes in crude nuclear extracts from a variety of mouse tissues and 
cell lines.
Crude nuclear extracts were prepared from several mouse tissues 
including liver and brain as well as from uninduced and induced MEL 
cells, a fibroblast cell line (STO), a macrophage cell line (J774.2) 
and an embryonal carcinoma cell line (F9) and two human cell lines K562 
and HeLa. Figure 4.2 shows the results of gel retardation assays 
carried out in the presence of these different crude nuclear protein 
extracts.
Figure 4.2A illustrates that while CCAAT box binding activity 
to (XP2a is present in both MEL (lane 1) and mouse brain (lane 4) 
nuclear extracts, binding activity to the NF-E1 recognition site is 
present only in MEL nuclear extracts (lane 1). NF-E1 binding can only 
be competed out with a 1000 M excess of (3G215 competitor, (lane 2) 
whereas binding to aP2a, which contains the mouse a-1 globin gene CCAAT 
box recognition site, is only competed out by a 1000 M excess of 
competitor aP2a (lane 3).
Figure 4.2B shows that the activity which binds to the GCCAA motif 
at -250 bp is present in MEL, STO, J774.2, K562 and Hela extracts and
is also present in mouse brain and liver extracts. This is consistent 
with the known tissue distribution of NF1.
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Binding to oligonucleotide probe (3CC containing the CACC 
recognition site from -90 bp of the mouse globin gene is shown
in figure 4.2C. There are two binding activities, (3CC1 the slower 
mobility complex and (3CC2 the faster mobility complex. (3CC1 binding 
activity is present in all the nuclear extracts tested but (3CC2 binding 
activity is present only in induced MEL, K562 and J774.2 crude nuclear 
extracts. Jackson et al. (1989) describe two different chicken 
erythrocyte nuclear binding activities which recognise the (3^ globin 
gene CACC box: the slower mobility complex is present in chicken
erythrocyte extracts at different stages of development whereas the 
faster mobility complex becomes less abundant in extracts from 
progressively later stages in development. They suggest that the slower 
mobility complex is an Spl bound complex suggesting that the slower 
mobility complex present in all mouse cell types looked at contains 
Spl. Competition studies with Spl oligonucleotide competitor have not 
yet been carried out. The tissue specificity of the higher mobility 
complex present only in extracts of haematopoietic origin suggests that 
it may play a role in regulation of differentiation.
Figure 4.2D shows the presence of two CCAAT binding activities 
that differ in their tissue-specific activity. pCTl is present in all 
crude nuclear extracts looked at except F9 nuclear extracts. (3CT2 is 
absent in induced MEL cell, mouse brain and liver nuclear extracts but 
present in all other extracts looked at. The absence of (3CT2 binding 
activity in induced MEL cell extracts suggests that it may play a role 
in the induction of pfna9or globin gene expression during 
differentiation. If it is an inhibitory binding factor, possibly acting 
by preventing binding of pCTl and preventing the formation of a
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functional transcription complex, then its absence in induced cells 
would lead to derepression of transcription. It would be acting in an 
analogous fashion to the CDP, (CCAAT Displacement Protein) involved in
the regulation of human globin gene (Superbi-Furga et_al (1989) and
sea urchin histone H2B gene (Barberis et al (1987).
pCT2 is present in the embryonal cell line, F9, while pCTl is 
absent suggesting a role for (3CT2 in repression of globin gene 
expression during development.
Box 1 binding activity is present in all tissues looked at except 
induced MEL cells, F9 and J774.2 cells (figure 4.2E) . Box 1 activity is 
present in uninduced MEL cells but absent in induced MEL cells 
suggesting a role for this factor in regulating the induction of j3rna^ or 
globin gene expression during differentiation. The significance of this 
pattern of binding activity will be further discussed in chapters 6 and 
7 when the functional role of the Box 1 sequence is assessed.
Table 4.2 summarises the results described here.
Table 4.2 TISSUE SPECIFICITY OF DNA BINDING.
Fr~ Fr+ Br. Liv. K562 HeLa STO F9 J774
(3G215 + + - - - - - - -
PNFl + + + + + + +
pCACC + + + - + + + •p +
pCTl + + + + + + •p - +
pCT2 + - - - + + + +
pBl + - + + + + ■p - -
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Figure 4.2 Tissue Specific Binding Activities .
Binding assays were carried out as desribed previously in section 2.35. 
Figure 4.2A
Lane 1 lOOpg aP2a probe and lOOpg (3G215 probe are coincubated with 2 
units of MEL nuclear extract, 6 |lg non-specific competitor polydldC, to 
a total volume of 20|ll with SB and a final salt concentration of 50 mM. 
Lane 2 As for lane 1, except lOOng of specific oligonucleotide 
competitor is added.
Lane 3 As for lane 1, except that lOOng of specific oligonucleotide 
competitor cxP2a is added.
Lane 4 As for lane 1, except that 2 units of mouse brain crude 
nuclear extract is added.
Figure 4.2B
lOOpg of probe (3NF1 is incubated with 6 \lg of non-specific competitor 
polydldC, 2 units of crude nuclear extract in a total volume of 20|ll 
with SB and a final salt concentration of 50 mM.
2 units of crude nuclear extract are added as follows:
Lane 1 Uninduced MEL cell nuclear extract
Lane 2 Mouse brain, Lane 3 Mouse liver, Lane 4 K562
Lane 5 HeLa, Lane 6 STO, Lane 7 J774.2
Figure 4.2C
lOOpg of probe pCACC is incubated with 6 (ig of non-specific competitor 
polydldC, 2 units of crude nuclear extract as described below, in a 
final volume of 20 |ll with SB and a final salt concentration of 50 mM. 
Lane 1 Uninduced MEL cell nuclear extract
Lane 2 Induced MEL cell
Lane 3 K562, Lane 4 HeLa, Lane 5 Mouse brain
Lane 6 Mouse liver, Lane 7 STO, Lane 8 J774.2
Figure 4.2D
lOOpg of probe pCT is incubated with 6|lg of non-specific competitor 
polydldC, 2 units of crude nuclear extract as described below, in a
total volume of 20|ll of SB and a final salt concentration of 50 mM.
Lane 1 uninduced MEL cell nuclear extract
Lane 2 induced MEL, Lane 3 K562 , Lane 4 HeLa, Lane 5 Mouse brain,
Lane 6 Mouse liver, Lane 7 STO, Lane 8 J774.2
Figure 4.2E
lOOpg of probe (3b1 is incubated with 6 |ig of non-specific competitor
polydldC, 2 units of crude nuclear extract as described below, in a
total volume of 20 |ll with SB and a final salt concentration of 50 mM.
Lane 1 uninduced MEL cell crude nuclear extract
Lane 2 induced MEL cell , Lane 3 J774.2, Lane 4 Mouse brain
Lane 5 Mouse liver, Lane 6 F9 cell, Lane 7 K562, Lane 8 HeLa
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4.3 The Phosphorylation State of Erythroid Factor 1.
The electrophoretic mobility of the NF-E1 nucleoprotein complex in 
gel retardation assays varied depending on whether it was performed 
with nuclear extracts prepared from MEL cells in the presence or 
absence of phosphatase inhibitors, (sodium orthovanadate and 
(3-glycerophosphate). Compare figure 4.2A where the MEL nuclear extracts 
were prepared in the absence of phosphatase inhibitors with figure 4.1A 
where the MEL extracts were prepared in the presence of phosphatase 
inhibitors. In figure 4.1 A, there are two shifted bands, one of high 
mobility (A) and one of lower mobility (B) . In figure 4.2A, only the 
high mobility complex (A) is present. This suggests a role for 
phosphorylation in altering the binding activity and therefore possibly 
the function, of NF-E1. The role of phosphorylation in modulating the 
binding activity of yeast ATF (Jones and Jones (1989) had been 
investigated in vitro using gel retardation assays and suggested a 
method by which to investigate the role of phosphorylation in the 
binding activity of NF-E1.
Crude nuclear extracts were therefore incubated at 37°C for 
15 minutes in the presence of 10 units of calf intestinal phosphatase 
and the dephosphorylation reaction arrested by the addition of 16 mM 
sodium orthovanadate. Control incubations were carried out in the 
absence of phosphatase. The nuclear extracts were then used in gel 
retardation assays as described in section 2.30. Two retarded complexes 
which differ in mobility are observed in gel retardation assays carried 
out with nuclear extracts prepared in the presence of phosphatase 
inhibitors (lane 1) . Both complexes are specifically competed out by 
excess of the (3215 oligonucleotide competitor (lane 2). Extracts which
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have been incubated at 37°C for 15 minutes in the absence of calf 
intestinal phosphatase as a control for degradation still show binding 
activity for both forms of the factor (lane 3) . When extract which has 
been incubated for 15 minutes with CIP is used in the assay only the 
high mobility complex is observed (Figure 4.3) . The slow mobility 
complex disappears. However there is not a subsequent increase in the 
amount of the high mobility complex formed as might be expected if the 
slow mobility complex formed by the dimerisation of the low molecular 
weight form of the protein. It is possible that the high molecular 
weight complex is a heterodimer consisting of NF-E1 and some other 
unidentified protein and these results suggest that phosphorylation is 
necessary for the formation of this complex.
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Figure 4.3 Phosphorylation of EF1.
Lane 1 Untreated extract prepared in the presence of phosphatase
inhibitors.
Lane 2 1000 M excess of specific oligonucleotide competitor (3G215.
Lane 3 Control extract incubated at 37 C for 15 minutes in the
absence of phosphatase
Lane 4 Extract treated with calf intestinal phosphatase for 15
minutes at 37 C.
PHOSPHORYL a TiON 
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CHAPTER 5 GENERATION OF MUTANT PROMOTER CONSTRUCTS.
INTRODUCTION.
Previous work has only analysed the functional importance of 
proximal promoter elements and the hitherto unidentified protein 
binding sites in the distal promoter remained to be assessed for their 
functional significance. Methods for studying the relative importance 
of different elements have in the past included taking individual 
elements out of context and testing their function in heterologous 
promoters or in isolation in artificial promoter constructs. These 
methods are less than satisfactory since it is now clear from work on 
the SV40 enhancer and other regulatory sequences that the context of 
the element determines its overall function. In many cases no one 
element is sufficient to ensure correct regulation of transcription. 
Where possible it is preferable to analyse the function of individual 
promoter elements in the context of their own promoters or enhancers.
I set out to analyse whether the elements I had identified as 
binding protein in in vitro assays had a functional role in modulating 
transcription from the mouse pma-'or globin gene promoter. In particular 
I was interested in the distal promoter elements which I had identified 
and characterised. As described in section 2.19, I used a PCR-mediated 
site-directed mutagenesis method to introduce carefully selected point 
mutations. Figure 5.1 summarises the method used.
All the mutant promoter constructs are based on the wild-type 
promoter construct, pP346GH, which contains 5' flanking sequence of the 
mouse prna-|or globin gene spanning from the transcription start site to 
346 bp upstream. Figure 5.2 illustrates the mutations introduced which
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were predicted to abolish protein binding and shown by gel retardation 
Aassay and DNAase 1 footprinting to do so and figure 5.3 illustrates the 
|l?CR products obtained by the method described in figure 5.1. Figure 5.4 
'■illustrates schematically the organisation of elements in the wild-type
:
, ir
fand mutant promoters.
Figure 5.1 PCR-Mediated Site Directed Mutagenesis.
All the mutant promoter constructs are based on the wild-type promoter 
construct, pp346GH. Figure 5.2 illustrates the mutations introduced 
which were predicted to abolish protein binding. The figure below 
illustrates the mutant and linker oligonucleotide primers used in the 
method described in section 2.19 to generate mutant promoter 
constructs.
PCR SITE DIRECTED MUTAGENESIS 
OLIGONUCLEOTIDE PRIMERS.
LINKER OLIGONUCLEOTIDES
ACG ACG GCC AGT GCC AAG CTT TGC TTC TCA
AGT GGT TCG GGG AGT TGG GCC TTG GGA TCC
MUTANT OLIGONUCLEOTIDES.
TGT TCT CTG CAC AGO TCC GGA CAA ACA TTA
GAA TAA TGT TTG TCC GGA GCT GTG CAG AGA
GAG CTG AGA CGT CCT CCT AAA GTG AGT
GTG CCA CTC ACT TTA GGA GGA* CGT CTC
TGA GCA AAT GCG TTC GCC GGT TAG GAT GCT
TAA AGC ATC CTA ACC GGC GAA CGC ATT TGC
CCT GAT TCC GTA GAG CTG CAG GAA GGT
ACC TTC CTG CAG CTC TAG GGA ATC AGG
TGC TCA CAC AGC TGC AGG AGG GCA GGA
TCC TGC CCT CCT GCA GCT GTG TGA GCA
Figure 5.2 Mutant [j1^ 017 Globin Gene Promoter Constructs.
The figure illustrates the mutations introduced (as described in figure 
5.1) into the mouse {^na^ °r globin gene promoter.
The recognition sites for the binding factors identified and 
characterised in chapters 3 and 4 were mutated as described below:
Pi GCCAA GCCGG
P2 GATAAG GCGCCG
P3 AAGCCAGT CCTAAAGT
P4 CACCCTG CTGCAGG
P5 AGGATAGA CTGCAGGA
LKS'U
LK3'L
B 2(A) 
A2(B) 
B3(A) 
B3(B) 
B1 (A) 
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B5 (A) 
BS(B)
Figure 5.3 PCR Products.
The figure illustrates the predicted size of PCR products from PCR 
reactions 1 and 2, and those actually obtained. The main products of 
each PCR reaction are of the expected size. These fragments are gel 
purified and used as templates for PCR reaction 3.
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Figure 5.4 Mutant Promoter Constructs.
The figure illustrates the organisation of elements in the mutant 
promoters compared to the wild-type promoter following PCR mediated 
mutagenesis.
Mouse fl-major globin gene promoter
-245 -215
I I
-160
1
-90  -75  -60
1 1 1
-30
I
( n fT )  ( e f i ) (boxT) ^ACC) (CAAT) C I f i) (tata) W.T
( e f i ) (ioxT) £ acc)  (caat)  C e f i) (tata) B-l
( nfT ) (S^T) £ acc)  (caat) C e f i) (tata) B-2
(nfT) C e fi ) £ acc)  (caat-) C e f i) (tata) B-3
(nfD  ( e f i  ) ( s o r t ) (c a a t ) C e f i) (tata) fi-4
(nfD  ( e f i  ) ( b° *T ) Ca m ) (c a a t) (tata) B-5
CHAPTER 6 FUNCTIONAL ANALYSIS OF THE MOUSE GLOBIN GENE
PROMOTER AND 3' SEQUENCES IN TRANSIENT TRANSFECTION ASSAYS.
INTRODUCTION.
Each of the systems which have been developed to analyse the
regulatory role of DNA sequences in the initiation of transcription, 
have their own specific merits and disadvantages. This chapter
describes the results of work using a transient transfection assay 
system to analyse the regulatory role of the protein-binding sites in 
the mouse ^na o^r globin gene promoter identified in Chapter 3 and 
further characterised in Chapter 4. The test constructs (Figure 2.3) 
were introduced into MEL or other non-erythroid cell lines by calcium 
phosphate precipitation as described in section 2.21. Expression from 
the test construct is assayed 24-48 hours after transfection as 
described in section 2.23 or 2.26. The benefit of transient 
transfection assay systems such as this is the speed with which a 
result can be obtained (5 days), unlike stable transfection assay
systems which take 3-4 weeks to set up. The main disadvantage of this 
system is the inability to look at changes in expression over longer 
culture periods. In particular, in order to look at changes in 
expression as the MEL cells are induced to differentiate it is 
necessary to generate stable transfectants as described in Chapter 7.
It is difficult to determine how closely results obtained in 
transient transfection assays approximate to the regulation of the same 
gene in vivo. By introducing a large copy number of test plasmid into 
cells, artificial conditions are created in which the ratio of protein: 
DNA binding site is reduced below that observed in vivo. Also, as
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extra-chromosomal DNA, test plasmid sequences are not under the cis 
regulatory effects of flanking chromosomal DNA and are not subject to 
the regulatory effects of changing chromatin conformation. However it 
is possible to compare the relative importance of different DNA 
sequences in these assay systems and this is what is attempted here.
6.1 Characterisation of the Assay System.
The human growth hormone (hGH) reporter gene and the hGH
radioimmunoassay were used for functional analysis of promoter/enhancer
sequences (as discussed in section 2.23) because of the sensitivity and
facility of the assay. The constructs used in the assays described here
are listed in Table 6.1. The amount of hGH secreted by cells
transfected by the appropriate test construct is measured indirectly as 
125the amount of I labelled hGH antibody bound covalently to an avidin
coated glass bead via hGH and a biotin-linked hGH antibody. The amount
125of y radiation emitted by I bound to the glass bead can be 
measured. The relationship between concentration of hGH and y counts 
is exponential as illustrated in figure 6.1.
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Figure 6.1 hGH Standard Curve.
hGH Standard Curve
hGH (ng/ml)
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The figure illustrates the relationship between y counts/minute
measured in the assay and the amount of hGH activity that these counts
represent for data presented in this chapter.
Known quantities of-hGH were injrj^ ated under the assay conditions 
described in 2.28 and the amount of I bound indirectly to the glass 
bead] was measured in a Beckman 20 Gamma Counter. By plotting hGH values 
against y c o u n t a  standard curve can be obtained as above from which 
the amount of hGH present in experimental samples can be determined
from the amount of yemission measured.
Table 6.1 
The table 
expression 
described 
promoter, 
construct. 
chapter 5.
Test Constructs used in Expression Assays.
illustrates promoter and enhancer constructs used in 
studies described in chapters 6 and 7 and based on plasmids 
in figure 2.1. The table describes the reporter gene, the 
the promoter mutation and the enhancer present in each 
Mutant promoter constructs were generated as described in
TEST CONSTRUCTS.
CONSTRUCT REPORTER PROMOTER MUTATION ENHANCER
GENE
pOGH hGH - - -
pTKGH hGH HSV-TK - -
pB346GH
pfilGH
hGH
hGH
Mouse Aaajor 
globin gena 
0 tO-346 bp 
n BNFl _
pB2GH hGH n G215 -
pB3GH hGH n Box 1 -
pB4GH hGH n CACC -
pB5GH 
pB (A)GH
hGH
hGH n
G60
Chicken A(A) 
globin gena 
enhancer
p6(M)GH hGH *■" Mouse A(M)globin gene 
3' sequences
pB745GH hGH
Mouse A(M) 
globin gena 
0 to -745bp
- -
paCATO CAT
Mouse a-1
globin gena 
0 to -52bp
- -
pCATl CAT
Mousa a-1
globin gena 
0 to -700bp
6.2 The Relationship Between hGH Production and Concentration of
Transfected DNA..
The efficiency with which a given cell line can be transfected with 
plasmid DNA is dependent upon a number of parameters including 
concentration of DNA, transfection method, pH of medium, (X^ 
concentration of medium, cell density etc. (Chen and Okayama (1987).
A calcium phosphate precipitation method has been established for 
the efficient transfection of MEL cells (Plumb et al. (1989), which 
involves the transfection of 20|ig of DNA into 1-2x10^ cells as 
described in 2.21.
I was interested to determine whether there was a concentration of 
test plasmid as a proportion of the total 20|lg of transfected DNA which 
gave an optimum expression level. Transfected DNA was made up to a 
total amount of 20|ig with pIC20R carrier plasmid, keeping the amount of 
reference plasmid, pHSV-pgal., constant at 5|ig. As described in section 
2.21, the pHSV-pgal. reference plasmid is cotransfected with the test 
plasmid to allow the assay results to be standardised for transfection 
efficiencies.
Figure 6.2 illustrates the results of experiments in which 
MEL cells are transfected with 20fig of plasmid DNA as follows 
test plasmid pHSV-IE-(3gal. pIC20R TOTAL
A. 2.5jug 5.0jlg 12.5jjg 20.0)lg
B. 5.0(ig 5.0|Jg lO.OMg 20.0|ig
C. lO.Ojig 5.0ng 5.0|ig 20.0|og
All the results are standardised for |3-galactosidase activity 
expressed from reference plasmid pHSV-pgal.
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There is an approximately linear relationship between hGH 
production and the concentration of test plasmid DNA. used in 
transfection when the hGH reporter gene is under the control of the 
Herpes simplex virus thymidine kinase (HSV-TK) gene promoter. However, 
when the hGH reporter gene is under the control of the mouse p0^ 027 
globin gene promoter, hGH production increases with increase in plasmid 
copy number until an apparent threshold level is reached. Above this 
threshold, increasing plasmid copy number does not appear to result in 
increased hGH production. This does not reflect the ability of the cell 
to take up plasmid DNA nor its ability to secrete hGH since the levels 
of expression from the HSV-TK promoter are higher. It probably reflects 
saturation of the transcriptional machinery necessary to effect 
transcription from the mouse pf12^ 027 globin gene.
Subsequently, all transient transfections were carried out at the 
following DNA concentrations:-
test plasmid pHSV-IE-|3gal. pIC20R TOTAL
5.0}ig 5.0|jg 10.0|ig 20.0pg
These concentrations allow maximal expression from test plasmids 
without saturating the system.
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Figure 6.2 The Relationship Between hGH Production and Concentration 
of 'l’e s t _P1 asm id DNA. ’
The figure shows the relationship between hGH production and the amount 
of test plasmid transfected into the MEL cell line used in these
experiments, F4-12B2.
Titration of Test Plasmid.
Mean hGH Activity (ng/ml)
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6.3 hGH Expression in Different Cell Lines.
The mouse p™^01" globin gene is tightly regulated in vivo as it is 
expressed exclusively in adult mouse erythroid tissue. Having set up a 
transient transfection system to study transcriptional regulation of 
this gene in MEL cells, I considered it important to show that the 
basic test promoter that I was using was poorly expressed in 
non-erythroid cell lines.
I looked at hGH expression from the P346 promoter fragment in 
seven different cell lines and compared expression in each with 
expression from the 0 promoter (negative control) and the HSV-TK 
promoter (positive control).
Optimal transfection conditions differed for each cell line used 
but to make comparisons as meaningful as possible, I tried to keep the 
conditions used similar to those used for transfection of the F4B12 
which was the cell line that I had worked with most extensively. Tabid 
6.3A illustrates the results obtained.
Measurement of p-galactosidase activity gives a measure of the 
efficiency of transfection for each experiment. Clearly, the efficiency 
of transfection in three of the seven cell lines (C88, J774.2, F9) is
low making the interpretation of these particular transfections less 
valid. Levels of |T-galactosidase activity were in the range 0.064-0.148 
and subsequently, I judged all experiments in which transfection was 
less than 0.150 as measured by p-galactosidase activity to be null 
experiments. Clearly this is an arbitrary determination of what is a 
significant level of (3-galactosidase activity and it may be argued that 
the results obtained with F9 cells whose p-galactosidase activity
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values are in the range 0.089-0.148, are indeed significant. However, 
to obtain these results, the cell lysates were incubated with the 
(3-galactosidase assay reagents at 37°C for up to two hours which is up 
to four times the length of time required to obtain a "significant" 
p-galactosidase activity value with extracts from transfected MEL, 
HeLa, 3T3 or STO cell lines. Using this parameter for efficient 
transfection, it is clear that transfection into four of the seven cell 
lines (F4B12, HeLa, 3T3 and STO) is efficient.
However, the hGH levels present in the media containing 
transfected STO and 3T3 cells, is very low even in the cells 
transfected with pTKGH. There are several possibile explanations, 
including: 1. the TK promoter is not promiscuous in fibroblast cell
lines, 2. the hGH message is unstable in these cell lines or 3. hGH 
itself is not being secreted from these cells into the medium.
It was possible to test this last explanation by generating cell 
lysates of transfected 3T3 and/or STO (as described in section 2.24) 
and carrying out the hGH assay on the cell lysates (Figure 6.3B).
From Table 6.3B, it is clear that hGH activity is present in cell 
lysates of STO/3T3 transfected cells and that these cells fail to 
secrete hGH efficiently.. The ability of fibroblast-derived cell lines 
to secrete hGH had not been previously tested by the manufacturers and 
if other cell lines lack this ability, it may represent a drawback to 
the use of this assay system.
Analysis of expression from the p346 promoter fragment in 3T3 or 
STO cell lines shows that expression is not above background level as 
measured by hGH expression from the promoter-less construct pOGH. In 
contrast, expression from the promiscuous HSV-TK promoter is well above
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background levels.
Unlike fibroblast derived cell lines, HeLa which is an epithelial 
derived cell line, and F4B12, which is an MEL cell line, secrete hGH at 
efficient levels into the growth medium of transfected cells. 
Comparison of hGH expression from the HSV-TK promoter in F4B12 and HeLa 
shows that expression levels are similar suggesting that HeLa is a good 
non-erythroid control cell line for F4B12.
To allow comparison of expression of different promoter/enhancer 
sequences in different cell types, the relative expression level (E) in 
different cell lines is defined as:
expression above background from test promoter
E = ----------------------------------------------
expression above background from control promoter
Xtk x0
It is clear from table 6.3C that the relative expression level from the 
mouse pma-,or globin gene promoter fragment p346 is at least 3 times 
greater in F4-12B2 cells than it is in STO cells and 30-60 times 
greater than in HeLa or 3T3 cells. This result is comparable to that 
obtained by Plumb et al. (1989) who showed that the mouse al globin 
gene promoter is 3-4 times more active in F4-12B2 cells than in STO 
cells. The results, supported by the protein binding data, confirm that 
there are elements in the promoter which confer erythroid specificity 
upon expression.
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Table 6.3A hGH Expression in Different Cell Lines.
Cell Line ycounts hGH (ng/ml)
F4B12
pOGH 1736 0.9
2017 1.0
pTKGH 8976 3.1
11321 3.8
p(3346GH 5734 2.1
6218 2.3
C88.
pOGH 912 0.6
776 0.6
pTKGH 4351 1.7
3289 1.4
pp346GH 1767 0.9
1583 0.8
HeLa.
pOGH 1310 0.7
1059 0.7
pTKGH 8762 3.1
12378 4.2
pp346GH 1002 0.7
1536 0.8
F9.
pOGH 782 0.6
897 0.6
pTKGH 2356 1.1
4812 1.8
pp346GH 2185 1.0
1976 1.0
J774.2.
pOGH 873 0.6
912 0.6
pTKGH 1234 0.7
2013 1.0
pp346GH 784 0.6
892 0.6
STO.
pOGH 345 0.4
491 0.5
pTKGH 367 0.5
512 0.5
PP346GH 713 0.6
412 0.5
3T3.
pOGH 634 0.5
721 0.6
pTKGH 591 0.5
666 0.5
pp346GH 683 0.6
647 0.5
p-gal.act. hGH/p-gal. X
0.297 3.0 3.1
0.315 3.2
0.264 11.7 12.55
0.283 13.4
0.224 9.4 8.4
0.309 7.4
0.123 4.9 5.05
0.115 5.2
0.098 17.3 14.6
0.118 11.9
0.137 6.6 6.4
0.130 6.2
0.187 3.7 3.5
0.211 3.3
0.237 13.1 15.25
0.242 17.4
0.231 3.0 3.3
0.192 3.6
0.108 5.6 5.3
0.121 5.0
0.148 7.4 10.5
0.132 13.6
0.089 11.2 10.0
0.113 8.8
0.087 6.9 7.4
0.076 7.9
0.102 6.9 8.9
0.092 10.9
0.064 9.4 8.15
0.087 6.9
0.321 1.2 1.45
0.298 1.7
0.315 1.6 1.7
0.276 1.8
0.287 2.1 2.0
0.269 1.9
0.287 1.7 2.05
0.255 2.4
0.247 2.0 1.85
0.293 1.7
0.311 1.9 1.7
0.325 1.5
Table 6.3B hGH Expression in Cell Lysates from 3T3/STO Cell Lines.
Plasmid y counts hGH (ng/ml) p-gal.act. hGH/pgal. X
STO
pOGH 1576 0.83 0.321 2.6 2.8
1789 0.89 0.298 3.0
pTKGH 9541 3.3 0.315 10.5 10.15
7603 2.7 0.276 9.8
p(3346GH 2317 1.1 0.287 3.8 3.95
2584 1.1 0.269 4.1
3T3
pOGH 1935 0.94 0.287 3.3 3.05
1201 0.71 0.255 2.8
pTKGH 8550 3.0 0.247 12.1 11.5
9129 3.2 0.293 10.9
pp346GH 2035 0.97 0.311 3.1 2.95
1857 0.92 0.325 2.8
Table 6.3C Relative Expression Levels in Erythroid and Non-erythroid 
Cell Lines.
Cell Line E
F4B12 0.56
HeLa 0.02
STO 0.16
3T3 0.01
6.4 Comparison of Wild-type and Mutant Promoters.
To determine the role in modulation of transcription of individual 
elements within the promoter, I generated a series of mutant constructs 
as described in Chapter 5. Each mutant construct is mutant in one
particular protein binding site. The mutant promoters are illustrated 
in figure 6.3 and are mutated either in the distal region of the
promoter or in the proximal region of the promoter.
The results of transient transfection of wild-type and mutant 
constructs (described in fig.6.1) into uninduced F4-12B2 cells are 
given in table 6.4A and figure 6.4 presents these values in graph form. 
Table 6.4B illustrates the expression values (E) for each construct 
relative to the pTKGH construct as defined in the previous section.
The results show that hGH expression from the distal promter
mutants, ppl (NF1-) GH, pp2 (NF-El") GH and pp3 (Boxl") GH, is 5.6, 3.7 and
6.7 fold greater respectively than expression from the wild-type 
promoter construct, pp346GH. However, hGH expression from the proximal 
promoter mutants, pP4 (CACC )GH and pp5 (NF-El )GH, is 3.3 and 52 fold 
less respectively than that from the wild-type promoter construct 
pp346GH. hGH expression from the longer wild-type promoter fragment 
p745 is 2.5 fold greater than that from p346, the shorter promoter 
fragment.
These results indicate that the distal promoter mutations 
upregulate transcription by 4-7 fold, that the proximal promoter 
mutations down-regulate transcription by 3-52 fold, and that there are 
sequences upstream between -346 and -745 bp which upregulate 
transcription by 2.5 fold. This suggests that CACC, NF-El, CCAAT and
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TATA elements in the proximal promoter are essential for promoter 
function. While demonstrating for the first time that there is an NF-El 
binding site in the proximal promoter, this data confirms the work of 
Myers et al. (1986) which showed an essential role for the TATA, CCAAT 
and CACC boxes in mouse pma-|0r globin gene promoter function. This work 
identifies NF-El, Box 1 and NF-1 elements in the distal promoter which 
exert a negative regulatory effect on expression in uninduced MEL 
cells. These elements may constitute a silencer element of the kind 
described for the human e globin gene (Cao et al (1989) . There are 
additional elements upstream which exert a small positive regulatory 
effect on transcription.
NF-El exerts a different effect on transcriptional initiation 
depending on the context of the NF-El binding site; the NF-El site in 
the distal promoter is a negative regulatory element while that of the 
proximal promoter is a positive regulatory element. This illustrates 
the inportance of context in determining the role of individual 
enhansons as described for the SV40 enhancer. The role of these 
regulatory elements in modulating transcription of the mouse 
globin gene as MEL cells are induced to differentiate is examined in 
stably transfected cell lines and is described in chapter 7.
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Table 6.4A Comparison of Wild-Type and Mutant Promoters.
Plasmid X S.E. n
pOGH 3.35 0.65 8
pTKGH 24.2 1.74 8
pp346GH 14.2 1.33 8
pplGH 64.2 2.85 8
pP2GH 43.7 2.34 8
pP3GH 75.7 3.08 8
pp4GH 6.6 1.48 3
pp5GH 3.5 1.08 3
PP745GH 31.2 3.22 3
Table 6.4B Relative Expression Values for Mutant and Wild-Type Promoter 
Constructs.
plasmid
pTKGH 1.00
pp346GH 0.52
pPlGH 2.9
pp2GH 1.9
p(33GH 3.5
p(}4GH 0.16
pP5GH 0.01
PP745GH 1.3
Figure 6.4 Expression from Wild-type and Mutant Promoters.
Mean hGH Activity (ng/ml) 
80 --------------------
pOGH pTKGH pG346GH pG1GH pG2GH pG3GH pG4GH pG5GH pG745GH
Plasmid Construct
hGH Activity
6.5 Comparison of hGH Expression from the Wild-type Promoter Modulated 
by the Chicken [3^ and Mouse ftmajQr Globin Gene 3' Sequences.
Section 3.4 described the identification of recognition sites for 
the NF-El and Box 1 DNA. binding proteins in a region 400 bp 3' of the 
poly adenylation site of the mouse ffna^ 0r globin gene. To determine 
whether these sequences had a functional role in the modulation of 
transcription, this region was cloned immediately 3' of the hGH gene 
controlled by the wild-type promoter fragment, (3346, as described in 
TabU ‘1 to generate construct Expression from this construct
was compared with expression from the analogous construct, p(3^ GH, 
containing the chicken (3^ globin gene enhancer 3' of the hGH gene. 
These plasmid constructs are illustrated in Tabk. 6.1. Table 6.5A and 
figure 6.5A illustrate the results of these experiments and table 6.5B 
gives the relative expression value for each construct.
Clearly expression from the wild-type promoter is enhanced by 6.0 
fold by sequences from the 3' region of the mouse pma o^r giokin gene in 
MEL cells. This enhancement is greater than that obtained for the 
chicken (3^ globin gene enhancer 4.8 fold but not significantly greater. 
The introduction of 3' enhancer sequences generates an up-regulation 
of transcription that is equivalent to that generated by mutation of 
distal promoter sequences. These functional results, combined with the 
protein binding data, suggest that these 3' mouse (3ma-,0r globin gene 
sequences do indeed constitute an enhancer element. Further work to 
determine whether the element can operate in either orientation is 
theoretically necessary to confirm that this element is a "classical" 
enhancer.
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Table 6.5A Comparison oil hGH Expression from the Wild-Type Promoter 
Modulated by the Chicken p Enhancer or by Mouse [3ffla^ or Globin Gene 3' 
Sequences.
Plasmid X S.E. n
pOGH 3.35 0.65 8
pTKGH 24.2 1.72 8
p(3346GH 14.2 1.33 8
pp^GH 56.4 2.66 8
ppffcH 69.0 4.80 3
Table 6.5B Relative Expression Levels from Wild-type Promoter Sequences 
modulated by Chicken and Mouse 3' Sequences.
Plasmid E
pTKGH
pp346GH
1.00
0.52
2.5
3.1
Figure 6.5 Enhancer Modulated Expression.
Mean hGH Activity (ng/ml)
pOGH pTKGH pB346GH p8(A)GH pB(M)GH
Plasmid Construct
hGH Activity
6.6 a-1 and |jna o^r Globin Gene Promoter Interactions.
As discussed in section 1.4, the regulation of human a and (3 
globin genes differ in a number of respects. Differences in the 
regulation of mouse a and (3 globin genes are less well characterised. 
Certainly, the regulation of the human a and the mouse al globin genes 
differs in that the human a globin gene promoter lies in an HTF island 
and can function in the absence of an enhancer when transfected into 
non-erythroid cell lines whereas the mouse gene is not promiscuous 
(section 1.2.2) and does not lie in an HTF island (Whitelaw et al. 
(1989) . It was interesting to look for evidence of a-(3 promoter 
interaction at the level of transcription by cotransfection of a-1 
promoter constructs and {3rna-^0r promoter constructs in the transient 
transfection assay systems described above. The al and p?Tia3C)r globin 
genes are not linked in vivo and in this study they are cotransfected 
on separate plasmid vectors; the chicken e and (3^ globin genes are 
linked in vivo and in work carried out by Choi & Engel (1988) to
compare the regulation of the chicken £ and (3^ globin genes, the two
genes were linked in cis and cotransfected on the same plasmid vector. 
The activity of the a-1 promoter could be distinguished from that of
the promoter on the basis that the a-1 promoter regulated
initiation of transcription from the CAT reporter gene whereas the 
pfna:]0r promoter regulated initiation of transcription from the hGH 
reporter gene. Figure 6.1 describes the constructs used. Table 6.6A and 
6.6B describe the results of these cotransfection experiments.
% CAT activity was determined by cutting spots A, B and C from the
14TLC plates, determining emission from them due to C in a
scintillation counter and expressing CAT activity as:
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A+B
%CAT activity = -------
A+B+C
14where A = 1, 3 - diacetyl C-Chloramphenicol
14B = 1 or 3 acetyl C-Chloramphenicol 
14C = C-Chloranphenicol
The % CAT activities were standarised to the p-galactosidase activities 
for each experiment.
The results show that CAT activity increases linearly with 
increase in CAT plasmid construct transfected (lanes 2, 3, 4 of figure 
6.6A) .
The effect of cotransfection is to down-regulate transcription 
from the a-1 promoter and to up-regulate transcription from the (3ma 0^r 
promoter. When pp346GH is cotransfected with paCATl there is a 9.1 fold 
down-regulation in CAT activity (figure 6.6B) and a 3.3 fold increase 
in hGH activity (figure 6.6C) .
It is known that during differentiation of the MEL cell that 
mouse a-1 globin gene is expressed earlier than the pma o^r gene. It is 
therefore interesting to note that initiation of transcription from the 
a-1 promoter in these cotransfection experiments is down-regulated by 
expression from the mouse pma-10r globin gene promoter. If a 
transcription factor which is necessary for initiation from both 
promoters is in limiting supply, this observation could be explained if 
the prna^ or promoter had a greater affinity for this factor than the a-1 
promoter. It is known that NF-El is required for modulation of 
transcription from both of these promoters. It is also known that the 
globin gene promoter has two NF-El binding sites, at -60 and
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-212 bp whereas the a-1 promoter has only one, at -180 bp (Plumb et al 
(1989) . When the NF-E1 (pp2GH) or Box 1 (pp3GH) binding sites in the 
distal promoter are mutated, there is a much smaller down 
regulation of CAT expression from the al promoter of 1.3-1.8 fold 
(figure 6.6B).
It is observed that mutation of pNFl (pplGH) in the pma90r 
promoter also gives a smaller down-regulation, compared with pP346GH, 
of transcription from the al promoter by 4.3 (Figure 6.6B) . Unlike 
NF-E1, NF-1 and Box 1 are not known to be involved in regulating 
transcription of the a-1 globin gene and it is initially difficult to 
explain why mutation of NF-1 or Box 1 should affect transcription from 
the al-globin gene promoter. However, if NF-E1 interaction with the 
distal region of the mouse pma‘“|0r globin gene promoter depends upon a 
cooperative interaction with pNFl and Box 1, then mutation of either 
pNFl or Box 1 will release NF-E1 to allow interaction with the a-1 
promoter.
These results suggest that the a-1 and p™^03- globin gene 
promoters are competing for NF-E1. It should be realised however that 
this transient transfection assay system creates artificial conditions, 
such as the high copy number of both the a-1 and the pma 0^r promoter 
constructs. This may be responsible for the competition effects 
observed since at low plasmid copy number it is unlikely that NF-E1 or 
other binding factors would be limiting.
Cotransfection of p346GH with equimolar amounts of paCATl 
results in a 3.3 fold stimulation of transcription from the pnfia^ °r 
promoter (Figure 6.6C). The upregulatory effect of cotransfection on 
the pma3or promoter is in contrast to the down-regulatory effect on the
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a-1 promoter. If it is assumed, as for the effect on CAT activity, that 
the a-1 and pma3°r pr0moters are competing for a limiting transcription 
factor, probably NF-E1, then the upregulatory effect on hGH expression 
may be explained as follows. The distal promoter region of prna-'°r 
globin gene contains an NF-E1 site and mutation of this NF-E1 site 
results in up-regulation from Qf g#3 fold in transient
transfection assays (section 6.4) . This leads to the hypothesis that 
this NF-E1 site is part of a negative regulatory element which also 
includes pNFl and Box 1. By competing out the binding of NF-E1 to this 
site, the a-1 promoter is derepressing transcription from the pma o^r 
promoter.
Cotransfection of paCATl with pplGH, pP2GH and pp3GH results in a 
4.3, 6.0 and 5.2 fold upregulation of hGH expression compared with
pp346GH (figure 6.6C) . This is equivalent to the effect observed when 
the mutant constructs are transfected alone (section 6.4) and suggests 
that, unlike its up-regulatory effect on wild-type p™3 0^17 promoter 
sequences, that cotransfection with paCATl has no effect on expression 
from the mutant promoter sequences. This is as expected if the mutant 
promoters have already been derepressed by mutation of NF-E1, Box 1 or 
NF-1.
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Figure 6.6 a-1 and ftmaJQr Globin Gene Promoter Interactions.
a-1-CAT and pma-10r-hGH promoter constructs were cotransfected as 
described in section 2.26 into F4-12B2 cells, cell lysates generated as 
described in 2.24 and CAT activity measured as described in 2.26. The 
results of the CAT assays are shown below.
Lane 1 5|lg paCATO, 5|ig pHSV-IE-pgal., lOfig pIC20R.
Lane 2 l|lg paCATl, 5|lg pHSV-IE-pgal., 14|ig pIC20R.
Lane 3 2.5|ig paCATl, 5|lg pHSV-IE-pgal., 12.5(lg pIC20R.
Lane 4 5|lg paCATl, 5|lg pHSV-IE-(3gal., 10|ig pIC20R.
Lane 5 5(lg paCATl, 5|lg pHSV-IE-pgal., 5fig pIC20R.
5[ig pp346GH
Lane 6 5|ig paCATl, 5|ig pHSV-IE-pgal., 5|Jg pIC20R 
5|ig pplGH
Lane 7 5|ig paCATl, 5|lg pHSV-IE-pgal., 5|lg pIC20R
5|ig pp2GH
Lane 8 5|lg paCATl, 5(lg pHSV-IE-pgal., 5pg pIC20R 
5|lg pP3GH
Table 6.6A a-1 and Globin gene Promoter Interactions.
Plasmid 
1. OCAT0
2. aCATl 
(1.0|lg
3. aCATl 
(2.5flg)
4. aCATl 
(5.0pg)
5. aCATl 
p346
6. aCATl
Pi
7. CXCATl 
P2
8. aCATl
P3
9. P346
lO.pOGH
Table 6.6B
1.
2.
3.
4.
5.
6.
7.
8 . 
9. 
10
ycounts hGH P-gal.act. hGH/p~gal. % CAT %CAT/p-gal
729 0.6 0.253 2.4 2.45 9.7
990 0.6 0.276 2.2 2.40 8.7
985 0.6 0.311 1.9 9.70 31.2
765 0.6 0.257 2.3 7.09 27.6
885 0.6 0.302 2.0 14.65 48.5
929 0.6 0.251 2.4 13.1 52.3
774 0.6 0.262 2.3 23.42 89.4
834 0.6 0.271 2.2 24.72 91.2
9520 3.3 0.253 13.0 2.58 10.2
12379 4.2 0.207 20.3 2.01 9.7
17414 5.7 0.266 21.4 6.04 22.7
20440 6.7 0.302 22.2 5.89 19.5
23250 7.5 0.231 32.5 15.5 67.3
24325 7.9 0.256 30.9 17.97 70.2
24913 8.1 0.294 27.6 14.5 49.5
23165 7.5 0.302 24.8 16.1 53.6
3486 1.4 0.275 5.1 - -
4211 1.6 0.319 5.0 — —
1762 0.89 0.287 3.1 - -
1235 0.72 0.271 2.7 - -
hGH
x
2.3
2.1
2.2
2.25
16.65
21.8
31.7
26.2
5.05
2.9
CAT
x
9.2
29.4
50.4 
90.3
9.95
21.1
68.75
51.55
M oan  %  C A T  Activ ity  
100   ---------
paCATO paCATl +pB346GH +p61GH +pf32GH +pB3GH
tlSsj CAT Activity
Figure 6.6B Changes in CAT Expression After Cotransfection.
Cotrans feet ion of wild-type promoter construct p[i346GH with equimolar 
amounts of paCATl results in a 9.1 fold down-regulation in CAT 
activity. Cotransfection of paCATl with pplGH, pp2GH and p{33GH results 
in a down-regulation in CAT activity of 4.3, 1.3 and 1.8 fold
respectively.
Mean hGH Activity 
35 ------------
n ®
fife
SB©®?
p CAT1 '-pOGH pB346GH pB346GH+ pB1GH+ pB2GH+ pB3GH+
p a c A T i  p a c A T .1  p a C A T l  p a C A T i
Mgsal hGH Activity
Figure 6.6C Changes in hGH Expression After Cotransfection.
Cotrans feet ion of wild-type promoter construct p|3346GH with equimolar 
amounts of paCATl results in a 3.3 fold increase in transcriptional 
initiation from the prQmoter. Cotransfection of paCATl with
PplGH, pp2GH and pp3GH results in an up-regulation of 4.3, 6.3 and 5.2 
fold respectively.
CHAPTER 7 FUNCTIONAL ANALYSIS OF THE MOUSE GLOBIN GENE
PROMOTER AND 3' SEQUENCES IN STABLE TRANSFECTION ASSAYS.
INTRODUCTION
As mentioned in Chapter 6, stable transfection assay systems are 
useful as they allow expression to be monitored over longer culture 
periods than that which transient transfection assay systems allow. It 
is therefore possible to monitor changes in reporter gene expression 
as the MEL cells are induced to differentiate. Stable transfectants for 
the promoter/enhancer constructs to be analysed were generated by 
cotransfection of test plasmid and a selection plasmid conferring 
neomycin resistance on cells (described in section 2.22). The stable
integration of the test plasmid into the host cell genome along with a
selective marker gene allows expression to be monitored through
successive cell divisions. One of the main disadvantages of this system 
is that although the test DNA sequences are stably integrated, there 
are often many copies integrated. Multiple copies may be integrated at 
different sites throughout the genome such that each copy is under 
different cis-acting influences such as differences in chromatin 
conformation or other flanking regulatory elements. While it is 
possible to determine the copy number of a given construct in the
genome, it is not easy to determine which copies are being actively 
transcribed or how many are inactive as a consequence of chromatin 
condensation at that locus.
However, the stable transfectants described here are generated 
such that for each test DNA introduced, a pool of cells is generated 
from at least one hundred different neomycin resistant colonies as
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described, in section 2.22. Each clone probably contains different 
plasmid copy numbers integrated at different sites in the genome. 
Differences in copy number and integration sites between clones should 
average out such that different pools of cells have approximately 
equivalent copies of integrated test plasmid.
7.1 Cell Growth Rate Under Different Inducing Conditions.
Stable transfectants were generated to analyse the effect that 
induction to differentiate had on hGH expression from the different 
promoter and enhancer constructs being studied. Two different types of 
Friend virus induced mouse erythroleukaemic cell lines were used; 
F4-12B2 and C88. Study of changes in transcriptional regulation as C88 
cells are induced to differentiate could be compared to the work in the 
laboratory of F.Grosveld on the transcriptional regulation of the human 
(3 globin gene in C88 cells (Antoniou et_ al. (1988) .
F4-12B2, which was isolated in the laboratory of Ostertag 
(1979) has a high transfection efficiency under the conditions used in 
this system and can be induced to differentiate rapidly (3-5 days) with 
either 2% DMSO or 4 mM HMBA. C88, which is deficient in adenine 
phosphoribosyl transferase (Deisseroth and Hendrick, (1978), transfects 
poorly in this system, and responds more slowly to induction (5-8 days) 
with 2% DMSO or 4 mM HMBA. Although the C88 cell line transfects 
poorly, this does not adversely affect its use in stable transfections 
since stringent selection procedures are used to confer growth 
advantage on successful transfectants. After selection, C88 
transfectants grow as well as F4-12B2 transfectants.
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To assay changes in hGH production during the induction of
differentiation, each stable transfectant was set up in triplicate in
■ 5 o5ml of medium at 1x10 cells/ml, 80 |jg/ml neomycin and incubated at 37 C
and 5% CC^. Twenty four hours after setting the cells up, 2% DMSO and
4mM HMBA were added to two of the three plates for each transfectant.
The third plate was not treated and the cells therein were allowed to
grow in the uninduced state. The medium was assayed for hGH activity at
24 hour intervals and is therefore a measure of the accumulation of hGH
in the media over the 7 day period.
Control plates were set up in parallel with each transfectant and 
grown under identical conditions. At twenty four hour intervals, the 
cell number in each control plate was determined for uninduced, DMSO 
induced and HMBA induced cells. Cell number was measured in control 
plates rather than in the plates from which medium was being removed 
for assay since determining cell number involved treating the cells 
with trypsin. By the end of the seven day period, both the F4-12B2 and 
the C88 transfectants had differentiated as judged by the extent of 
haemoglobin present in these cells and the resulting red to purple 
colour of the cell pellets.
The results of measuring cell growth rate for C88 and F4-12B2 
cell lines under uninduced, DMSO induced and HMBA induced conditions 
are illustrated in figures 7.1A and B. The results show that both C88 
and F4-12B2 cells grow exponentially over a 7 day period and that 
induction to differentiate with either DMSO or HMBA causes the rate of 
proliferation to decrease dramatically over the same period. The growth 
rate of F4-12B2 cells decreases more rapidly in response to induction 
from a doubling time of 16 hours prior to induction to 30 hours 4 days
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post induction, than the growth rate of C88 cells which decreases from 
a doubling time of 16 hours prior to induction to 30 hours measured 5 
days post induction. This is consistent with the more rapid rate of 
differentiation of F4-12B2 cells in response to chemical induction.
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Figure 7.1A F4-12B2 Growth Curve.
5
F4-12B2 cells were set up at 1x10 cell/ml in 5 ml of medium and 
allowed to grow for 7 days under uninduced conditions, DMSO induced 
conditions or HMBA induced conditions as described in the text.
F4 Growth Curve
s
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Days post induction
—  uninduced - + -  induced 2% DMSO induced 4frig( HMBA
Figure 7.IB C88 Growth Curve.
5
C88 cells were set up at 1x10 cell/ml in 5 ml of medium and allowed to 
grow for 7 days under uninduced conditions, DMSO induced conditions or 
HMBA induced conditions as described in the text-
C88 Growth Curve
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7.2 The Effect of Induction on Expression from Wild-Type and Mutant
Promoters.
In section 6.4 , results were presented which showed that mutation
of PNFl, NF-E1 or Box 1 recognition sites in the distal region of the
mouse globin gene promoter resulted in transcriptional
upregulation from that promoter of 4 - 7 fold. This suggested that the 
distal promoter region is a negative regulatory element, whereas the 
proximal promoter region is absolutely required for transcription from 
the mouse pma o^r globin gene.
These results were obtained in transient transfection assay 
systems and did not take account of the effect that induction to 
differentiate might have on the rate of transcriptional initiation from 
mutant promoters. It was therefore of interest to look at the role of 
the negative regulatory element during differentiation. In particular, 
it was of interest to determine whether the activity of this element
was repressed or altered following induction to differentiate.
By generating cell lines stably transfected with the test 
constructs, it was possible to examine changes in hGH expression over a 
7 day period as these cell lines were induced to differentiate. The 
cells were set up as described in section 7.2 and 2x100 (il aliquots of 
growth medium were harvested at 24 hour intervals and assayed for hGH 
activity.
To compare changes in hGH production per cell between stable 
transfectants and to obtain a measure of the level of induction under 
different conditions and at different time points, an induction ratio 
is defined as:
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hGH/cell on day x
I = ---------------
hGH/cell on day 2
The cells are induced to differentiate on day 2, thus I gives a 
measure of the change in hGH expression following induction and is 
independent of copy number and of integration site since hGH levels are 
being compared within each pool of transfectants. For the purposes of 
this study, which is to compare the effects of different mutations and 
the role of enhancer sequences in the reponse to induction, I gives a 
meaningful comparison of expression levels.
The effects of induction to differentiate upon expression 
from the wild-type and mutant promoter constructs stably transfected 
into F4-12B2 are shown in figure 7.2. There is a 10-20 fold increase in 
hGH production from the wild-type promoter construct but only a 5-10 
fold increase in expression from the mutant promoter constructs (figure 
7.2A) . When the levels of hGH production are standardised for cell 
number and expressed relative to expression on day 2, (figure 7.2B) it 
can be seen that while the induction value for the wild-type promoter 
in F4-12B2 cells induced to differentiate increases 2-4 fold, that the 
induction value under uninduced conditions is less and decreases to 
less than 0.5 on day 5. The induction values for the mutant promoter 
constructs under all three growth conditions are similar to those 
obtained for the wild-type promoter construct in cells grown under 
uninduced growth conditions.
The responses of the C88 cell lines to the three growth 
conditions (uninduced, induced 2% DMSO, induced 4 mM HMBA) are shown in 
figure 7.3A. There is a 12-25 fold increase in hGH production from the
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wild-type promoter construct and only a 5-10 fold increase in hGH 
production from the mutant promoter constructs in the C88 cell lines 
under all three growth conditions. However, there is a 20 fold increase 
in hGH production from mutant construct pplGH in uninduced C88 cells.
When hGH production by all stable transfectants was standardised 
for cell number and expressed relative to hGH production per cell prior 
to induction (Figure 7. 3B), hGH production from the mutant promoter
constructs in C88 cells are equivalent, including that from promoter
construct pplGH. The induction values for these constructs are less 
than one and up to 40 fold less than that obtained for the wild-type 
promoter construct under all three growth conditions.
It was observed in figure 7.3A that hGH production from the 
wild-type promoter construct in C88 cells, grown under uninduced growth 
conditions, is as high as that obtained under induced growth conditions 
(either 2% DMSO or 4 mM HMBA induced) . When hGH production is 
standardised for cell number and expressed relative to expression on 
day 2, the induction value obtained for the wild-type promoter 
construct on days 3, 4 and 5 under uninduced growth conditions is
greater than that obtained on those days for cells induced with DMSO or 
HMBA. However, it was observed that the rate of decrease in hGH
production after day 2 was greater in uninduced cells than in those
induced to differentiate-
The effects of the two inducing agents on each cell line 
transfected with the wild-type promoter construct are different. The 
induction effect of 2% DMSO on both C88 and F4-12B2 stably transfected 
with pp346GH appears to be less than the effect of 4 mM HMBA on the 
same cells. Neither inducing agent succeeds in inducing hGH expression
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from the mutant promoter constructs in either MEL cell line. The 
absolute hGH expression levels from the mutant promoters are as high as 
the induced level of hGH expression from the wild-type promoter for 
both F4-12B2 and C88. This leads to the suggestion that mutation of the 
negative regulatory element in the distal region of the mouse jjna3°r 
globin gene results in constitutive expression from that promoter. This 
is consistent with the observation that this element is responsible for 
down-regulating expression from the wild-type mouse (fna-)°r globin gene 
promoter in uninduced MEL cells.
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The Effect of Induction on Expression from Wild-type and Mutant
Promoters.
Figure 7.2A F4-12B2 hGH Production.
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7.3 Modulation of Induction of Expression from the Mouse Globin
Gene Promoter by Chicken and Mouse [3ma Q^r Globin Gene Enhancers.
As mentioned at the end of section 7.2, the observed level of 
induction from the wild-type mouse (^na-|0r globin gene promoter in 
transfected F4-12B2 and C88 cells induced with either 2% DMSO or 4mM 
HMBA is not as high as would be expected based on the observed 12-fold 
induction by 2% DMSO of endogenous haem production in Friend cells 
(Paul and Hickey (1974).
Sequences found 3' of the mouse ^Tia^ or globin gene have been shown
to bind NF-E1 and Box 1 by DNAase 1 footprinting and are suspected of
constituting an enhancer element based on transient transfection assays 
descibed in section 6.5. These sequences were cloned 3' of the hGH 
reporter gene as described previously and stably transfected into 
F4-12B2 and C88 cells to determine whether they enhanced the level of 
induction with DMSO or HMBA of hGH expression observed from the 
wild-type mouse prna^ °r globin gene promoter fragment (3346. This 
experiment was also carried out with the chicken (3^ globin gene 
enhancer cloned 3' of the hGH gene and the effect of the mouse 
sequences on inducible expression was compared with that of the chicken 
13^ globin gene enhancer.
The hGH production results are illustrated in figure 7.4 and 
figure 7.5. There is no appreciable increase in hGH production from 
either of the enhancer constructs compared with the wild-type promoter 
construct, in F4-12B2 cells induced to differentiate with either DMSO
or HMBA (figure 7.4) . However with C88 transfectants, a 70-80 fold
induction of hGH expression is observed with both DMSO and HMBA
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compared with a 20-fold induction from the wild-type promoter construct 
(Figure 7.5) . This difference in induction between the enhancer and the 
promoter constructs is not observed in the uninduced cells.
When the hGH values are standardised for cell number and to 
expression on day 2 prior to induction, it can be seen that the 
response to induction in F4-12B2 cell transfectants is greater with 
HMBA. induced cells than for DMSO cells (Figure 7.4) . This is consistent 
with work with F4-12B2 cells transfected with the mutant promoter 
constructs and suggests that DMSO induction is less efficient than HMBA 
induction for this cell line. The 2 to 3-fold induction by DMSO of hGH 
expression observed with the enhancer constructs is not significantly 
greater than the induction value obtained for expression from the 
wild-type promoter without any linked enhancer sequences. When these 
cells are induced with 4 mM HMBA, the induction values for expression 
from the enhancer constructs range from 2 to 6-fold compared with 2 to
3.5 fold for the wild-type promoter construct. These results suggest 
that the enhancer sequences are enhancing the effect of HMBA mediated 
induction of expression from the mouse |3ma-|0r globin gene promoter but 
that this effect is not significant with DMSO mediated induction.
In contrast, the effect of a 3' linked enhancer sequence on 
expression from the pmaJor globin gene promoter in C88 cells is 
significant with both DMSO and HMBA mediated induction (Figure 7.5) . 
With DMSO induced expression, induction levels from the enhancer 
constructs is 4 fold greater than that from the promoter alone. With 
HMBA induced cells, the effect is similar to that of DMSO induced cells 
with an induction level almost 5-fold higher for cells transfected with 
the enhancer constructs compared with the cells transfected with the
135
wild-type promoter construct.
In conclusion, it is apparent that the induction of expression 
from the mouse pma 0^r globin gene depends upon which cell line is used 
and also upon which inducing agent is used to analyse the effect. 
However, the up-regulatory effect upon induction of the enhancer 
sequences is consistently observed except in DMSO induced F4-12B2 
transfected cells. These results together with the results in section 
7.3 present a picture of the induction of transcription from the mouse 
pma-|0r globin gene dependent upon activity of 3' enhancer sequences and 
upon derepression of the negative regulatory element in the distal 
promoter.
Derepression of transcription from this promoter in vivo will be 
occurring in response to natural inducing agents, developmental and 
differentiation signals. How far the observations made here with DMSO 
and HMBA. mediated induction are related will be discussed in Chapter 8 
but clearly the variability, both qualitative and quantitative suggests 
that a better model system is required.
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Modulation of Induction of Expression from the Mouse |3ma o^r Globin Gene 
Promoter by Chicken (3 and Mouse (3 ^Qr Globin Gene Enhancers.
Figure 7.4A F4-12B2 hGH Production.
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CHAPTER 8 DISCUSSION.
8.1 Summary of Results.
The results presented demonstrate that transcriptional 
regulation of the mouse pfTia3or gi0bin gene shares features with the 
regulation of other globin genes but that there are additional features 
to its regulation that have not been previously described. Before these 
features are discussed, I shall summarise the results which have been 
presented.
In vitro DNAase 1 footprinting revealed that elements in the 
proximal promoter region, TATA, CCAAT, CACCC, known to be essential for 
transcription, fail to bind their cognate DNA binding factors present 
in MEL cell crude nuclear extracts. However, when these extracts are 
partially purified, footprints over these sites are observed. In 
contrast, sites within the distal promoter region did bind their 
cognate binding factors in footprint experiments when incubated with 
crude nuclear extracts. These distal promoter sites had not been 
previously described and sequence analysis and competition studies 
revealed that these sites bound an NF-1 like factor (-249 bp) and the 
erythroid specific factor NF-E1 (-220 bp) . A third site, known as Box 1 
(-165 bp) , and identified as being potentially iirportant on the basis 
of sequence homology to the Box 1 sequence of the human (3 globin gene 
(Antoniou et al (1988) failed to bind factor in crude nuclear extracts. 
Sequences further upstream contain a second NF-E1 binding site (-550 
bp) and a Box 1 site (-650 bp) which do bind in footprint experiments, 
factors present in MEL cell nuclear extracts but not those of STO or 
mouse kidney. Sequences 3' of the mouse p^O017 globin gene coding 
region were also shown to contain NF-E1 and Box 1 binding site .
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Gel retardation assays were used to further characterise the 
factors binding to sites present in the ^na o^r globin gene 5' or 3' 
flanking sequence. This revealed that the NF-E1 binding site present in 
the distal promoter has a greater affinity for NF-E1 factor than the 
sites present in the chicken p^ globin gene enhancer (Emerson et al
(1987), the mouse globin gene intron 2 (Galson & Housman (1988),
or the NF-E1 site in the proximal region of the pma o^r globin gene. 
Evidence was presented which suggested that NF-E1 binding activity is 
altered by phosphorylation. Band shift assays also revealed that there 
are two CCAA.T box binding activities which show different tissue 
specificities : pCTl, is competed out by the sequence recognised by the 
factor CXCPl while binding by |3CT2 is partially competed out by the 
sequence recognised by pNFl. However neither PNFl or NF1 binding is 
competed out by pCT competitor. Binding to the Box 1 recognition 
sequence is competed out by binding to pCT. Both the Box 1 and (3CT2 
binding activities are present in uninduced MEL cell crude nuclear 
extracts and absent in induced MEL cell extracts. There are two CACCC 
box binding activities; one of which is present in all nuclear extracts 
looked at and the second of which is present only in induced MEL cell, 
K562 and J774.2 nuclear extracts.
The relative importance in transcriptional regulation of 
sequences identified and characterised in protein binding studies was 
determined in transient and stable transfection assays. Transient 
assays revealed that site directed mutagenesis of elements in the 
distal promoter, pNFl, NF-E1 and Box 1, resulted in up-regulation of 
expression from the p346 promoter fragment and that mutation of the 
NF-E1 and CACCC site in the proximal promoter resulted in 
down-regulation. This suggests that the distal promoter element is a
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negative regulator of transcriptional regulation. It was shown that 
there are sequences upstream of -346 bp (Box 1, NF-E1) which may be 
involved in upregulating transcription and sequences 3' of the gene 
(Box 1, NF-E1) which are analogous to the 3' enhancer of the chicken 
pk globin gene.
Cotransfection of a-1 and pp^or globin gene promoter 
constructs revealed promoter competition could be an artefact of the 
transfection system but could equally reflect genuine promoter 
competition occurring in vivo.
Induction to differentiate leads to upregulated transcription 
from the wild-type promoter but not from promoter constructs mutant in 
distal promoter sequences. The greatest effect of induction is observed 
with HMBA induced expression from the wild-type promoter, modulated 
either by the 3' enhancer of the p^ globin gene or by sequences 3' of 
the pfria30r globin gene itself. DMSO mediated induction is less 
efficient than that of HMBA.
Together these results introduce two new elements : 1. a
potential silencer element in the distal promoter which down regulates 
transcription from the ^na-^or globin gene promoter and which is 
derepressed upon induction to differentiate, and 2. a putative 3' 
enhancer which up-regulates transcription and whose activity in 
addition to derepression of the distal promoter in uninduced MEL cells 
is necessary to achieve maximal expression following induction to 
differentiate.
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8.2 Organisation of Regulatory Elements in the 5'and 3' Flanking Region 
of the Mouse Globin Gene.
The modular nature of promoter and enhancer sequences has 
been extensively described for viral and cellular systems (Fromenthal 
et al (1988) and my analysis of the mouse pma o^r globin gene 5' and 3' 
flanking sequence has shown that it too is organised on a modular 
basis. Figure 1.5 illustrates the organisation of regulatory elements 
in a number of different globin genes and shows that the same types of 
element are present in their promoter regions but that the organisation 
of these elements within each promoter is unique.
The organisation of elements within the mouse p™^017 and the 
human (3 globin gene promoters are similar. Both promoters appear to be 
organised into distal and proximal regions: the distal region
containing an NF-1 like binding activity at the 5' boundary, an 
adjacent high affinity NF-El binding site and a Box 1 site while the 
proximal promoter region contains the TATA box, CCAAT box, CACC box and 
a low affinity NF-El binding site.
The human promoter differs from the mouse promoter in that at 
high protein concentration binding to the NF-1 like sequence prevents 
binding to the adjacent NF-El site in MEL cells (de Boer et al (1988) ; 
this competition does not occur in the mouse promoter. However, DNAase 1 
footprinting of the human promoter with lower protein concentrations 
shows simultaneous binding to both sites suggesting that the 
competition effect observed at high protein concentrations is due to 
protein-protein interactions off the DNA and is not because binding to 
the NF-1 like sequence and the NF-El site is mutually exclusive.
The human promoter has two CACC boxes in its proximal
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promoter region while the mouse gene has only one. It has been 
demonstrated that the CACC box cooperates with the NF-El box in the 
promoter of the human PBG-D gene (Walker et al pers.comm.) and with the 
GRE in the tryptophan oxidase gene promoter (Schule et al (1988b) . The 
CACC box may be mediating the interaction of the distal promoter region 
with the proximal promoter region in both the mouse pmaJor 3^  the 
human P globin genes by cooperating with the NF-El site in the distal 
promoter. It is not clear what function the extra CACC box of the human 
P promoter plays; it may be mediating interaction with the 3' enhancer 
of the human P globin gene. The single CACC box of the mouse pma3or 
globin gene may mediate interaction with both the distal promoter,
which in the case of the mouse gene has a negative regulatory effect,
and with 3' sequences which have a positive regulatory effect. If these 
interactions are mutually exclusive, it suggests a mechanism by which 
the mouse giobin gene is transcriptionally regulated.
The proximal region of the prna-^0r promoter fails to footprint 
with crude nuclear extracts from a number of different cell types but 
the same region does footprint with partially purified extracts. As 
discussed in section 3.1, this has also been observed for the chicken 
pP globin gene and may be explained if the relative protein
concentrations (5-10 mg/ml) in the crude extracts favours
protein-protein interactions off the DNA which prevent binding to the 
DNA whereas the comparatively dilute protein concentrations (0.3 - 0.6
mg/ml) in the partially purified extracts may favour the formation of 
the DNA-bound complex. It is unlikely that failure to obtain a 
footprint with crude nuclear extracts over the proximal region is due 
to low binding affinity of the sites since in gel retardation assays 
the same sites bind strongly.
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The CCAAT box of the mouse pma“|0r globin gene binds two 
factors in gel retardation assays, (3CT1 and pCT2. (3CT1 binding activity 
can be competed out by the mouse a-1 globin gene CCAAT box sequence, 
aP2a, and is present in both uninduced and induced MEL cell crude 
nuclear extracts. pCT2 is absent from induced MEL cell crude nuclear 
extracts. One of these activities may therefore be a CCAAT displacement 
factor in a manner analogous to the displacement factors of the mouse 
a-1 globin gene (Bamhardt et al (1988) and the human globin gene 
(Superti-Furga et al (1989) . Given that (3CT2 disappears upon induction, 
it is more likely to be that activity.
pCT2 is partially competed out by binding to the pma3or 
globin gene NF-1 like sequence. However it is unlikely that the (3CT2 
binding activity is the same as the pNFl binding activity since the 
latter is present in induced MEL cell nuclear extracts and binding to 
pNFl cannot be competed out by binding to pCT. 
pNFl TTCGCCAAAAA
BOX 1 TAAGCCAGTGA
pCT GGGGCCAATCT
pCT2 binding activity does not share its pattern of tissue 
specificity with BOX 1 binding activity either although they are both 
absent in induced MEL cell extracts and although Box 1 binding activity 
can be competed out by (3CT. Thus, while the (3CT, (3NF1 and Box 1
activities share similar recognition sequences, it is unlikely that 
they are the same factors.
De Boer et al (1988) have shown that an NF-El site and the 
Box 1 sequence from the distal promoter region of the human (3 globin 
gene cooperate in the up-regulation of transcription upon induction to 
differentiate. Work presented here involving the mutation of the Box 1,
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NF-El and NF-1 recognition sequences in the distal promoter of the 
mouse P^-^017 globin gene shows that these elements play the same role 
in this promoter as Box 1 and NF-El do in the human p globin gene 
promoter. Both results imply that modulation of Box 1 activity is 
necessary but not sufficient for the up-regulation of transcription 
following induction to differentiate. In uninduced MEL cells, Box 1 in 
the distal promoter is part of a modular negative regulatory element 
and mutation of this sequence or induction to differentiate, overcomes 
this negative effect. As already mentioned Box 1 binding activity 
disappears upon induction of MEL cells. Thus induction may derepress 
transcription of the mouse g]_Qbin gene by altering Box 1 binding
activity. In addition to the Box 1 binding site in the distal promoter 
region, there are also sites in the upstream region and in the 3' 
region. What their role is in these different contexts, is not known.
The NF-El binding site in the distal region (-220 bp) of the 
mouse globin gene has a different role from the NF-El site in
the proximal region as shown by the effect on transcription of mutating 
these different sites. Mutating the distal NF-El site has an 
up-regulatory effect on transcription whereas mutating the proximal 
site has a down-regulatory effect in uninduced MEL cells. The two 
elements differ in their affinities for NF-El, the distal element has a 
higher affinity than the proximal element and has an equivalent 
affinity to the NF-El site in the mouse a-1 globin gene promoter (Plumb 
et al (1989) . There are also NF-El binding sites in the second intron 
of the gene and in the 3' region. Consequently there are four NF-El 
sites which all differ in their affinity for NF-El.
G215 > p^3 > p1^ 2 > G60 
From the functional work presented here, the role of the NF-El sites in
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the promoter is clear: the distal NF-El site is part of a negative
regulatory element which represses transcription prior to induction, 
while the proximal NF-El is part of the basal transcription complex. 
Ptashne has proposed that differential usage of regulatory elements 
which differ in affinity for the same factor may be an important way of 
regulating a gene. When a given factor is in low abundance or modified 
such that a small proportion of available molecules can bind DNA, only 
the high affinity binding sites will be bound. As the factor becomes 
more abundant or its protein-protein interactions alter, the other low 
affinity binding sites will be bound. The roles of different affinity 
sites is likely to be important in determining which gene in a locus is 
to be expressed at a given time during development. Choi & Engel (1988) 
first suggested the idea of stage-selector elements from their work on 
the chicken P globin gene locus where it was shown that the chicken 
embryonic (£) and adult (p^ -) gene promoters compete with each other for 
productive interaction with the chicken p globin gene enhancer.
The chicken p globin gene enhancer contains four protein 
binding regions, I - IV. Regions I and III can be mutated and the 
function of the enhancer maintained. However, both regions II and IV 
are necessary for function of the enhancer and mutation of either of 
these regions reduces the function of the enhancer. Region II contains 
an AP-1 and an AP-2 binding site and mutation of either site is as 
effective in down-regulating as mutating both sites suggesting that 
factors bound at these sites are interacting cooperatively. Region TV 
of the enhancer contains an inverted repeat of the NF-El binding site 
and while mutation of either NF-El site reduces the function of the 
enhancer, mutation of both NF-El sites reduces the activity of the 
enhancer to a greater extent. Thus, unlike region II, the enhansons of
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region IV do not interact cooperatively (Reitman & Felsenfeld (1988).
The mouse (Jna o^r globin gene 3' flanking sequence contains
five putative NF-El binding sites, one Box 1 site, an AP-1 site and an
AP2 site as described in figure 3.8B. However, DNAase 1 footprinting as 
shown in figure 3.9, reveals binding only to one of the NF-El sites and 
to the Box 1 site. Further footprinting needs to be carried out since 
it is possible that improved footprinting conditions may reveal more 
extensive binding to this region. The functional assays described in 
chapters 6 and 7 certainly indicate that this region 3' of the coding 
region is important in regulating expression of the mouse gio^in
gene. At the level of DNA sequence there are great deal of 
similarities between the chicken and the mouse enhancers: they both
possess an inverted repeat of the NF-El binding sites and adjacent API 
and AP2 sites. It is interesting to note that Reitman and Felsenfeld
(1988) mention without describing a negative regulatory element that 
they have identified 3' of the chicken p globin enhancer. This element 
may be analogous to the negative regulatory element found in the distal 
region of the mouse ^[na^ or globin gene. It may also suggest that the
region that I have identified 3' of the mouse pfTia3or g]_0bin gene may
include negative regulatory elements which when deleted from this 
region generate an enhancer which has greater activity than that 
measured in the assays described in chapters 6 and 7.
Unpublished work on the dominant control regions (DCRs) of 
the human p globin gene has shown that they contain multiple NF-El 
binding sites which may be involved in setting up an active globin 
chromatin domain in erythroid tissue prior to the expression of 
specific globin genes. These sites may also be involved in maintaining 
an open chromatin domain and in interacting with sites within the
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promoter and enhancer regions of individual genes of the domain during 
development (Fraser et al pers. comm.).
Evidence is presented which demonstrates that phosphorylation 
of NF-El alters its DNA binding activity. Dephosphorylation results in 
the loss of a higher molecular weight binding form which may be either 
a homodimer or a heterodimer of the NF-El protein and some other 
unknown activity. Clearly phosphorylation does not affect DNA binding 
since the dephosphorylated low molecular weight form is still active in 
this respect. It is possible therefore that phosphorylation is 
modulating the activator domain of the protein by altering the 
interaction of DNA-bound NF-El with other factors to generate an 
altered conformation of transcription complex. It will be interesting 
to determine whether this phosphorylation of NF-El occurs in vivo and 
whether it correlates with response to an extracellular signal 
transmitted through the signal transduction pathway of cells inducing 
them to differentiate.
8.3 Negative Regulation of Transcription.
Mutating the Boxl, NF-El and the pNFl sites in the distal 
promoter such that they no longer bind protein, derepresses 
transcription and these constitutively active promoters do not then 
respond to induction. That mutation of any of the three elements has 
this same effect suggests that they interact with each other to form a 
complex which blocks transcription by some as yet unknown mechanism.
Until recently negative regulation was not considered to be a 
major feature of transcriptional regulation in higher eukaryotes unlike
146
the situation in prokaryotes and yeast. However, recent work has 
revealed that negative regulation is a more commonly employed mechanism 
than was thought.
Mutation and deletion of sequences flanking the 
immunoglobulin heavy chain enhancer have identified two distinct 
negative regulatory elements which lead to up-regulation of the heavy 
chain gene in non-lymphoid cells and down-regulation in lymphoid cells 
(Kadesch et al (1986), Wasylyk & Wasylyk (1986), Imler et al (1987), 
Schuermann & Chen (1989) . Transcriptional stimulation by such a mutated 
enhancer transiently transfected into non-lymphoid cells was weaker 
when transfection efficiency was low and it was suggested that negative 
regulatory factors were being titrated out at higher efficiencies 
(Wasylyk & Wasylyk (1987) . The factor, which binds to these negative 
regulatory sequences, has been identified: NF-pNR (Schuermann & Chen
(1989) . NF-fiNR binding activity is present in immature B-cells, 
T-cells, macrophage and fibroblast but is absent from mature B-cells; 
that is, NF-|lNR is absent from cells which are expressing the 
immunoglobulin heavy chain. The function of the immunoglobulin enhancer 
can be restored in non-expressing cells by deletion of the NF-|0NR 
binding sites. This suggests that the developmental and tissue 
specificity of the immunoglobulin enhancer is in part determined by 
negative regulation in non-expressing cells. It is suggested that there 
are three types of enhanson in the immunoglobulin enhancer:
1. sites like (IE 1-4, which are necessary for functional activity in 
any cell type and which have limited functional redundancy,
2. the octabox, which is necessary for positive activation in the , 
appropriate cell-type, and
3. flanking NF-(iNR sequences, which repress enhancer function in
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inappropriate cell types.
Negative regulation is dominant to positive regulation since 
fusion of mature B-cells with non-B-cells extinguishes immmunoglobulin 
enhancer activated transcription (Junker et al (1988) . Zaller et al
(1988) demonstrated that Immunoglobulin heavy chain expression in 
myeloma cell lines was suppressed after fusion with a T lymphoma or 
fibroblast cell line and that the immunoglobulin enhancer suppressed 
expression in T-cells, from a heterologous promoter which is normally 
expressed in T-cells.
Transcriptional silencer elements have been identified in the 
flanking sequence of several genes, including the rat insulin-1 gene 
where a silencer element was identified 2-4 kb downstream (Laimins et 
al (1986), Nir et al (1986) but the reporting of a transcriptional 
silencer in the 5' flanking region of the human e globin gene was of 
particular interest since it represented a precedent for the use of 
negative regulation in the regulation globin genes. Cao et al (1989) 
identified a region from -177 to -392 bp of the human £ globin gene 
which had a negative regulatory effect on expression of a linked CAT 
reporter gene in transient transfection assays in K562 and HeLa cells. 
The repression was 3 fold greater in HeLa cells than in K562 and the 
element was shown to operate in a position and orientation independent 
manner and on a heterologous promoter. Sequence homology to the 
silencer of the chicken lysozyme gene was made but no homology is 
apparent between this region and the distal promoter of the mouse 
(Jna o^r globin gene. It would be interesting to determine whether the 
distal promoter of the ppna3or gene can be taken out of context and 
shown to operate in an orientation independent fashion and on 
heterologous promoters.
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Basal expression of the chicken erythroid specific histone H5 
gene is under negative control in addition to positive and the upstream 
negative regulatory element has been mapped to a position -95 to -115 
bp upstream of the gene (Rousseau et al (1989) . The negative regulatory 
element can down-regulate heterologous promoters and is non-cell type 
specific suggesting a role for repression in non-erythroid tissue. The 
negative regulatory element contains a polypyrimidine tract and an 
indirect repeat of an element AGGCA, which bears homology to the Box 1 
sequence of the mouse pma-|0r globin gene distal promoter negative
regulatory element but also to the Box 1 sequence in the 3' enhancer of
the same gene.
Interestingly, site 3 of the human |3-globin gene 5' DCR 
contains, in addition to positive regulatory elements, a negative 
regulatory region made up of NF-El sites and other unidentified 
elements (Fraser pers.comm.) . Again this illustrates that the NF-El 
site can act in a negative or a positive regulatory role depending on
its context. What the role of a negative regulatory element in the DCR
is unclear.
Cell fusion experiments involving the fusion of globin gene 
expressing human K562 cells and a non-erythroid myeloma cell line, 
(P3HR-1), demonstrated that globin gene expression was not suppressed 
by factors in the non-erythroid cell line and Grosveld et al (1988) 
suggested that this is because of the dominance of the dominant control 
regions at the human ^-globin gene locus boundaries. However, fusion of 
adherent fibroblast cell lines with suspension Friend cell lines 
resulted in two types of hybrid: suspension hybrids, which could be
induced to synthesise haemoglobin, and adherent hybrids which could not 
(Allan et al (1980) . Meanwhile, work demonstrating that erythroid
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differentiation in a Friend erythroleukaemic x lymphoma hybrid cell 
line is limited suggested that the mechanism of suppression was 
post-transcriptional since globin mRNA was inducible although 
haemoglobin synthesis was not taking place.
The use of cell fusion experiments to identify negative 
regulatory elements is exemplified in work by Poole et al (pers.comm.) 
who have correlated the suppression of the transformed phenotype in RSV 
transformed rat embryo fibroblast x human mononucleocyte hybrids with 
down regulation of proviral transcription which is in turn determined 
by the site of retroviral integration. It is proposed that DNA 
sequences flanking the provirus are exerting a negative regulatory 
effect on proviral transcription and retroviral probes may be used to 
identify cellular regulatory elements and trans-acting factors that 
have not been identified by other means.
Fusion of non-growth hormone producing mouse L cells with 
growth hormone producing rat pituitary GH3 cells, resulted in three 
hybrids (McCormick et al (1988) . Two of the hybrids were non-producers 
of growth hormone and one hybrid was a producer but only after mouse 
chromosomal loss. The extinction of growth hormone expression was 
associated with loss of trans activator, GHF-1 in the hybrids.
Viral genomes, such as SV40 and MuLV are not efficiently 
expressed in undifferentiated embryonal carcinoma cells (F9), but are 
in the differentiated derivatives. However, when SV40 is transfected 
into undifferentiated F9 cells, expression of viral genes is observed 
and it is proposed that the higher copy number of viral genome 
introduced by transfection is titrating out negative regulatory factors 
(Gorman et al (1985) . The MSV LTR promoter does not operate in 
undifferentiated F9 cells although when cotransfected with the RSV LTR,
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MSV LTR promoter activity is observed. Again it is suggested that the 
RSV LTR is competing with the MSV LTR for negative regulatory factors. 
It was observed that mutants of adenovirus which were defective in Ela 
function, cannot replicate in differentiated F9 cells but are able to 
do so in undifferentiated cells suggesting that undifferentiated F9 
cells have a cellular homologue of Ela which down-regulates viral 
enhancers and is involved in the maintenance of the undifferentiated 
state. Enhansons of the SV40 enhancer are individually repressed by Ela 
and it has been suggested that Ela mediated phosphorylation of 
transcription factors may be responsible for their repression 
(Rochette-Egly et al (1990).
Deletion of the 3' end of the p-interferon enhancer results 
in up-regulation of transcription of the human p-interferon gene 
(Goodbourn et al (1986) . Negative regulation of the human P~interferon 
gene is relieved by induction of fibroblasts with virus or double 
stranded RNA and characterisation of the changes in DNA-protein and 
protein-protein interactions as transcription of the gene is induced 
reveals features which may be shared by other inducible genes, such as 
the p-globin genes in the MEL cell system. The factors which bind to 
the P~interferon enhancer have been identified (Zinn et al (1986), 
Goodbourn & Maniatis (1988) and the pattern of binding to the enhancer 
changes when transcription of the gene is induced. In uninduced cells, 
a positive regulatory factor is bound, PRD I which allows basal levels 
of expression. A negative regulatory factor, NRD I is also bound and 
prevents binding by PRD II, which is necessary for induced levels of 
expression. Following induction, NRD I binding is inactivated to allow 
PRD II to bind and PRD I binding activity increases. The binding sites 
for NRD I and PRD II overlap and thus, negative regulation of
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p- interferon can be explained in terms of competition between 
transcription factors for DNA-binding sites. However, negative 
regulation has been shown to operate using non-overlapping DNA-binding 
sites which are effective in repression even when placed at a distance 
upstream or downstream of a gene. This is the case for the negative 
regulation of "a" type genes in a-type cells in yeast (Johnson & 
Herskowitz (1985) where the MAT a2 gene product, a2 interacts 
cooperatively with the GRM protein, to repress transcription from the 
operator site in the promoters of "a” type genes (Keleher et al (1988) . 
In "a" type cells, GRM activates "a" type genes and in a type cells, a2 
activates a type genes. Two models for repression were proposed: the
masking model, where 0(2 blocks contact between GRM and the 
transcription machinery, and the locking model, where the 0(2/GRM 
complex interacts too strongly with the transcription machinery.
The negative regulatory activity of Fos and Jun has been 
described for some genes. In vitro translated Fos and Jun bind 
cooperatively to the negative regulatory element of the human c-myc 
promoter (Hay et al (1989). Fos trans-represses c-fos transcription and 
this repression appears to be mediated by the serum response element
since repression can occur in the absence of the TPA response element
and the cAMP response element of the c-fos promoter. The leucine zipper 
of c-fos is necessary for its repressor activity and although the serum 
response factor does not have a leucine zipper, it is suggested that a 
Fos-Jun complex may be modifying an already existing SRE bound complex 
(Lucibello et al (1989).
Jun-B, c-jun and jun-D all bind to the IRE as Jun homodimers
or as Fos-Jun heterodimers but while c-Jun activates, Jun-B inhibits
activation of promoters containing single TREs. Promoters containing
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multiple TREs are activated by both c-Jun and Jun-B suggesting that 
Jun-B requires cooperative interactions between adjacently bound 
factors in order to activate transcription (Chui et al (1989) . 
Cotransfection of Jun-B and c-Jun into fibroblast cell lines decreases 
AP-1 trans-act ivation and it has been suggested that the Jun-B/c-Jun 
heterodimer is inactive since cotransfection of c-Jun and Fos does not 
have this effect. It is also possible that Jun-B and c-Jun are 
competing for AP-1 binding sites. The transformation activity of Jun-B 
is less than that of c-Jun and it cooperates less well with Ras to 
transform rat fibroblasts and cotransfection of jun-B with ras and 
c-jun results in decreased transformation compared with ras and c-jun 
alone (Schutte et al (1989) . How the inhibitory activity of Jun-B in 
transcription correlates with its reduced transformation capacity 
remains to be determined.
Negative regulation is widely used in the regulation of 
developmental genes of Drosophila where the products of the engrailed 
and even-skipped genes down-regulate the up-regulatory effect of the 
fushi-tarazu and paired gene products. The ultrabithorax gene is 
down-regulated by the even-skipped gene product but unlike the negative 
regulation of fushi-tarazu and paired which is mediated by 
protein-protein interactions, the negative regulation of ultrabithorax 
is effected by the binding of the even-skipped gene product to a site 
in the DNA. 5' of the ultrabithorax gene (Biggin & Tjian (1989) .
These studies of eukaryotic systems has allowed a theory of 
repression to be proposed in which repression is postulated to occur by 
one of three mechanisms:
1. Competition between factors for DNA binding sites.
2. Alteration in the function of the activator domain.
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3. Squelching.
All three mechanisms have the effect of preventing the 
formation of a functional transcription initiation complex. This 
complex can be visualised as an allosteric protein complex consisting 
of primary transcription factors which undergoes conformational change 
in response to the binding of secondary transcription factors which may 
be cell-specific or stage specific. The function of this complex is to 
interact with RNA polymerase II to initiate transcription in a tightly 
regulated fashion from the transcription initiation site. The complex 
will include factors bound to DNA at different sites, the DNA linking 
these sites, and non-DNA bound factors. The nature of the interaction 
with RNA polymerase is not as well characterised as the interactions of 
prokaryotic factors, such as X  repressor with prokaryotic RNA 
polymerase where the amino acid contacts with the major groove of the 
DNA binding site have been established (Pabo & Sauer (1984) . The 
transcription complex may be modulated like other allosteric proteins; 
its activity altered by covalent modification or by interaction with 
inhibitory factors which block interaction with other factors or block 
conformational change. Whether a given factor is a repressor or an 
activator will depend upon the other factors in the initiation complex 
and its interaction with them.
8.4 The Effects of Induction to Differentiate.
Friend erythroleukaemic cell lines are used to study the 
transcriptional regulation of the mouse globin gene. As
discussed in the general introduction, this cell line and its
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derivatives are arrested in the erythroid differentiation pathway and 
can be induced to continue differentiating by treatment with 4 mM HMBA 
or 2% DMSO amongst other agents. This method of induction is effective 
in inducing globin gene expression but since these agents are not used 
in vivo, this system and all others involving chemical induction are 
not optimal. To study the effect of induction to differentiate upon 
globin gene expression, it would be preferable to use a cell line which 
could be induced with erythropoietin. Such a cell line has recently 
been produced and any future work on induction will involve its use. 
The results presented in chapter 7 show that induced expression of the 
hGH reporter gene is observed from the wild-type promoter fragment (3346 
and higher levels are observed from this promoter when its activity is 
modulated by either the chicken (3^ globin gene or by mouse 3' 
sequences. This effect is seen with induction by both 4 mM HMBA and 2% 
DMSO and for both Friend cell lines, F4B12 and C88. However the effect 
observed for HMBA induced cells is 3 fold greater than that observed 
for DMSO. Clearly there are differences in the way in which these 
agents operate. It has already been reported that HMBA is more 
efficient in inducing globin gene expression than DMSO. Maximal globin 
gene expression in MEL cells is observed after 2-3 days in HMBA but not 
until 3-4 days in DMSO and only 60% of cells become committed to 
differentiate with DMSO compared to 95% with HMBA (U.Nudel Cell 12 
463-469 (1977) . In this way it is possible that the general stress
responses of the cells to these chemical agents could be distorting the 
changes in globin gene expression observed as the cells differentiate.
Another problem with analysis of data obtained from this 
system is the problem with standardisation to allow comparison with the 
regulation of expression of other genes measured in other systems.
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Different laboratories use different cell lines, different inducing 
agents and different methods of analysing their results. This work 
compares two different cell lines and shows that the effect of 
induction to differentiate on globin gene expression varies depending 
upon the agent used. To analyse the results obtained here, expression 
levels in terms of hGH produced were first standardised for cell number 
since clearly uninduced and induced cells grow at different rates and 
then the expression level per cell was standardised to expression level 
per cell prior to induction. In this way the effect upon 
transcriptional activity of the mouse (3ma^°r globin gene promoter and 
flanking sequence could be analysed. It is difficult to compare these 
results with work done by some other groups since they have not made it 
clear how they standardised their results.
The results obtained following induction of MEL cells stably 
transfected with different promoter and enhancer constructs shows that 
mutation of any of the three elements in the distal promoter results in 
constitutive expression from the promoter that does not respond to 
induction but that induction generates a 2-3.5 fold increase in 
expression from the wild-type promoter and a 2-6 fold increase from the 
wild-type promoter modulated by chicken (3^ enhancer sequences or by 
mouse (3ma-|C>r 3' flanking sequence. These results show the presence of a 
"silencer" in the distal promoter of the gene which down-regulates 
transcription and whose effect is overcome by mutation or by induction 
to differentiate. These results and the results obtained from
transient transfection assays show that the sequences from 3' of the 
mouse (3ma-,or globin gene used in these assays effect the same level of 
enhancement upon expression as the chicken (3^ enhancer. It is necessary 
to show that the activity of these sequences is position and
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orientation independent and that they act on promoters other than that 
of the mouse giobin gene. The activity of a 3' ’’enhancer”
sequence is required to achieve optimal levels of expression. It was 
suggested earlier that the CACC box in the proximal region of the 
promoter may be interacting with both the "silencer" and the "enhancer" 
in a mutually exclusive fashion and that this suggested a mechanism by 
which the mouse ^na^)or globin gene was regulated. Early in 
differentiation and in development when the mouse pma^°r globin gene is 
not yet expressed transcription factor bound at the CACC box interacts 
with EF1, Box 1 and pNFl in the distal promoter region which results in 
repression of expression. As the erythroid cell differentiates, the 
activity of the Box 1 binding factor decreases such that the distal 
promoter repressor complex cannot form. The CACC box factor then 
cooperates with the proximal promoter - 3' enhancer complex to
up-regulate transcription from the mouse globin gene promoter.
This mechanism is purely speculative but work with the chicken 
globin gene promoter has revealed a central role for the CACC element 
in developmental regulation through its interactions with other 
elements in the promoter (PAL) and in the enhancer (NF-E4) .
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